

THRU ONLINE FILING

July 10, 2026

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
(Scrip Code : 506919)

Dear Sir,

Sub: Annual Report 2025-26

We are enclosing herewith copy of our Annual Report for the financial year ended 31st March, 2026 for your perusal and record.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Makers Laboratories Limited

Piyush Ajmera
Company Secretary
ACS 58712



ANNUAL REPORT 2025-26

MAKERS LABORATORIES LIMITED



Five Years' Highlights (Standalone)

(₹ Lacs)

	2021-22	2022-23	2023-24	2024-25	2025-26
Total Income	5322.37	4368.40	5024.04	5386.81	5094.01
Profit /(Loss) Before Tax	31.32	(677.57)	(695.78)	492.86	(201.13)
Profit /(Loss) After Tax	17.18	(636.09)	(695.19)	464.11	(171.98)
Share Capital	491.70	590.04	590.04	590.04	590.04
Reserves & Surplus	4538.32	5238.42	4554.68	5017.50	4853.37
Net Worth	5030.02	5828.46	5144.72	5607.54	5443.41
Earnings Per Share (₹)	0.34	(10.58)	(11.78)	7.87	(2.91)
Book Value Per Share (₹)	102.30	98.78	87.19	95.04	92.25

BOARD OF DIRECTORS

R. K. P. Verma	- Chairman / Independent Director	(DIN 02166789)
Vishal Jain	- Independent Director	(DIN 00137986)
Dipti Shah	- Independent Director	(DIN 07995542)
Prashant Godha	- Non-Independent Director	(DIN 00012759)
Saahil Parikh	- Wholetime Director	(DIN 00400079)
Nilesh Jain	- Wholetime Director	(DIN 05263110)

COMPANY SECRETARY

Piyush Ajmera (ACS 58712)

AUDITORS

N V C & Associates LLP
Chartered Accountants
Firm Regn. No. 106971W / W101085
903-904, 9th Floor, Raheja Chambers
213, Nariman Point,
Mumbai-400 021

COST AUDITORS

Poddar & Co.
Cost Accountants
B-205, Chandulal Park,
Station Road,
Bhayandar (W),
Thane 401 101

BANKERS

Yes Bank Ltd.

REGISTERED OFFICE

54-D, Kandivli Industrial Estate,
Charkop, Kandivli (West),
Mumbai 400 067
Tel : 022 - 2868 8544 Fax : 022 - 2868 8544

REGISTRARS & SHARE TRANSFER AGENTS

MUFG Intime India Private Limited
C-101, 247 Park,
LBS Marg, Vikhroli (West)
Mumbai – 400 083
Tel : 8108116767

WORKS

Plot No. 29/3, Phase III,
GIDC Industrial Estate,
Naroda, Ahmedabad 382 330
Gujarat.
Tel : 079 - 2281 3057
Fax : 079 - 2282 2133

Plot No. 30/4, Phase III,
GIDC Industrial Estate,
Naroda, Ahmedabad 382 330
Gujarat.
Tel : 079 - 2281 3057
Fax : 079 - 2282 2133

CONTENTS

Notice.....	3
Directors' Report.....	27
Report on Corporate Governance.....	36
Secretarial Audit Report.....	62
Independent Auditors' Report (Standalone Financial Statements)	65
Standalone Balance Sheet.....	76
Standalone Statement of Profit and Loss.....	77
Standalone Cash Flow Statement.....	78
Independent Auditors' Report (Consolidated Financial Statements)	123
Consolidated Balance Sheet.....	132
Consolidated Statement of Profit and Loss.....	133
Consolidated Cash Flow Statement.....	134
Five Years' Highlights.....	Inside Front Cover

NOTICE is hereby given that the 41st ANNUAL GENERAL MEETING (AGM) of Makers Laboratories Limited will be held on Friday, 7th August, 2026 at 12.30 p.m. through Video Conferencing / Other Audio Visual Means (VC/OAVM) to transact the following business.

ORDINARY BUSINESS:

1. To receive, consider and adopt:
 - a) the Audited Financial Statements of the Company for the financial year ended on 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon; and
 - b) the Audited Consolidated Financial Statements of the Company for the financial year ended on 31st March, 2026 together with the Report of the Auditors thereon.
2. To appoint a Director in place of Mr. Saahil Parikh (DIN 00400079) who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution :

“RESOLVED THAT pursuant to Section 188 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder and pursuant to applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Regulations) as applicable and subject to such other approvals, consents, permissions and sanctions of any authorities as may be necessary, consent of the Company be and is hereby accorded to the Board of Directors of the Company to enter into/continue to enter into contracts/transactions with M/s. Ipca Laboratories Limited, a related party, on such terms and conditions as may be mutually agreed upon, to purchase, sell or supply any materials, goods, plant & machineries or capital goods and also availing of / rendering of services like contract manufacturing services or loan license manufacturing services, lease agreements or provision of any other services, the value of which all taken together may exceed ten per cent of the turnover of the Company subject to however that the value of all the transactions aforesaid during any financial year, including financial year 2026-27, shall not exceed in aggregate an amount of ₹30 crores (Rupees Thirty Crores Only).

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to sign and execute necessary documents and papers on an ongoing basis and to do and perform all such acts, deeds and things as may be necessary in this regard.”

4. To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 (3) and such other applicable provisions, if any, of the Companies Act, 2013 read with rules made thereunder, M/s. Poddar & Co., Cost Accountants (Firm Registration No. 101734) who have been appointed as the Cost Auditors of the Company by the Board of Directors on the recommendation of the Audit Committee, to conduct the audit of the cost records maintained by the Company for the financial year 2026-27, be paid remuneration of ₹ 1,50,000/- (Rupees One Lac Fifty Thousand Only) plus applicable tax and reimbursement of traveling and other out of pocket expenses.”

IMPORTANT NOTES:

1. Pursuant to General Circulars issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) from time to time and in compliance with the provisions of the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), the 41st AGM of the Company is being conducted through VC/OAVM Facility, which does not require physical presence of members at a common venue. The deemed venue for the 40th AGM shall be the office of the Company situated at Plot No. 54D, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067.
2. Pursuant to the provisions of the act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. However, since this AGM is being held pursuant to the MCA circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for this AGM and hence the proxy form, attendance slip and route map of AGM are not annexed to this notice.
3. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (“the Act”) setting out material facts concerning the business under Item Nos. 3 and 4 of the accompanying Notice is annexed hereto. The Board of Directors of the Company at its meeting held on 26th May, 2026, considered that the special business under Item Nos. 3 and 4 being unavoidable, be transacted at the 41st AGM of the Company.
4. Additional information pursuant to Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (**‘SEBI Listing Regulations’**) and Secretarial Standard on General Meetings (‘SS-2’) issued by The Institute of Company Secretaries of India, in respect of Director being re-appointed / retiring by rotation and seeking re-appointment at this Annual General Meeting (**‘Meeting’** or **‘AGM’**) is furnished as **Annexure** to this Notice.
5. General instructions for accessing and participating in the 41st AGM through VC/OAVM Facility and voting through electronic means including remote e-Voting
 - a. In terms of the circulars issued by MCA since the physical attendance of Members has been dispensed with, there is no requirement of appointment of proxies. Accordingly, the facility of appointment of proxies by Members under Section 105 of the Act will not be available for the 41st AGM. However, in pursuance of Section 112 and Section 113 of the Act, representatives of the Members may be appointed for the purpose of voting through remote e-Voting and for participation in the 41st AGM through VC/OAVM Facility and e-Voting.
 - b. The Members can join the AGM in the VC/OAVM mode between 30 minutes before and 15 minutes after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large shareholders (shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors, etc. who are allowed to attend the AGM without restriction of first come first served basis.
 - c. Since the AGM will be held through VC/OAVM Facility, the Route Map of the AGM venue, proxy form and attendance slip is not annexed in this Notice.
 - d. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended), and the

Circulars issued by the Ministry of Corporate Affairs from time to time, the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a Member using remote e-Voting system as well as voting on the date of the AGM will be provided by NSDL.

- e. In accordance with the aforesaid MCA Circulars and the applicable SEBI Circulars, 41st AGM and the Annual Report for the financial year 2025-26 including therein, inter-alia, the Audited Standalone and Consolidated Financial Statements for the financial year ended 31st March, 2026 are being sent ONLY through electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories, unless any Member has requested for a physical copy of the same.

Therefore, those Members, whose email address is not registered with the Company or with their respective Depository Participant/s and who wish to receive the Notice of the 41st AGM and the Annual Report for the year 2025-26 and all other communication sent by the Company, from time to time, can get their email address registered by following the steps as given below:-

- a. For Members holding shares in physical form, please send scan copy of a signed request letter mentioning your folio number, name, complete address, email address to be registered along with scanned self attested copy of the PAN and any document (such as Driving Licence, Passport, Bank Statement, AADHAR) supporting the registered address of the Member, by email to the Company's email address investors@makerslab.com.
- b. For the Members holding shares in demat form, please update your email address through your respective Depository Participant/s.
- f. In line with the circulars issued by MCA and SEBI, the Notice of the 41st AGM will be available on the website of the Company at www.makerslabs.com and on the website of BSE Limited at www.bseindia.com and also on the website of NSDL at www.evoting.nsdl.com.
- g. Attendance of the Members participating in the 41st AGM through VC/OAVM Facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
- h. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Act, and the Register of Contracts or Arrangements in which the directors are interested, maintained under Section 189 of the Act, will be available for inspection by the members during the AGM. All documents referred to in the Notice will also be available for inspection without any fee by the members from the date of circulation of this Notice up to the date of AGM. Members seeking to inspect such documents can send an email to investors@makerslabs.com.
- i. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC. Corporate members intending to authorize their representatives to participate and vote at the meeting are requested to send a certified copy of the Board resolution / authorization letter to the Company or upload on the VC portal / e-voting portal.
- j. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India ("ICSI") and Regulation 44 of Listing Regulations read with circulars issued by MCA and SEBI in this regard, the Company is providing remote e-Voting facility to its Members in respect of the business to be transacted at the 41st AGM and facility for those Members participating in the 41st AGM to cast vote through e-Voting system during the 41st AGM.

- k. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with circulars issued by MCA and SEBI from time to time.
6. The Company has sent individual letters to all the Members holding shares of the Company in physical form for furnishing their PAN, KYC and Nomination details. Members holding shares of the Company in physical form are requested to go through the requirements on the website of the Company at www.makerslabs.com to furnish the abovementioned details. Further, relevant FAQs published by SEBI on its website can be accessed at: https://www.sebi.gov.in/sebi_data/faqfiles/jan-2024/1704433843359.pdf.
7. In accordance with Regulation 40 of the SEBI Listing Regulations, as amended, the Company had stopped accepting any fresh transfer requests for securities held in physical form. Members holding shares of the Company in physical form are requested to kindly get their shares converted into demat/electronic form to get inherent benefits of dematerialisation. Further, Members may please note that SEBI has mandated listed companies to issue securities in demat form only while processing any service requests viz. issue of duplicate securities certificate; claim from Unclaimed Suspense Account; renewal/exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR-4 / ISR-5, the format of which is available at www.makerslabs.com. It may be noted that any service request or complaint can be processed only after the folio is KYC compliant.
8. SEBI has established a common Online Dispute Resolution Portal ('ODR Portal') for resolution of disputes arising in the Indian Securities Market. Pursuant to this, post exhausting the option to resolve their grievance with the RTA / Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (<https://smartodr.in/login>) and the same can also be accessed through the Company's Website at www.makerslabs.com.
9. The Instructions for Members for Remote E-Voting and joining General Meeting are as under:-
- a. The remote e-voting period begins on Monday, 3rd August, 2026 at 9.00 a.m. and ends on Thursday, 6th August, 2026 at 5.00 p.m. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Friday, 31st July, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 31st July, 2026.
- b. Any person who is not a Member as on the cut off date should treat this notice for information purpose only. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently
- c. **How do I vote electronically using NSDL e-Voting system?**





The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
<p>Individual Shareholders holding securities in demat mode with NSDL.</p>	<ol style="list-style-type: none"> Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsd.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp
	<ol style="list-style-type: none"> Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsd.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience. <p>NSDL Mobile App is available on</p> <p>  App Store  Google Play </p> <div style="display: flex; justify-content: space-around; align-items: center;">   </div>

<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"> 1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then use your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile and Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
<p>Individual Shareholders (holding securities in demat mode) login through their depository participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site. After successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned websites.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free No. 1800 22 55 33

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

1. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered
2. If you are unable to retrieve or have not received the " Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
3. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
4. Now, you will have to click on “Login” button.
5. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle is live.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to scrtunizer@makerslabs.com with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "**Upload Board Resolution / Authority Letter**" displayed under "**e-Voting**" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to Ms. Pallavi Mhatre at evoting@nsdl.co.in.

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investors@makerslabs.com.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to investors@makerslabs.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. **Login method for e-Voting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by listed companies, individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.
5. The instructions for members for e-voting on the day of the AGM are as under :
 - a. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
 - b. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not cast their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
 - c. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
 - d. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.
6. Instructions for Members for attending the AGM through VC/OAVM are as under:
 - a. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM link" placed under **"Join Meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
 - b. Members are encouraged to join the meeting through laptops for better experience.
 - c. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

- d. Please note that participants connecting from mobile devices or tablets or through laptop connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.
 - e. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at investors@makerslabs.com. The same will be replied by the Company suitably.
 - f. Shareholders who would like to express their views may pre-register themselves as a speaker by sending their request mentioning their name, demat account number/folio number, email id and mobile number at investors@makerslabs.com
7. The voting rights of Members shall be in proportion to their share in the paid up equity share capital of the Company as on the cut-off date of 31st July, 2026.
 8. Any person, who acquires shares of the Company and becomes Member of the Company after the Company sends the Notice of the 41st AGM by email and holds shares as on the cut-off date i.e. 31st July, 2026, may obtain the User ID and password by sending a request to the Company's email address investors@makerslabs.com. However, if you are already registered with NSDL for remote e-Voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com.
 9. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-Voting or casting vote through e-Voting system during the AGM.
 10. Ms. Jigyasa N. Ved (Membership No. FCS6488 CP6018) or failing her Mr. P. N. Parikh (Membership No. FCS327 CP1228) or failing them Mr. Mitesh Dhaliwala (Membership No. FCS8331 CP9511) of M/s. Parikh & Associates, Practising Company Secretaries have been appointed as the Scrutinizer to scrutinize the remote e-Voting process (including e-Voting at the meeting) in a fair and transparent manner.
 11. During the 41st AGM, Members will be provided with the facility for voting through remote electronic voting system during the proceedings at the AGM and Members participating at the AGM, who have not already cast their vote by remote e-Voting, will be eligible to exercise their right to vote at the end of discussion on such resolution(s) upon announcement by the Chairman. Members who have cast their vote on resolution(s) by remote e-Voting prior to the AGM will also be eligible to participate at the AGM through VC/OAVM but shall not be entitled to cast their vote on such resolution(s) again.
 12. The Scrutinizer shall after the conclusion of e-Voting at the 41st AGM, unblock the votes cast through remote e-Voting and shall make a consolidated scrutinizer's report of the total votes cast in favour or against, invalid votes, if any, and such Report shall then be sent to the Chairman or a person authorized by him, within 48 (forty eight) hours from the conclusion of the 41st AGM, who shall then countersign and declare the result of the voting forthwith.
 13. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company at www.makerslabs.com immediately after the declaration of Results by the Chairman or a person authorized by him. The results shall also be immediately forwarded to the BSE Limited (BSE).

14. Pursuant to the circulars issued by MCA and SEBI from time to time the Notice of the 41st AGM and the Annual Report for the financial year 2025-26 including therein, inter-alia, the Audited Standalone and Consolidated Financial Statements for the financial year ended 31st March, 2026, the Auditors Reports and Directors Report are being sent only by email to the Members. Therefore, those Members, whose email address is not registered with the Company or with their respective Depository Participant/s and who wish to receive the Notice of the 41st AGM and the Annual Report for the year 2025-26 and all other communication sent by the Company from time to time, can get their email address registered by following the steps as given below:-
- a. For Members holding shares in physical form, please send scan copy of a signed request letter mentioning your folio number, name, complete address, email address to be registered along with scanned self attested copy of the PAN and any document (such as Driving Licence, Passport, Bank Statement, AADHAR) supporting the registered address of the Member, by email to the Company's email address investors@makerslabs.com.
 - b. For the Members holding shares in demat form, please update your email address through your respective Depository Participant/s.
15. Members are requested to:
- (a) intimate to the Company / their Depository Participant ("DP"), changes, if any, in their registered address at an early date;
 - (b) quote their Registered Folio No. and/or DP Identity and Client Identity number in their correspondence;
 - (c) encash the dividend warrants on their receipt as dividend amounts remaining unclaimed for seven years are required to be transferred to the 'Investor Education and Protection Fund' established by the Central Government under the provisions of the Companies Act, 2013. Pursuant to Section 124(5) of the Companies Act, 2013, all unclaimed dividend declared and paid upto dividend for the financial year 2017-18 have been transferred by the Company to the Investor Education and Protection Fund. Members who have not encashed their dividend warrants for subsequent period are requested to encash the same immediately.
 - (d) Pursuant to the provisions of Section 124 (6) of the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, the Company has transferred all shares in respect of which dividend has not been encashed by the shareholders for seven consecutive years or more in the name of Investor Education and Protection Fund (IEPF). The shareholders who wish to claim the said shares from the IEPF may claim the same by filing e-form No. IEPF-5 as prescribed under the said Rules available on iepf.gov.in.
 - (e) Members holding shares in dematerialized form are requested to intimate all changes pertaining to their bank details such as bank account number, name of the bank and branch details, MICR code and IFSC code, mandates, nominations, power of attorney, change of address, change of name, e-mail address, contact numbers, etc., to their depository participant (DP). Changes intimated to the DP will then be automatically reflected in the Company's records which will help the Company and the Company's Registrars and Transfer Agents, MUFG Intime India Pvt. Ltd. (MUFG Intime) to provide efficient and better services. Members holding shares in physical form are requested to intimate such changes to MUFG Intime.

The Securities and Exchange Board of India (“SEBI”) has mandated the submission of Permanent Account Number (PAN), KYC details and nomination by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit the said details to their depository participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit these details to MUFG Intime India Pvt. Ltd. SEBI vide its circular dated 16th March, 2023 has mandated the RTA’s to freeze the folios not having these details after 1st October, 2023.

16. As per Regulation 40 of SEBI Listing Regulations, as amended from time to time, securities of the listed companies can be transferred only in dematerialized form with effect from 1st April, 2019 except in case of transmission or transposition or for re-lodged transfer requests. Further, SEBI vide its circular dated 2nd December, 2020 had fixed 31st March, 2021 as the cut-off date for re-lodgement of transfer deeds and the shares re-lodged for transfer shall be issued only in demat mode. Therefore, Members holding shares in physical form are requested to consider converting their shareholding to dematerialised form to eliminate all risks associated with physical shares for ease of portfolio management as well as for ease of transfer.

Registered Office:
54-D, Kandivli Industrial Estate
Kandivli (West)
Mumbai – 400 067
Tel : 022 – 28688544
E-mail: investors@makerslabs.com
Website: www.makerslabs.com
CIN: L24230MH1984PLC033389

Mumbai
26th May, 2026

By Order of the Board
For Makers Laboratories Limited

Piyush Ajmera
Company Secretary
ACS 58712

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

This explanatory statement is in terms of Regulation 36(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), and as per Section 102 of the Companies Act, 2013.

Item 3

Regulation 23(4) of Listing Regulations as amended provides that all material related party transactions as defined under sub-regulation (2) of Regulation 23 shall require in addition to prior approval of the Audit Committee, the approval of the shareholders by means of an Ordinary resolution. A transaction with a related party shall be considered material, if the transaction(s) to be entered into, individually or taken together with previous transactions, during a financial year, exceeds the limits as prescribed under Schedule XII of the Listing Regulations. For the Company, this threshold limit is 10% of the annual consolidated turnover of the Company as per the last audited financial statements. This provision is applicable even if the transactions are in the ordinary course of the business of the Company and at an arms’ length basis.

It is in this context that the Resolution at Item No. 3 is proposed for the approval of the Shareholders of the Company.

The Audit Committee and the Board of Directors of the Company had, on the basis of relevant details provided by the management and as required by law, reviewed and approved these proposed related party transaction(s), subject to the approval of the shareholders of the Company. It may be noted that these related party transactions are on an arms’ length basis and in the ordinary course of business and are in accordance with Company’s Policy on Materiality of Related Party Transactions. These transactions not only help in strengthening business operations of the Company but also ensures consistent flow of desired quality and quantity of goods and services without interruption and also generates revenue and business to the Company.

The Audit Committee of the Company reviews, on a quarterly basis, the details of all related party transactions entered into by the Company pursuant to its prior approvals. The Audit Committee has also reviewed the certificate provided by the Managing Director and CEO of the Company on the proposed related party transactions as required under the Industry Standards Note issued by the SEBI vide its circular dated June 26, 2025.

Both the Company as well as Ipca Laboratories Limited (“Ipca”) are promoted by the same promoter group and accordingly, treated as related parties under Regulation 2(1) of the Listing Regulations.

The details as required under Regulation 23 of Listing Regulations read with SEBI Circular bearing reference no. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated June 26, 2025, to provide minimum information relating to the material related party transactions before the Audit Committee and Shareholders of the Company for approval of Related Party Transactions (“**RPT Industry Standards**”) are set forth hereinbelow:

Pursuant to the SEBI Circular dated June 26, 2025, the Minimum Information relating to the proposed related party transaction(s) to be provided to the shareholders for approval

Sr. No.	Particulars	Information provided by the management
1.	Information as placed before the Audit Committee in the format as specified in the RPT Industry Standards, to the extent applicable	Refer below table titled as “Annexure – A”
2.	Justification as to why the proposed transaction is in the interest of the listed entity, basis for determination of price and other material terms and conditions of RPT	<p>Ipca Laboratories Limited (Ipca) along with its subsidiaries is serving its customers located across the globe. All Ipca entities are engaged in highly regulated business of manufacturing/ marketing of pharmaceuticals and related products. In this business, it is not possible to change the approved source of materials as the same is approved by regulatory authorities from different countries. Post development of the products, the same also need to be registered with regulatory authority of each and every country where the product is proposed to be marketed/ distributed. It is also important in the pharmaceutical business to maintain confidentiality/intellectual property rights. Considering the above, it is generally not feasible to conduct the type of business covered under these related party transactions with any third parties so easily, they besides time consuming and costly proposition. However, transactions contemplated are on an arm’s length basis and are in the ordinary course of business as well as in compliance with transfer pricing norms with terms and conditions that are generally prevalent in the industry segments that the Company operates in.</p> <p>The Company and Ipca, each operates independently with as distinct legal entities with distinct commercial responsibilities. The proposed transactions are designed to harness the synergies of both to ensure continuity and reliability in the supply of goods and services beneficial to both companies.</p> <p>No Loans or payment Royalty is planned under the proposed transactions between the Company and Ipca. Further advances against supplies, if transacted, will always be in compliance with Section 186 of the Companies Act, 2013 (Act) and shall be carried out on an arm’s length basis. The major part of the proposed related party transactions relate to the Company developing, registering, manufacturing and supplying eye drops and injectables to Ipca Laboratories Ltd. for selling/distributing within India and the Rest of the World markets.</p>

Sr. No.	Particulars	Information provided by the management
3.	Disclosure of the fact that the Audit Committee has reviewed the certificates provided by the CEO/Managing Director/ Whole Time Director/ Manager and CFO of the Listed Entity as required under the RPT Industry Standards	Yes
4.	Disclosure that the material RPT or any material modification thereto has been approved by the Audit Committee and the Board of Directors recommends the proposed transaction to the shareholders for approval	Yes. The proposed related party transactions is approved by the Board and Audit Committee of the Company and it is recommended to the shareholders for the approval of the same.
5.	Web-link and QR Code, through which shareholders can access the valuation report or other reports of external party, if any, considered by Audit Committee while approving the RPT	Not Applicable
6.	Affirmation that the Audit Committee and Board of Directors, while providing information to the shareholders, have redacted the commercial secrets and such other information that would affect competitive position of listed entity and in its assessment, the redacted disclosures still provide all the necessary information to the public shareholders for informed decision making	Not Applicable
7.	Any other information that may be relevant	None

Annexure – A

Part A: Minimum information of the proposed RPT, applicable to all RPTs:

A(1): Basic details of the related party

Sr. No.	Particulars	Information provided by the management
1.	Name of the related party	Ipca Laboratories Limited
2.	Country of incorporation of the related party	India
3.	Nature of business of the related party	Ipca is a leading research driven global Indian pharmaceutical company, with its Active Pharmaceutical Ingredients (APIs) and formulations being marketed in India and over 100 other countries across the globe.

A(2): Relationship and ownership of the related party

Sr. No.	Particulars	Information provided by the management
1.	Relationship between the listed entity/ subsidiary (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	The Company and Ipca Laboratories Ltd. both are promoted by the same promoter group.
2.	Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party.	The Company holds 960 equity shares (0.00%) in the paid-up equity share capital of Ipca Laboratories Ltd. Ipca Laboratories Ltd. does not hold any equity shares of the Company.
3.	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary).	Not Applicable
4.	Shareholding of the related party, whether direct or indirect, in the listed entity/ subsidiary (in case of transaction involving the subsidiary).	Ipca Laboratories Ltd. does not hold any shares of the Company.

A(3): Details of previous transactions with the related party

Sr. No.	Particulars	Information provided by the management		
		#	Nature of Transactions	FY 2024-25 (₹ Crs)
1.	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year.			
		1.	Sale/Purchase of goods or services/ product development charges/ reimbursement of expenses/ common services/ supplier advance/rent payment/ interest payment, etc.	₹ 32.23 (include sale of office building at Mumbai : ₹ 18.50 crores)
2.	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought. The Company had obtained shareholders' approval for FY 2025-2026			
		1.	Sale/Purchase of goods or services/ product development charges/ reimbursement of expenses/ common services/ supplier advance/rent payment/ interest payment, etc.	Not Applicable This Notice is dated 26 th May, 2026
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year.	None		

A(4): Amount of the proposed transactions

Sr. No.	Particulars	Information provided by the management		
		#	Nature of Transactions	FY 2025-26 (₹ Crs)
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.			
		1.	Sale/Purchase of goods or services/product development charges/ reimbursement of expenses/ common services/payment of rent/payment for contract manufacturing, etc.	30.00
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes		

Sr. No.	Particulars	Information provided by the management								
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	21.08%								
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable								
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available	0.31%								
6.	Financial performance of the related party for the immediately preceding financial year (FY 2025-26):	<table border="1"> <thead> <tr> <th>Ipca Laboratories Ltd. (Consolidated)</th> <th>FY 2025-26 (₹ Crs)</th> </tr> </thead> <tbody> <tr> <td>Turnover</td> <td>9,821</td> </tr> <tr> <td>Profit After Tax</td> <td>1,191</td> </tr> <tr> <td>Net worth</td> <td>9,524</td> </tr> </tbody> </table>	Ipca Laboratories Ltd. (Consolidated)	FY 2025-26 (₹ Crs)	Turnover	9,821	Profit After Tax	1,191	Net worth	9,524
Ipca Laboratories Ltd. (Consolidated)	FY 2025-26 (₹ Crs)									
Turnover	9,821									
Profit After Tax	1,191									
Net worth	9,524									

A(5): Basic details of the proposed transaction

Sr. No.	Particulars	Information provided by the management
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	<ol style="list-style-type: none"> 1. sale/purchase of goods or services 2. reimbursement of expenses/product development charges 3. lease and license in furtherance of business 4. transfer of any resources, services or obligations to meet its business objectives/requirements 5. conversion of materials on job work basis, contract manufacturing services 6. common services on pro-rata basis 7. advances against supplies, if necessary, and such other transactions for the furtherance of the business
2.	Details of each type of the proposed transaction	As mentioned in A(4) above

Sr. No.	Particulars	Information provided by the management	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	For a period of one year from 1st April, 2026 to 31st March, 2027.	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	These transactions are proposed to be entered during FY 2026-27 upto maximum aggregate amount of 30 crores.	
6.	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	Same as provided above	
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.	The promoters of the Company are also the promoters of Ipca Laboratories Ltd.	
a.	Name of the director / KMP of the Company and Related Party who may be concerned/deemed to be concerned, directly or indirectly, in the proposed transactions	Makers Laboratories Ltd.	Ipca Laboratories Ltd.
		Mr. Prashant Godha, Director	Mr. Premchand Godha, Executive Chairman Mr. Pranay Godha, Managing Director/CEO Mr. Prashant Godha, Executive Director
b.	Shareholding of the director / KMP, whether direct or indirect, in the related party	Mr. Prashant Godha, Director of the Company is part of the Promoter group of the related party, Ipca Laboratories Ltd. He along with his family members and companies owned by them (Promoter Group) holds 36.73% in the paid-up equity share capital of Ipca Laboratories Ltd. The Promoter Group also holds 58.78% in the paid-up equity share capital of the Company. Their interest or concern or that of their relatives in the proposed transactions is limited only to the extent of their directorship/shareholding in the Company and in the related party.	
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	Not Applicable	
9.	Other information relevant for decision making	None	

Part B: Details for specific transactions

B(1): Sale, purchase or supply of goods or services, contract manufacturing, loan licence manufacturing, product development or any other similar business transaction and related trade advances

Sr. No.	Particulars	Information provided by the management
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	<p>Ipca Laboratories Ltd. (Ipca), the related party is marketing its pharmaceutical products to more than 100 countries across the globe including India. Ipca is engaged in highly regulated business of manufacturing/marketing of pharmaceuticals. In this business, it is not possible to change the approved/registered source of formulations/materials as the same are approved/registered by the regulatory authorities from different countries. Ipca markets, inter-alia, eye drops and injectables manufactured by the Company within India and other Rest of the World markets, mostly in its own brand name and sources such products which are developed/manufactured by the Company and registered with the regulatory authorities. It is also important in the pharmaceutical business to maintain confidentiality/intellectual property rights. Considering the above, bidding or other process is generally not feasible and alternative method (for instance cost-plus mark-up) is considered.</p> <p>Transactions are on arm's length basis and in the ordinary course of business as well as in compliance with transfer pricing norms with terms and conditions that are generally prevalent in the industry segments that both the companies operates in.</p>
2.	Basis of determination of price	As mentioned in (1) above.
3.	<p>In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:</p> <p>a. Amount of Trade advance</p> <p>b. Tenure</p> <p>c. Whether same is self-liquidating?</p>	Not applicable

B(7): Transactions relating to payment of royalty

Sr. No.	Particulars	Information provided by the management
1.	Purpose for which royalty is proposed to be paid to the related party in the current financial year.	
	a. For use of brand name / trademark	Not Applicable
	b. For transfer of technology know-how	Not Applicable
	c. For professional fee, corporate management fee or any other fee	Not Applicable
	d. Any other use (specify)	Not Applicable
2.	a. The listed entity may confirm whether the parent company charges royalty at a uniform rate from all group companies in other jurisdiction.	No Royalty is charged and hence not Applicable.
	b. If No, furnish information below. If royalty is paid to the parent company, disclose royalty received by the parent company from group entities in other jurisdiction: <ul style="list-style-type: none"> • Minimum rate of royalty charged along with corresponding absolute amount • Maximum rate of royalty charged along with corresponding absolute amount 	Not Applicable.
3.	Sunset Clause for Royalty payment, if any.	Not Applicable

Part C: Details for specific transactions

Information to be provided only if a specific type of RPT mentioned below proposed to be undertaken is a material RPT and is in addition to Part A and B

C(6): Disclosure only in case of transactions relating to payment of royalty

Sr. No.	Particulars	Information provided by the management		
1.	Gross amount of royalty paid by the listed entity or subsidiary to the related party during each of the last three financial years	Not Applicable		
	FY 2023-24			
	FY 2024-25			
	FY 2025-26			
2.	Purpose for which royalty was paid to the related party during the last three financial years.	Not applicable		
	a. For use of brand name / trademark			
	b. For transfer of technology know-how			
	c. For professional fee, corporate management fee or any other fee			
3.	Royalty paid in last 3 FYs as % of Net Profits of previous FYs	Not Applicable		
	FY 2023-24			
	FY 2024-25			
	FY 2025-26			
4.	Percentage or Rate at which royalty has increased in the past 3 years, if any, vis-à-vis rate at which the turnover and profits after tax have increased during the same period.	Not Applicable		
5.	<p>Peer Comparison: Listed entity or its subsidiary paying royalty for any purpose shall also disclose whether any relevant Industry Peer pays royalties for the same purpose, which is disclosed in its audited annual financial statements for the relevant period:</p>			
		Listed Entity / Subsidiary	Peer 1	Peer 2
	Royalty payment over last 3 years	Aggregate amount	Aggregate amount	Aggregate amount
	Royalty paid as a % of net profits over the last 3 years	Not applicable	Not applicable	
	Annual growth rate of Turnover over last 3 years			

The Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) is a party to the aforesaid transactions or not), shall not vote to approve resolutions under Item 3.

Except as mentioned above, none of the Directors and/ or Key Managerial Personnel of the Company and/ or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution mentioned at Item No. 3 of the Notice.

Basis the consideration and approval of the Audit Committee, the Board of Directors recommends the Ordinary Resolution forming part of Item No. 3 of the accompanying Notice for approval of the Members.

Item No. 4

The Board of Directors on the recommendation of the Audit Committee has appointed M/s Poddar & Co., Cost Accountants (Firm Registration No. 101734), as the Cost Auditors of the Company for the financial year 2026-27. A Certificate issued by the firm regarding their eligibility for appointment as Cost Auditors is available for inspection from the date of circulation of this Notice up to the date of AGM. Members seeking to inspect this certificate can send an email to Company's e mail ID investors@makerslabs.com.

As per Rule 14 of the Companies (Audit and Auditors) Rules 2014, the remuneration payable to the Cost Auditors is to be ratified by the shareholders. The Board has decided the remuneration payable to M/s Poddar & Co. as Cost Auditors as mentioned in the resolution on the recommendation of the Audit Committee. Hence this resolution is put for the consideration of the shareholders.

None of the Directors and Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in this resolution set out at Item No. 4.

The Board of Directors accordingly recommend the resolution set out at Item No. 4 of the accompanying Notice for the approval of the Members.

Registered Office:
54-D, Kandivli Industrial Estate
Kandivli (West)
Mumbai – 400 067
Tel : 022 – 28688544
E-mail: investors@makerslabs.com
Website: www.makerslabs.com
CIN: L24230MH1984PLC033389

By Order of the Board
For Makers Laboratories Limited

Piyush Ajmera
Company Secretary
ACS 58712

Mumbai
26th May, 2026

DETAILS OF DIRECTOR RETIRING BY ROTATION AND SEEKING RE-APPOINTMENT

(In pursuance of Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard – 2 on General Meetings) :

Name	Mr. Saahil Parikh
DIN	00400079
Date of Birth and Age	27 th January, 1975 / 51 years
Date of first appointment as a Director of the Company	11 th August, 2011
Qualifications	B.Sc in Bio-Chemistry / Diploma in Management Studies
Expertise in specific functional areas	Research & Development, Technical, Manufacturing & Marketing, Commercial, Regulatory, Finance, Legal & General Management
Terms and Conditions of appointment and re-appointment	Mr. Saahil Parikh is retiring by rotation and is seeking re-appointment as a Director at the ensuing Annual General Meeting. He is also appointed as the Wholetime Director by the shareholders for a period of 3 (three) years from 11.08.2023 to 10.08.2026.
Details of Annual Remuneration last drawn including benefits	Rs. 73.34 Lacs
Details of Remuneration sought to be paid	This is re-appointment of Director retiring by rotation.
Number of Board meetings attended during the Financial Year 2025-26	5 out of 5 meetings held
Directorships held in other companies	None
Listed Entities from which he/she has resigned as Director in past 3 years	None
Memberships / Chairmanships of committees of other companies (excluding foreign companies)	None
Number of Equity Shares held in the Company	21,741

DIRECTORS' REPORT

TO THE MEMBERS

Your Directors have pleasure in presenting the 41st Annual Report and Financial Statements for the year ended 31st March, 2026.

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

	STANDALONE		CONSOLIDATED	
	For the year ended 31.3.2026 (₹Lacs)	For the year ended 31.3.2025 (₹Lacs)	For the year ended 31.3.2026 (₹Lacs)	For the year ended 31.3.2025 (₹Lacs)
Total Income	5094.01	5386.81	14230.44	13263.76
Profit / (Loss) before finance cost, depreciation and taxation	132.34	871.48	1644.82	2027.25
Finance Cost	53.07	93.98	77.12	128.50
Depreciation & Amortisation	280.40	284.64	452.77	478.59
Exceptional items – Income / (Expenses)	-	-	-	(79.10)
Profit / (Loss) before tax	(201.13)	492.86	1114.93	1341.06
Tax Expense	(29.15)	28.75	328.85	250.31
Net Profit / (Loss) after Tax	(171.98)	464.11	786.08	1090.75
Less : Share of non-controlling interest	-	-	(550.95)	(341.68)
Profit for the period attributable to owners of the Company	-	-	235.13	749.07

TRANSFER TO RESERVES

The Company does not propose to transfer any amount to the general reserve.

FINANCIAL STATEMENTS

The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

In accordance with Indian Accounting Standard (Ind AS-110), the audited consolidated financial statements are also provided in the Annual Report.

CREDIT RATING

CARE Ratings has assigned the following ratings to the Company's long term bank facilities of ₹ 8.00 crores CARE BBB+; Stable (Re-affirmed).

MANAGEMENT DISCUSSION AND ANALYSIS**(a) Financial Performance and Operations Review**

On a standalone basis, the sales and other income of your Company for the financial year under report amounted to ₹ 5094.01 lacs as compared with ₹ 5386.81 lacs for the previous year, de-growth of 5%.

On a standalone basis, the operations have resulted in a profit of ₹ 132.34 lacs before interest, depreciation and taxation as compared to a profit of ₹ 871.48 lacs in the previous financial year. After providing for depreciation, finance cost and tax expense, the standalone operations of the Company have resulted in a net loss of ₹ 171.98 lacs as compared to a net profit of ₹ 464.11 lacs in the previous financial year.

On a consolidated basis, sales and other income for the financial year under report amounted to ₹ 14230.44 lacs as compared to 13263.76 lacs in the previous financial year, a growth of 7%. The consolidated operations have resulted in a net profit (after share of non-controlling interest) of ₹ 235.13 lacs as compared to a net profit (after share of non-controlling interest) of ₹ 749.07 lacs in the previous financial year.

The financial figures for the financial year under report and that of the previous financial year are not strictly comparable. The operations of the previous financial year include other income and profit made on sale of Company's office premises situated at Mumbai for a consideration of ₹ 1850.00 lacs.

Your Company markets generic formulations in the Indian market and also manufactures liquid injectables on contract manufacturing basis. Your Company also manufactures ophthalmic eyedrops for the domestic and ROW markets. The generic formulations are mainly used by the dispensing doctors, nursing homes and hospitals. Due to lower prevalence of acute diseases in the country during the financial year under report, there was lower growth in the Company's generic business. The demand for the liquid injectables manufactured by your Company was also lower in the financial year under report due to above reason.

The depreciation charges, finance cost and other overheads relating to new ophthalmic eye drops manufacturing facility of your Company situated at GIDC, Naroda, Ahmedabad, Gujarat, which was commercialised in the later part of the financial year 2020-21, impacted the profitability of the Company in the financial year under report. This manufacturing unit, apart from manufacturing few products commercially for the Indian market has also started manufacturing few eye drops for the Eurasia market in the later part of the financial year under report. Few more product dossiers of the Company that were filed in the earlier financial years are under registration process in the ROW markets. Your Company is also in the process of development of more ophthalmic eye drops for the Indian as well as Rest of the World (ROW) markets. Product development, submission and dossier registration by regulatory authorities is a lengthy and time consuming procedure.

As the commercial production from this new manufacturing unit gradually increases, post commercialisation of more products for the India and ROW markets, the same shall result in improved financials of this manufacturing unit as well as that of the Company.

During the year, the Company added few generic formulations in the market place as well as increased its geographical coverage in the country through appointment of new distributors.

Key Financial Ratios

		31 st March, 2026	31 st March, 2025
1.	Debtors Turnover Ratio	8.13	7.25
2.	Inventory Turnover Ratio	2.92	2.56
3.	Interest Coverage Ratio	2.49	9.27
4.	Current Ratio	1.13	1.19
5.	Debt Equity Ratio	0.07	0.03
6.	Operating Profit Margin (%)	2.60	16.18
7.	Net Profit Margin (%)	(3.38)	8.62
8.	Return on Net Worth	(3.16)	8.28

Due to lower business and losses incurred during the financial year on a standalone basis, there is deterioration in several of the key financial ratios including profitability ratios in the financial year under report vis-a-vis that of previous financial year.

(b) Opportunities, Threats, Risk and Concerns

The Indian generic formulations market is currently in the growth phase. It is expected that use of generic formulations will gradually increase in India. However, cut throat competition, quality issues of generics manufactured in the country and non existence of organised generic formulations distribution and retailing system are the few causes of concern that is hampering the growth of generic formulations market in the country.

During the year under report, there was no change in the nature of the Company's business.

(c) Internal Control Systems

The Company has an adequate internal control system including suitable monitoring procedures commensurate with its size and the nature of the business. The internal control systems provide for all documented policies, guidelines, authorisation and approval procedures. The statutory auditors while conducting the statutory audit, review and evaluate the internal controls and their observations are discussed with the Audit Committee of the Board.

(d) Human Resources

Your Company continued to have cordial and harmonious relations with its employees at all levels.

Your Company has adopted quality culture across the organisation in all line and staff functions at all the locations. The quality culture has helped your Company in achieving productivity improvement, cost reduction and waste elimination through employee involvement at all levels.

Your Company had 114 permanent employees as at 31st March, 2026.

(e) Cautionary Statement

Certain statements in the Management Discussion and Analysis may be forward looking within the meaning of applicable securities laws and regulations and actual results may differ materially from those expressed or implied. Factors that would make differences to Company's operations include competition, price realisation, changes in government policies and regulations, tax regimes and economic development within India.

MATERIAL CHANGES AND COMMITMENTS AFTER THE END OF THE FINANCIAL YEAR

No material changes or commitments affecting the financial position of the Company have occurred between the end of the financial year to which financial statements in this report relate and the date of this report.

SHARE CAPITAL

The paid-up equity share capital of the Company as at 31st March, 2026 is ₹ 590.04 lacs. The Company currently has no outstanding shares issued with differential rights, sweat equity or ESOS.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

Your Company has defacto control over the affairs of M/s. Resonance Specialties Ltd., a listed entity with 45.48% shareholding in the said company. Therefore, the Company treats Resonance Specialties Ltd. as its subsidiary.

During the financial year under report, this subsidiary achieved a total income of ₹ 9199.93 Lacs (previous financial year ₹ 7878.69 lacs) and net profit of ₹ 1039.58 lacs (previous financial year ₹ 656.62 lacs).

RESEARCH & DEVELOPMENT

During the year under report, the Company has spent an amount of ₹ 21.27 lacs as R&D expenditure (0.42% of the turnover) as against ₹ 12.20 lacs spent in the previous financial year (0.28% of the turnover).

DIVIDEND

In view of the losses incurred in the standalone financials, the Board of Directors do not recommend any dividend for the financial year under report.

INVESTORS EDUCATION AND PROTECTION FUND (IEPF)

The Company has transferred to the Investors Education and Protection Fund (IEPF) all the unpaid dividend amount required to be so transferred on or before the due date for such transfer. The Company has also transferred to IEPF, such of the Company's equity shares in respect of which the dividend declared has not been paid or claimed for seven consecutive years.

The details of the unpaid / unclaimed dividend for the last seven financial years are available on the website of the Company (www.makerslabs.com).

The Company has appointed the Company Secretary as its nodal officer under the provisions of IEPF.

DIRECTORS

Mr. Saahil Parikh retires as a director by rotation at the ensuing Annual General Meeting and, being eligible, offers himself for re-appointment.

The shareholders have approved the appointment of Ms. Dipti Shah as Independent director for a second term of five years w.e.f 29th January, 2023, Mr. R. K. P. Verma as Independent Director for a second term of five years w.e.f 13th February, 2024 and Mr Vishal Jain as Independent Director for a second term five years w.e.f. 4th November, 2025.

Terms and conditions of their appointment as Independent Directors have been disclosed on the website of the Company www.makerslabs.com.

The shareholders have also approved the appointment of Mr. Prashant Godha as Non-Executive, Non-Independent Director of the Company liable to retire by rotation with effect from 4th November, 2020.

The Shareholders of the Company have approved the re-appointments of Mr. Saahil Parikh as the Whole-time Director for a further period of 3 years w.e.f. 11th August, 2023 and that of Mr. Nilesh Jain as the Whole-time Director for a further period of 3 years w.e.f. 13th February, 2025.

Mr. R. K. P. Verma, Ms. Dipti Shah and Mr. Vishal Jain who are independent directors have submitted declaration that each of them meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and SEBI (LODR) Regulations and there has been no change in the circumstances which may affect their status as independent directors during the year.

None of the directors of the Company are debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.

In the opinion of the Board, the independent directors possess appropriate balance of skills, experience and knowledge, as required.

A brief note on Director retiring by rotation and eligible for re-appointment is furnished in the Report on Corporate Governance, annexed herewith.

KEY MANAGERIAL PERSONNEL (KMP)

During the financial year under report, the following persons continue to be the Key Managerial Personnel of the Company:

Mr. Saahil Parikh	-	Wholetime Director / CEO
Mr. Nilesh Jain	-	Wholetime Director
Mr. Sandeep Kadam	-	Sr. Manager – Accounts / CFO
Ms. Piyush Ajmera	-	Company Secretary

POLICY ON DIRECTORS' APPOINTMENT, REMUNERATION AND OTHER DETAILS

The Nomination and Remuneration Committee has laid down the criteria for Directors' appointment and remuneration including criteria for determining qualifications, positive attributes and independence of a Director. The following attributes/criteria for selection have been laid by the Board on the recommendation of the Committee:

- the candidate should possess the positive attributes such as leadership, entrepreneurship, industrialist, business advisor or such other attributes which in the opinion of the Committee the candidate possess and are in the interest of the Company;
- the candidate should be free from any disqualifications as provided under Sections 164 and 167 of the Companies Act, 2013;
- the candidate should meet the conditions of being independent as stipulated under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 in case of appointment as an independent director; and
- the candidate should possess appropriate educational qualification, skills, experience and knowledge in one or more fields of finance, law, management, sales, marketing, administration, research, corporate governance, technical operations, infrastructure, medical, social service, professional teaching or such other areas or disciplines which are relevant for the Company's business.

BOARD EVALUATION

The Nomination and Remuneration Committee lays down the criteria for performance evaluation of independent directors, Board of Directors and Committees of the Board. The criteria for performance evaluation is based on the various parameters like attendance and participation at meetings of the Board and Committees thereof, contribution to strategic decision making, review of risk assessment and risk mitigation, review of financial statements, business performance and contribution to the enhancement of brand image of the Company.

The Board has carried out evaluation of its own performance as well as that of the Committees of the Board and all the Directors.

PROFICIENCY OF DIRECTORS

All the Independent Directors of the Company have registered their names in the database maintained by the Indian Institute of Corporate Affairs, Manesar. Those Independent Directors who are not otherwise exempted have appeared and passed the common proficiency test conducted by the said institute within the prescribed time.

REMUNERATION POLICY

The objective and broad framework of the Company's Remuneration Policy is to consider and determine the remuneration, based on the fundamental principles of payment for performance, potential and growth. The Remuneration Policy reflects on certain guiding principles of the Company such as aligning remuneration with the longer term interests of the Company and its shareholders, promoting a culture of meritocracy and creating a linkage to corporate and individual performance and emphasising on line expertise and market competitiveness so as to attract the talent. The Nomination and Remuneration Committee recommends the remuneration of Directors and Key Managerial Personnel, which is approved by the Board of Directors, subject to the approval of shareholders, where necessary. The level and composition of remuneration shall be reasonable and sufficient to attract, retain and motivate the directors, key managerial personnel and other employees of the quality required to run the Company successfully. The relationship of remuneration to performance should be clear and meet appropriate performance benchmarks. The remuneration to directors, key managerial personnel and senior management personnel should also involve a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company and its goals. The Remuneration Policy is placed on the Company's website www.makerslabs.com.

Information about elements of remuneration package of individual directors is provided in the Annual Return as provided under Section 92(3) of the Companies Act, 2013 which is placed on the website of the Company.

FAMILIARISATION PROGRAM FOR INDEPENDENT DIRECTORS

Details of the familiarisation program of independent directors are disclosed on the website of the Company www.makerslabs.com.

MEETINGS OF THE BOARD AND COMMITTEES THEREOF

This information has been furnished under Report on Corporate Governance, which is annexed.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- i) that in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- ii) that your Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year March 31, 2026 and of the loss of the Company for the financial year on a standalone basis;

- iii) that your Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv) that your Directors have prepared the annual accounts on a going concern basis;
- v) that your Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and
- vi) that your Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CORPORATE GOVERNANCE

As per the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has complied with the requirements of Corporate Governance in all material aspects.

A report on Corporate Governance (Annexure 1) together with a certificate of its compliance from the Practising Company Secretary, forms part of this report.

FIXED DEPOSITS

Your Company has not accepted any deposits from the public during the year under review and as such no amount of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

AUDIT COMMITTEE

Details of the Audit Committee along with its constitution and other details are provided in the Report on Corporate Governance.

AUDITORS, AUDIT REPORT AND AUDITED ACCOUNTS

M/s. N V C & Associates LLP, Chartered Accountants (Firm Registration No. 106971W / W101085) were re-appointed as the Statutory Auditors to carry out statutory audit activities of the Company for a further period of 5 (five) years from the conclusion of the 37th AGM of the Company and till completion of 42nd Annual General Meeting of the Company and this appointment was approved by the shareholders of the Company at the 37th Annual General Meeting of the Company held on 12th August, 2022.

The Auditors' Report read with the notes to the accounts referred to therein are self-explanatory and therefore, do not call for any further comments. There are no qualifications, reservations or adverse remarks made by the Auditors.

COST AUDIT

Pursuant to the provisions of Section 148 of the Companies Act, 2013, M/s Poddar & Co., Cost Accountants (Firm Registration No. 101734) were appointed as the Cost Auditors of the Company for the financial year 2025-26.

The Cost Audit Report for the financial year 2024-25, which was due to be filed with the Ministry of Corporate Affairs by 6th September, 2025 was filed on the 5th September, 2025.

The Company has maintained the cost accounts and cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013.

SECRETARIAL AUDIT

Pursuant to the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013, M/s. Parikh & Associates, Practising Company Secretaries are appointed as the Secretarial Auditors for auditing the secretarial records of the Company.

The Secretarial Auditors' Report is annexed hereto. There are no qualifications, reservations or adverse remarks made by the Secretarial Auditors.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The provisions of Section 135 of the Companies Act, 2013 pertaining to Corporate Social Responsibility (CSR) is not applicable to the Company.

SAFETY, ENVIRONMENT AND HEALTH

The Company considers safety, environment and health as the management responsibility. Regular employee training programmes are carried out in the manufacturing facility on safety and environment.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

The Company has not given any loans or guarantees or made investments in contravention of the provisions of the Section 186 of the Companies Act, 2013. The details of the loans and guarantees given and investments made by the Company are provided in the notes to the financial statements.

RELATED PARTY TRANSACTIONS

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of Company's business.

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company https://www.makerslabs.com/pdf/Corporate_Policy/Related_Party_Transactions.pdf.

All the related party transactions are placed before the Audit Committee as well as the Board for approval on a quarterly basis. Omnibus approval was also obtained from the Audit Committee on an annual basis for repetitive transactions. Approval of the shareholders is also obtained, wherever necessary, in this regard.

Related party transactions are disclosed in the notes to the financial statements. Prescribed Form No. AOC-2 pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014 is furnished as Annexure 2 to this report.

PARTICULARS OF EMPLOYEES

The information required pursuant to Section 197 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the names and other particulars of the employees drawing remuneration and other details as set out in the said rules are provided as an Annexure 3 in this annual report. The Company had no employee drawing remuneration in excess of the amount as mentioned under Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The necessary information in respect of top 10 employees of the Company in terms of remuneration drawn is furnished in Annexure.

However, having regard to the provisions of the first proviso to Section 136(1) of the Act and as advised, the Annual Report excluding the aforesaid information under Explanation (2) to the above Rule is being sent to the members of the Company. The said information is available for inspection at the registered office of the Company during working hours excluding Saturdays and any member interested in obtaining such information may write to the Company Secretary and the same will be furnished on request.

CODE OF CONDUCT

The Board has laid down a code of conduct for Board members and senior management personnel of the Company. The code also incorporates the duties of independent directors as laid down in the Companies Act, 2013. The said code of conduct is posted on Company's website www.makerslabs.com. The Board members and senior management personnel have affirmed compliance with the said code of conduct. A declaration signed by the Wholetime Director / CEO is given at the end of this Report.

WHISTLE BLOWER POLICY / VIGIL MECHANISM

There is a Whistle Blower Policy in the Company and no personnel has been denied access to the Chairman of the Audit Committee. The policy provides for adequate safeguards against victimization of persons who use vigil mechanism. The Whistle Blowing Policy is posted on the website of the Company www.makerslabs.com.

PREVENTION OF INSIDER TRADING

The Board has adopted a Code of Prevention of Insider Trading based on the SEBI (Prohibition of Insider Trading) Regulations, 2015. The same has been placed on the website of the Company www.makerslabs.com.

All the Directors, senior management employees and other employees who have access to the unpublished price sensitive information of the Company are governed by this code. During the year under Report, there has been due compliance with the said code of conduct for prevention of insider trading.

CONSTITUTION OF COMMITTEE UNDER SEXUAL HARRASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has adopted a policy in line with the requirements of Prevention of Sexual Harassment of Women at the Workplace and a Committee has been set-up to redress sexual harassment complaints received, if any.

During the financial year under report, no complaint was received by this Committee.

BUSINESS RISK MANAGEMENT

Pursuant to the provisions of Section 134 of the Companies Act, 2013, the Company has constituted a Risk Management Committee. The details of the Committee and its terms of reference are provided in the Report on Corporate Governance, which is annexed.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant or material orders passed by any regulator, tribunal or court that would impact the going concern status of the Company and its future operations.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

In accordance with the requirements of Section 134 of the Companies Act, 2013, statement showing particulars with respect to conservation of energy, technology absorption and foreign exchange earnings and outgo is furnished as Annexure 4 to this report.

ANNUAL RETURN

In accordance with the requirements of Section 92 (3) of the Companies Act, 2013 and Rule 12 (1) of the Companies (Management and Administration) Rules, 2014, a copy of Annual Return in Form MGT-7 is placed on the website of the Company.

SECRETARIAL STANDARDS

The Company has complied with all the applicable Secretarial Standards.

ACKNOWLEDGEMENT

Your Directors place on record their appreciation for the co-operation and support extended to the Company by its bankers. Your Directors also place on record their appreciation of the continued hard work put in by employees at all levels.

For and on behalf of the Board

Mumbai
26th May, 2026

R. K. P. Verma
Chairman

ANNEXURE 1

REPORT ON CORPORATE GOVERNANCE

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, given below is a report on the Corporate Governance in the Company:

1. Company's philosophy on Code of Corporate Governance is to ensure :

- i) that the Board and top management of the Company are fully apprised of the affairs of the Company that is aimed at assisting them in the efficient conduct of the Company's business so as to meet Company's obligation to the stakeholders.
- ii) that the Board exercises its fiduciary responsibilities towards shareholders and creditors so as to ensure high accountability.
- iii) that all disclosure of information to present and potential investors are maximised.
- iv) that the decision making process in the organisation is transparent and are backed by documentary evidences.
- v) The Company is in compliance with the requirements stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to Corporate Governance.

2. Board of Directors

a) Composition and Category of directors

The present strength of the Board of Directors of the Company is 6 directors of which 2 are professional Non-Promoter Whole-time Directors, 1 Non-Executive, Non-Independent, Promoter Director and 3 Directors who are Non-Executive Independent Directors (including one woman director) comprising of at least one half of the total strength of the Board with independent judgment in the deliberation and decisions of the Board. The Chairman of the Board is an Independent Director.

b) Details of attendance of each director at the meeting of the board of directors and the last annual general meeting and shareholding held by them in the Company

Name of the Director	Category	No. of board meetings		Attendance at last AGM (8.8.2025)	No. of Equity shares held in the Company **
		Held	Attended		
Mr. R. K. P. Verma (DIN 02166789)	Chairman, Non-Executive Independent Director	5	5	Yes	Nil
Ms. Dipti Shah (DIN 07995542)	Non-Executive Independent Director	5	5	Yes	Nil
Mr. Vishal Jain (DIN 00137986)	Non-Executive Independent Director	5	5	Yes	7,874
Mr. Prashant Godha (DIN 00012759)	Non-Executive, Non-Independent Promoter Director	5	5	Yes	1,22,937
Mr. Saahil Parikh (DIN 00400079)	Executive, Non Independent Director	5	5	Yes	21,741
Mr. Nilesh Jain (DIN 05263110)	Executive, Non Independent Director	5	5	Yes	Nil

**The above shareholding as at 31st March, 2026 is in respect of shares which are held by Directors as a first holder and in which shares they have beneficial interest.

c) Number of other companies or committees in which the Director is Member or Chairperson

Name of Director	No. of other companies in which Director (including private companies)	No. of committees in which Member (other than Makers)	No. of committees of which he/she is Chairman (other than Makers)
Mr. R. K. P. Verma	5	3	2
Ms. Dipti Shah	1	2	None
Mr. Vishal Jain	1	None	None
Mr. Prashant Godha	7	1	None
Mr. Saahil Parikh	None	None	None
Mr. Nilesh Jain	1	None	None

Chairmanship and Membership of Audit Committee and Stakeholders Relationship Committee are only considered.

Mr. R. K. P. Verma is an Independent Director on the Board of Directors of M/s. Resonance Specialties Ltd., a listed entity. He is the Chairman of the Board of Directors, Audit Committee and CSR Committee of the Board of Directors of M/s. Resonance Specialties Ltd. He is also a member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee of the said Company.

He has retired as the Independent Director from the Board of Krebs Biochemicals and Industries Limited, a listed entity upon completion of his 2nd term of 5 consecutive years as an Independent Director of the said company.

Ms. Dipti Shah is an Independent Director on the Board of Directors of M/s. Krebs Biochemicals & Industries Ltd., a listed entity. She is the Member of the Audit Committee, Nomination & Remuneration Committee and Stakeholders Relationship Committee of the Board of Directors of the said company.

Mr. Prashant Godha is a Director on the Board of M/s. Ipca Laboratories Ltd. (Executive Director), M/s. Lyka Labs Ltd. (Non-Executive, Non-Independent) and M/s. Resonance Specialties Ltd. (Non-Executive, Non-Independent), listed companies. He is the member of the Nomination & Remuneration Committee and Corporate Social Responsibility Committee of the Board of Directors of M/s. Resonance Specialties Ltd. He is also a Member of Audit Committee, Corporate Social Responsibility Committee and Risk Management Committee of the Board of Directors of M/s. Ipca Laboratories Ltd.

Mr. Nilesh Jain is a Director on the Board of M/s. Resonance Specialties Ltd. (Non-Executive, Non-Independent), a listed company.

None of the other Directors of the Company are on the Board of Directors of any listed company.

None of the Directors on the Board is a Member of more than ten (10) Committees and Chairperson of more than five (5) Committees [Committees being Audit Committee and Stakeholders Relationship Committee as per Regulation 26(1) of the SEBI Listing Regulations] across all the public companies in which he/she is a Director.

None of the Directors hold office in more than ten (10) public limited companies as prescribed

under Section 165(1) of the Act. No Director holds Directorships in more than seven (7) listed companies. None of the Non-Executive Director is an Independent Director in more than seven (7) listed companies as required under the SEBI Listing Regulations. Further, the Wholetime Director & CEO does not serve as an Independent Director in any listed company.

Every Director informs the Company about the Committee positions he or she occupies in the other listed entities and any changes in them as and when they take place, if any.

d) Number of meetings of the board of directors held during the financial year 2025-26 and dates on which held

5 (Five) board meetings were held during the Financial Year 2025-26. The dates on which the said meetings were held are as follows:

18 th April, 2025	26 th May, 2025	8 th August, 2025
7 th November, 2025	10 th February, 2026	

The last Annual General Meeting of the Company was held on 8th August, 2025.

e) Disclosure of relationships between directors inter-se

None of the Directors are related to each other.

f) Number of shares and convertible instruments held by Non-Executive Directors

This information about number of shares held by Non-Executive Directors in the Company is given in table above. None of the Directors hold any convertible instruments of the Company.

g) Web link where details of familiarisation programmes imparted to independent directors is disclosed

The Company has conducted familiarisation programs for the Independent Directors with regards to their role, rights and responsibilities as Independent Directors. The Independent Directors are also regularly briefed on the nature of the pharmaceuticals industry and the Company's business model. The familiarisation programs have been uploaded on the website of the Company at <http://www.makerslabs.com/pdf/appoinment/Familiarisation-Programs-for-2025-26.pdf>.

h) A chart or a matrix setting out the skills / expertise / competence of the board of directors

The Board considers that the following core skills / expertise / competence of the Board of Directors are required in the context of its business and its sector for it to function effectively: research & development, technical, manufacturing, marketing, commercial, regulatory, finance, legal and general management.

In the opinion of the Board, these skills / expertise / competence are actually available with its Board of Directors.

Skills / Expertise / Competence of the Board of Directors that are required in the context of business of the Company	Names of the Directors who have such skills / expertise / competence
Research & Development	Mr. Saahil Parikh
Technical	Mr. Saahil Parikh
Manufacturing & Marketing	Mr. Saahil Parikh Mr. Nilesh Jain Mr. R. K. P. Verma Mr. Vishal Jain Mr. Prashant Godha

Skills / Expertise / Competence of the Board of Directors that are required in the context of business of the Company	Names of the Directors who have such skills / expertise / competence
Commercial	Mr. Saahil Parikh Mr. Nilesh Jain Mr. R. K. P. Verma Mr. Vishal Jain
Regulatory	Mr. Saahil Parikh
Finance	Mr. Saahil Parikh Mr. Nilesh Jain Mr. R. K. P. Verma Ms. Dipti Shah Mr. Vishal Jain Mr. Prashant Godha
Legal And General Management	Mr. Saahil Parikh Mr. Nilesh Jain Mr. R. K. P. Verma Mr. Prashant Godha Ms. Dipti Shah Mr. Vishal Jain

i) Confirmation that in the opinion of the board, the independent directors fulfill the conditions specified in these regulations and are independent of the management.

It is confirmed that in the opinion of the Board, the Independent Directors fulfill the conditions specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are independent of the management.

j) Detailed reasons for the resignation of any independent director who resigns before the expiry of his tenure along with a confirmation by such director that there are no other material reasons other than those provided

During the financial year under report, none of the Independent Directors have resigned from the Board of Directors of the Company.

3. Audit Committee

a) Brief description of terms of reference

The terms of reference to this Committee, inter-alia, covers all the matters specified under Section 177 of the Companies Act, 2013 and also all the matters listed under Part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 such as oversight of the Company's financial reporting process; recommending the appointment/re-appointment, remuneration and terms of appointment of statutory auditors; review and monitor the Auditors independence and performance and effectiveness of audit process; approval of transactions with related parties; sanctioning of loans and investments; evaluation of internal financial control and risk management system; reviewing with the management annual financial statements and Auditors report thereon; quarterly financial statements and other matters as covered under role of Audit Committee in Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee has powers, inter-alia, to investigate any activity within its terms of reference and to seek information from any employee of the Company as well as seek outside legal and professional advice.

The Audit committee reviews all the information that is required to be mandatorily reviewed by it under the corporate governance.

b) Composition, name of members and chairperson

The Audit Committee of the Company currently comprises of Mr. Vishal Jain, Chairman of the Committee, Mr. R. K. P. Verma and Ms. Dipti Shah, all being Independent Directors with independent judgment in the deliberation and decisions of the Board as well as Audit Committee and Mr. Nilesh Jain, Wholetime Director. All members of the Audit Committee have knowledge on financial matters and ability to read and understand financial statements. The Chairman of the Audit Committee is a successful entrepreneur having set-up and nurtured manufacturing units in the field of plastic household goods and ROPP closures. Mr. Saahil Parikh, Wholetime Director / CEO and Mr. Sandeep Kadam, Sr. Manager – Accounts / CFO who is in-charge of Finance function of the Company along with Statutory Auditors, Internal Auditors and Cost Auditors are invitees to the meetings of the Audit Committee.

Mr. Piyush Ajmera, Company Secretary is the Secretary of this Committee.

M/s. Nayan Parikh & Associates, Chartered Accountants were appointed as the Internal Auditors of the Company under the provisions of Section 138 of the Companies Act, 2013 for the financial year 2025-26.

c) Audit Committee meetings and the attendance during the financial year 2025-26

There were 5 (Five) meetings of the Audit Committee during the Financial Year 2025-26. The gap between the two meetings did not exceed 120 days. The dates on which the said meetings were held are as follows:

18 th April, 2025	26 th May, 2025	8 th August, 2025
7 th November, 2025	10 th February, 2026	

The attendance of each member of the Audit Committee in the committee meetings is given below:

Name of the Director	No. of meetings held	No. of meetings attended
Mr. Vishal Jain	5	5
Mr. R. K. P. Verma	5	5
Ms. Dipti Shah	5	5
Mr. Nilesh Jain	5	5

The previous annual general meeting of the Company was held on 8th August, 2025 and was attended by Mr. Vishal Jain, the Chairman of the Audit committee.

4. Nomination and Remuneration Committee

The terms of reference to Nomination and Remuneration Committee, inter-alia, covers all the matters specified under Section 178 of the Companies Act, 2013 read with Regulation 19 of SEBI (LODR) Regulations, 2015 and also all the matters listed under Part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations.

a) Brief description of terms of reference

- i. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to the remuneration of the directors, key managerial personnel and other employees;
- ii. for every appointment of an independent Director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare the description of role and capabilities required of an Independent Director. The person recommended to the Board for appointment as Independent Director shall have the capabilities identified in such description.

- iii. formulation of criteria for evaluation of performance of independent directors and the board of directors;
- iv. devising a policy on diversity of board of directors;
- v. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the board of directors their appointment, remuneration and removal; and
- vi. whether to extend or continue the term of appointment of the independent directors on the basis of the report of performance evaluation of independent directors.
- vii. recommend to the board remuneration payable to senior managerial personnel of the Company.

b) Composition, name of members and chairperson

The Company has a Nomination and Remuneration Committee of the Board which currently comprises of Mr. Vishal Jain, Chairman of the Committee, Mr. R. K. P. Verma and Ms. Dipti Shah, all independent directors to function in the manner and to deal with the matters specified in Part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also to review the overall compensation structure and policies of the Company to attract, motivate and retain employees.

The Nomination and Remuneration Committee has adopted the following policies which are displayed on the website of the Company:

- i. Formulation of the criteria to recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel, senior management personnel and other employees (http://www.makerslabs.com/pdf/Corporate_Policy/Remuneration_Policy.pdf).
- ii. Formulation of criteria for evaluation of Independent Directors and the Board (http://www.makerslabs.com/pdf/Corporate_Policy/Evaluation_of_Directors.pdf).
- iii. Devising a policy on Board diversity (http://www.makerslabs.com/pdf/Corporate_Policy/Policy_on_Board_Diversity_of_the_Company.pdf).
- iv. Oversee the familiarization programmes for directors (http://www.makerslabs.com/pdf/appointment/Familiarisation_Programme_for_Independent_Directors.pdf).
- v. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board their appointment and removal (https://makerslabs.com/pdf/Corporate_Policy/Criteria_for_selection_of_Candidates_for_Senior_Management_and_Members_on_the_Board.pdf).

c) Meeting and attendance during the financial year 2024-25

There were 3 (Three) meetings of this Committee during the Financial Year 2025-26. The dates on which the said meetings were held are as follows:

26 th May, 2025	8 th August, 2025
10 th February, 2026	

The attendance of each member of the Nomination and Remuneration Committee in the committee meetings is given below:

Name of the Director	No. of meetings held	No. of meetings attended
Mr. Vishal Jain	3	3
Mr. R. K. P. Verma	3	3
Ms. Dipti Shah	3	3

d) Performance evaluation criteria for Independent Directors

Performance criteria for evaluation of Independent Directors and the Board is displayed on the Company's website (weblink http://www.makerslabs.com/pdf/Corporate_Policy/Evaluation_of_Directors.pdf).

5. Remuneration of Directors

a) All pecuniary relationship or transactions of the non-executive directors vis-à-vis the listed entity shall be disclosed in the annual report

During the financial year under report, the non-executive Directors had no pecuniary relationship or transactions with the Company.

b) Criteria of making payments to non-executive directors

The non-executive Directors are paid only sitting fees and re-imburement of out of pocket expenses incurred for attending the meetings of the Board of Directors and Committees thereof.

Details of payments made to Non-Executive Directors in the Financial Year 2025-26 are as under:

Name of the Director	Sitting fees Paid (₹)	Commission paid (₹)
Mr. R. K. P. Verma	1,85,000	Nil
Ms. Dipti Shah	1,65,000	Nil
Mr. Vishal Jain	2,05,000	Nil
Mr. Prashant Godha	75,000	Nil

None of the Independent Directors have received any remuneration or commission from Company's holding or subsidiary companies except Mr. R. K. P. Verma who is a Independent Director on the Board of Company's subsidiary M/s. Resonance Specialties Ltd. and has received sitting fees from the said company for attending its Board and Committee Meetings.

c) Disclosures with respect to remuneration paid / payable to Wholetime Directors for the financial year 2025-26

i. The details of the remuneration paid/payable to Wholetime Directors for the Financial Year 2025-26 are given below

Name of Directors	Salary*	Benefits / Perquisites / Pension etc.*	Commission (performance linked)	Stock Options	Total (₹)
Mr. Saahil Parikh (Wholetime Director/CEO)	44,70,000	28,64,143	-	-	73,34,143
Mr. Nilesh Jain (Wholetime Director)	27,06,000	14,68,983	-	-	41,74,983

* Fixed Component

ii. Details of fixed component and performance linked incentives, along with the performance criteria

The required details are given in the table above.

iii. Service contracts, notice period, severance fees

The appointment of Whole-time Directors is contractual and is generally for a period of three (3) years. The Company has entered into agreement with Mr. Saahil Parikh on 22nd May, 2023 which is valid upto 10th August, 2026 and with Mr. Nilesh Jain on 23rd May, 2024 which is valid upto 12th February, 2028. Either party is entitled to terminate the agreement by giving not less than 60 days notice in writing to the other party. There is no separate provision for payment of severance fee in the agreements signed by the Company with them.

iv. Stock option details, if any and whether issued at a discount as well as the period over which accrued and over which exercisable

The Company currently has no outstanding stock options or other convertible instruments.

6. Stakeholders Relationship Committee

The terms of reference to Stakeholders Relationship Committee, inter-alia, covers all the matters specified under Section 178 of the Companies Act, 2013 read with Regulation 20 of SEBI (LODR) Regulations, 2015 and also all the matters listed under Part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations.

a) Name of Non-Executive Director heading the committee

The Stakeholders Relationship Committee currently comprises of Mr. R. K. P. Verma, Non-Executive / Independent Director, Chairman of the Committee, Mr. Vishal Jain, Non-Executive Independent Director and Mr. Saahil Parikh, Wholetime Director/CEO. This Committee functions in the manner and deals with the matters specified in Part D of Schedule II of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The committee monitors share transfers, transmissions and other shareholders related activities including redressal of investor grievances.

Meetings held and attendance during the financial year 2025-26

There was Two (2) meetings of this committee during the financial year 2025-26. The date on which the said meetings was held is as follows:

26 th May, 2025	10 th February, 2026
----------------------------	---------------------------------

The attendance of each member of the Stakeholders Relationship Committee in the committee meeting is given below:

Name of the Director	No. of meetings held	No. of meetings attended
Mr. R. K. P. Verma	2	2
Mr. Vishal Jain	2	2
Mr. Saahil Parikh	2	2

Mr. R. K. P. Verma, the Chairman of the Committee attended the last Annual General Meeting of the Company held on 8th August, 2025.

b) Name and designation of Compliance officer

Mr. Piyush Ajmera was appointed as the Company Secretary & Compliance Officer of the Company at the meeting of the Board of Directors held on 23rd May, 2024. (email id : investors@makerslabs.com / Tel : 28688544).

c) Number of shareholders' complaints received

During the year, the Company received no complaints from the shareholders.

d) Number not solved to the satisfaction of shareholders

The Company had no unattended request pending for transfer of its equity shares or any unattended complaints at the close of the financial year.

e) Number of pending complaints

Nil

7. Particulars of senior management including the changes therein since the close of previous financial year

The particulars of Senior Management Personnel (SMP) of the Company are as follows:

No.	Name	Designation	Particulars of change during the financial year
1.	Mr. Saahil Parikh	Wholetime Director/CEO	-
2.	Mr. Nilesh Jain	Wholetime Director	-
3.	Mr. Sandeep Kadam	Sr. Manager – Accounts / CFO	-
4.	Mr. Piyush Ajmera	Company Secretary	-

8. General Body Meetings

a) Details of the location and time where the last three Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) were held

AGM for the financial year ended	Day, Date & Time of AGM	Place of AGM	Special Resolutions Passed
31-3-2025	Friday, 8 th August, 2025 at 12.30 p.m.	Through Audio-Visual Means	<ul style="list-style-type: none"> Re-appointment of Mr. Vishal Jain (DIN 00137986) as Independent Director for 2nd term of five consecutive years with effect from 4th November, 2025 till 3rd November, 2030
31-3-2024	Tuesday, 6 th August, 2024 at 11.30 a.m.	Through Audio-Visual Means	<ul style="list-style-type: none"> None
31-3-2023	Monday, 14 th August, 2023 at 11.30 a.m.	Through Audio-Visual Means	<ul style="list-style-type: none"> Re-appointment of Mr. R. K. P. Verma (DIN 02166789) as Independent Director for 2nd term of five consecutive years with effect from 13th February, 2024 till 12th February, 2029 and continuation in his appointment even after his attaining age of 75 years on 22nd March, 2024

All the resolutions as set out in the respective notices calling the AGM were passed by the shareholders.

There is no proposal to pass any special resolution through postal ballot at the ensuing Annual General Meeting.

b) Whether any special resolutions passed in the previous three annual general meetings

Details of special resolutions passed in the previous three Annual General Meetings are given in the table above.

c) Whether any special resolution passed last year through postal ballot

No special resolution was passed in the last financial year using postal ballot.

d) Person who conducted the postal ballot exercise

Not Applicable

e) Whether any special resolution is proposed to be conducted through postal ballot

No special resolution is currently proposed to be conducted through postal ballot.

f) Procedure for postal ballot

Not applicable since no resolution is currently proposed to be passed through postal ballot.

9. Means of communication

- a) Quarterly / Annual Results : The results of the Company are submitted to the stock exchange where the shares of the Company are listed and published in the newspapers after the approval of the Board.
- b) Newspapers wherein results normally published : The Business Standard, Free Press Journal and Nav Shakti.
- c) Website, where displayed : www.makerslabs.com
- d) Whether website also displays official news releases : Yes
- e) Presentation made to institutional investors or to the analysts : Presentations were not made to institutional investors or analysts during the financial year 2025-26.

10. General Shareholders Information

- a) AGM : Date, Time and Venue : Friday, 7th August, 2026 at 12.30 p.m. through video conferencing / other audio visual means (VC/OAVM). Plot No. 54D, Kandivli Industrial Estate, Kandivli (West), Mumbai shall deemed to be the venue of the AGM.
- b) Financial Year : 1st April –31st March
First quarter results : first week of August*
Second quarter results : first week of November*
Third quarter results : first week of February*
Annual results : last week of May*
* tentative
- c) Dividend Payment dates : The Company has not declared any dividend for the financial year ended 31st March, 2026.
- d) Date of Book closure : Not Applicable

- e) The name and address of each stock exchange(s) at which the Company's securities are listed and a confirmation about payment of annual listing fee to each of such stock exchange(s) : • BSE Ltd. (BSE)
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 023
Listing fee has been paid to BSE for the financial year 2026-27 in April, 2026. The fees of the depositories for the financial year 2026-27 were also paid on receipt of their invoices.
- f) Stock code – Physical and ISIN : 506919 on BSE
Number for NSDL and CDSL : INE 987A01010
Corporate Identity Number allotted by Ministry of Corporate Affairs : L24230MH1984PLC033389
- g) Market price data: high, low during each month in last financial year : Please see Annexure 'A'
- h) Stock performance in comparison to BSE Sensex : Please see Annexure 'B'
- i) In case the securities are suspended from trading, the directors report shall explain the reason thereof : The securities of the Company are not suspended from trading by the Stock Exchange.
- j) Registrars and share transfer agents : MUFG Intime India Private Limited
C-101, 247 Park,
LBS Marg, Vikhroli (West)
Mumbai – 400 083
Tel. No. (022) 4918 6000
Fax. No.(022) 4918 6060
E-mail: rnt.helpdesk@in.mpms.mufg.com
Website: www.in.mpms.mufg.com
- k) Share transfer system : In terms of Regulation 40 (1) of SEBI (LODR) Regulations, as amended from time to time, securities can be transferred only in dematerialised form with effect from April 1, 2019. The requests for effecting transfer / transmission / transposition of securities shall not be processed unless the securities are held in dematerialized form. Transfer of shares in electronic form are effected through the depositories with no involvement of the Company. Members holding shares in physical form are requested to consider converting their shareholding to dematerialized form.
- l) Distribution of shareholding/ shareholding pattern as on 31.3.2026 : Please see Annexure 'C'

- m) Dematerialisation of shares and liquidity : 98.63% of the paid-up share capital has been dematerialised as on 31st March, 2026.
- n) Outstanding GDRs/ADRs/warrants/ convertible instruments, conversion date and likely impact on equity : Not applicable since none of the said instruments are ever issued.
- o) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities : The Company is not materially exposed to commodity price / foreign exchange risk. The Company also does not carry out any commodity or currency hedging activities.
- p) Plant Location : 1. Plot No. 29/3, Phase III
GIDC Industrial Estate
Naroda, Ahmedabad – 382 330
Gujarat
2. Plot No. 30/4, Phase III
GIDC Industrial Estate
Naroda, Ahmedabad – 382 330
Gujarat
- q) Address for Correspondence : Mr. Piyush Ajmera
Company Secretary & Compliance Officer
Makers Laboratories Limited
54D, Kandivli Industrial Estate
Kandivli (W), Mumbai 400 067
E-mail: investors@makerslabs.com
Tel: (022) 2868 8544
Fax: (022) 2868 8544
- r) List of all credit ratings obtained by the entity along with any revisions thereto during the relevant financial year, for all debt instruments of such entity or any fixed deposit programme or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad : CARE Ratings has assigned the following ratings to the Company's long term bank facilities of ₹ 8.00 crores (Reduced from ₹ 8.40 crores) - CARE BBB+; Stable (Re-affirmed)
- s) Share transfer and other communications may be addressed to the Registrars : MUFG Intime India Private Limited
C-101, 247 Park,
LBS Marg, Vikhroli (West)
Mumbai – 400 083
Tel. No. (022) 4918 6000
Fax. No.(022) 4918 6060
E-mail: rnt.helpdesk@ in.mpms.mufg.com

11. Other Disclosures

- a) Details of material subsidiaries of the listed entity; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries.**

The Company has a material subsidiary M/s. Resonance Specialties Ltd. (CIN L25209MH1989PLC051993) with its registered office situated at 54D, Kandivli Industrial Estate, Kandivli (West). This company was incorporated on 1st June, 1989.

M/s. Kailash Chand Jain & Co., Chartered Accountants are the statutory auditors of this company who were appointed as the Statutory Auditors by the shareholders of the Company to hold office from the conclusion of 32nd Annual General Meeting held on 26th August, 2021 till 37th Annual General Meeting of the Company to be held in the calendar year 2026.

At the meeting of the Board of Directors of the Company held on 26th May, 2026 and as recommended by the Audit Committee, M/s. Kailash Chand Jain & Co., Chartered Accountants were re-appointed as the Statutory Auditors of the Company for a second term of five years to hold office from the conclusion of 37th Annual General Meeting till conclusion of the 42nd Annual General Meeting of the company to be held in the calendar year 2031. This re-appointment is subject to the approval of the shareholders at the said company's ensuing Annual General Meeting

- b) Disclosure by listed entity and its subsidiaries of 'Loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount.**

The Company and its subsidiary have not given any loan or advances in the nature of loan to firms/companies in which directors are interested.

- c) Disclosures on materially significant related party transactions that may have potential conflict with the interest of the Company at large**

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company (Weblink https://www.makerslabs.com/pdf/Corporate_Policy/Related_Party_Transactions.pdf). There were no materially significant related party transactions during the year that may have potential conflict with the interest of the Company.

The Register of Contracts containing the related party transactions is placed before the Board and Audit Committee regularly for its approval. Disclosures from directors and senior management staff have been obtained to the effect that they have not entered into any material, financial and commercial transactions where they have personal interest that may have potential conflict with the interest of the Company at large.

Transactions with the related parties are disclosed in the notes to the accounts forming part of this Annual Report.

- d) Details of non-compliance by the Company, penalties, strictures imposed on the Company by Stock Exchange(s) or the board or any other statutory authorities on any matter related to capital market during the last 3 financial years**

None

- e) Details of establishment of vigil mechanism, whistle blower policy and affirmation that no personnel has been denied access to the audit committee**

There is a Whistle Blower Policy in the Company and that no personnel has been denied access to the Chairman of the Audit Committee. The policy provides for adequate safeguards against victimization of persons who use vigil mechanism. The Whistle Blowing Policy is posted on the website of the Company www.makerslabs.com.

f) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements;

The Company has complied with all the applicable mandatory requirements of corporate governance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details about adoption of non-mandatory requirements are given in the table below.

g) Web link where policy for determining 'material' subsidiaries is disclosed

The Board has approved a policy for determining 'material' subsidiaries which has been uploaded on the website of the Company. (Weblink https://www.makerslabs.com/pdf/Corporate_Policy/Policy_on_Material_Subsiidiaries.pdf).

h) Web link where policy on dealing with related party transactions is disclosed

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company (Weblink https://www.makerslabs.com/pdf/Corporate_Policy/Related_Party_Transactions.pdf).

i) Disclosure of commodity price risks and commodity hedging activities

The Company is engaged in the manufacturing and marketing of pharmaceuticals. Since the Company does not consume large quantities of commodities in its manufacturing activities, the Company is not materially exposed to commodity price risks nor does the Company do any commodity hedging.

j) Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)

The Company has not raised any funds through preferential allotment or through qualified institutional placement of its shares during the year.

k) A certificate from a Company Secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority

The Company has obtained a certificate in this regard from a Company Secretary in practice.

l) Where the board had not accepted any recommendation of any committee of the board which is mandatorily required, in the relevant financial year, the same to be disclosed along with reasons thereof

The Board has accepted and acted on all the mandatory recommendations of its committees during the financial year under report.

m) Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part.

The fees paid by the Company to its Statutory Auditors are stated in the appended Audited Financial Statements of the Company. The Company's deemed subsidiary has not made any payment to Company's Statutory Auditors.

n) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

Number of complaints filed during the calendar year 2025 : None
 Number of complaints disposed of during the calendar year 2025 : None
 Number of complaints pending as on end of the calendar year 2025 : None

12. Non-Compliance of any requirement of Corporate Governance Report with reasons thereof

None

13. Adoption of Discretionary Requirements

A. The Board	The Company currently has a Non-Executive Chairman of the Board of Directors. However, the Company has not maintained any office for him.
B. Shareholders Rights	At present, the Company does not send the statement of half yearly financial performance to the household of each shareholder.
C. Modified opinion(s) in audit report	The Company's financial statements are with unmodified audit opinion.
D. Reporting of internal auditor	The firm of Internal Auditors reports to the Wholetime Director / CEO as well as to the Audit Committee.
E. Independent Directors endeavour to meet twice without management	The Independent Directors have met once during the financial year.

14. The disclosures of the compliance with corporate governance requirements specified in Regulations 17 to 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46

- a) The Company has a process to provide, inter-alia, the information to the Board as specified in Part A of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to Corporate Governance. The Board also periodically reviews the compliances by the Company of all applicable laws.
- b) The Board of Directors in their meeting regularly discuss and are satisfied that the Company has plans in place for orderly succession for appointment to the Board of Directors and Senior Management.
- c) Code of Conduct for Board and Senior Managerial Personnel

The Board has laid down a code of conduct for Board members and senior management personnel of the Company. The code also incorporates the duties of independent directors as laid down in the Companies Act, 2013. The said code of conduct is posted on Company's website www.makerslabs.com.

The Board members and senior management personnel have affirmed compliance with the said code of conduct. A declaration in this regard signed by the Wholetime Director / CEO is given at the end of this Report.

The Company has adopted a code of conduct for prevention of insider trading based on SEBI (Prohibition of Insider Trading) Regulations, 2015. The same has been placed on the website of the Company www.makerslabs.com. All the Directors, senior management employees and other employees who have access to the unpublished price sensitive information of the Company are governed by this code. During the year under Report, there has been due compliance with the said code of conduct for prevention of insider trading.

- d) The Company complies with the requirement of placing minimum information before the Board of Directors as contained in Part A of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- e) The CEO/CFO compliance certification under Part B of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 forms part of this Annual Report.
- f) The Company has a Risk Management Committee which monitors and reviews risk management plan. The Board of Directors also periodically reviews and monitors the risk management plan of the Company.
- g) The Board on an annual basis evaluates the performance of Independent Directors. The Independent Directors have also given declarations that they fulfill the criteria of independence as specified in SEBI (LODR) Regulations, 2015 and that they are independent of the Company's management. They have also provided confirmation that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence.

h) Risk Management Committee

The Risk Management Committee was re-constituted by the Board of Directors at its meeting held on 13th February, 2019 and consists of the following members:

Mr. Vishal Jain, Independent Director (Chairman of the Committee), Mr. Saahil Parikh, Wholetime Director/CEO, Mr. Nilesh Jain, Wholetime Director and Mr. Sandeep Kadam, Sr. Manager Accounts/CFO.

The roles and responsibilities of the Risk Management Committee are as prescribed under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and includes monitoring and review of risk management plan and reporting the same to the Board of Directors periodically as it may deem fit, in addition to any other terms as may be referred to them by the Board of Directors, from time to time.

The risk management policy is displayed on the Company's website (weblink https://www.makerslabs.com/pdf/Corporate_Policy/Risk_Management_Policy.pdf).

There was two (2) meetings of the Risk Management Committee held during the financial year 2025-26. The dates on which the said meetings was held is as follows:

26 th May, 2025	7 th November, 2025
----------------------------	--------------------------------

The attendance of each member of the Risk Management Committee in the committee meeting is given below:

Name of the Director/Executive	No. of meetings held	No. of meetings attended
Mr. Vishal Jain	2	2
Mr. Saahil Parikh	2	2
Mr. Nilesh Jain	2	2
Mr. Sandeep Kadam (Sr. Manager Accounts / CFO)	2	1

- i) The Company has formulated a policy on materiality of related party transactions and dealing with related party transactions including clear threshold limits approved by the Board which is available on the website of the Company (weblink https://www.makerslabs.com/pdf/Corporate_Policy/Policy_for_Determination_of_Materiality_of_Event.pdf).

- j) All related party transactions entered into by the Company with related parties are at an arms length basis and in the ordinary course of Company's business. Transactions with related parties are disclosed under notes forming part of the accounts. The Board and the Audit Committee periodically reviews the details of the related party transactions entered into by the Company. Omnibus approval from the Audit Committee is also obtained before entering into related party transactions. The necessary shareholders resolution is also obtained wherever required.
- k) No employee including Key Managerial Personnel or Director or Promoter of the Company has entered into any agreement for himself or on behalf of other person with any shareholder or any other third party with regard to compensation or profit sharing in connection with dealings in the securities of the Company.

l) **Subsidiary Companies**

The Company has defacto control over the affairs of M/s. Resonance Specialties Ltd., a listed entity with 45.48% shareholding in the said company. Therefore, the Company treats Resonance Specialties Ltd. as its subsidiary.

Mr. R. K. P. Verma, Independent Director of the Company is a member of the Board of Directors of Resonance Specialties Ltd. as an Independent Director.

The minutes of board meetings of subsidiary company is regularly placed before the Board of Directors of the Company. The Board of Directors of the Company also reviews all significant transactions and arrangements, if any, entered into by the subsidiary.

- m) None of the Director of the Company is a director or act as independent director in more than seven listed entities and none of the Wholetime Director serve as an Independent Director in more than 3 listed entities.

None of the Directors on the Board is a member of more than 10 committees and Chairman of more than 5 committees across all the companies in which they are Directors. All directors have disclosed their committee positions to the Company. For determining this limit, Chairpersonship and Membership of Audit Committee and Stakeholders Relationship Committee only are considered.

The shareholders have approved the appointment of Ms. Dipti Shah as Independent director for a second term of five years w.e.f 29th January, 2023 and Mr. R. K. P. Verma as Independent Director of the Company for a second term of five years w.e.f 13th February, 2024. The shareholders have approved the appointment of Mr Vishal Jain as the Independent Director for a second term of five years w.e.f 4th November, 2025 till 3rd November, 2030.

Terms and conditions of their appointment as Independent Directors have been disclosed on the website of the Company www.makerslabs.com.

The shareholders have also approved the appointment of Mr. Prashant Godha as Non-Executive, Non-Independent Director of the Company liable to retire by rotation with effect from 4th November, 2020.

In accordance with requirements of Section 149(6) and (7) of the Companies Act, 2013 and and Reg 16(1)(b) of SEBI LODR Regulations, all the independent directors have given declaration of independence in the first board meeting of the current financial year held on 26th May, 2026.

n) Independent Directors Meeting

During the financial year under review, the Independent Directors met on 10th February, 2026 without the attendance of non-independent directors and members of the management, inter-alia, to discuss:

- i. Evaluation of the performance of Non-Independent Directors and the Board of Directors as a whole;
- ii. Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive and Non Executive Directors; and
- iii. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the independent Directors were present at the said meeting.

o) The Company maintains a functional website (www.makerslabs.com) containing the basic information about the Company. The Company has disseminated all the required information on its website as required under Regulation 46 (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

p) Information on Directors retiring by rotation and seeking appointment / re-appointment

Mr. Saahil Parikh

Mr. Saahil Parikh aged 51 years has done his graduation in Bio-Chemistry from Gujarat University. He has also done his Diploma in Management Studies from Ahmedabad Management Association. He has about 25 years of experience in pharma production, quality control, projects and general management.

He holds 21,741 equity shares of the Company.

He does not hold Directorship in any listed entity not he has retired/resigned as a Director of any listed entity in the past 3 years.

He is not related to any Director or Key Managerial Personnel of the Company. Number of Board Meetings held and attended by him during his tenure as Director of the Company are given in the Company's Corporate Governance Reports.

He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

Number of Board Meetings held and attended by him during his tenure as Director of the Company are given in the Corporate Governance Report of the respective financial year annexed with the Company's Annual Reports which are available on the Company's website www.makerslabs.com. During the financial year 2025-26, he has attended all the 5 board meetings held by the Company.

q) Reconciliation of Share Capital Audit:

A qualified Practicing Company Secretary carries out a share capital audit to reconcile the total admitted equity share capital with NSDL and CDSL and the total issued and listed equity share capital of the Company. The audit report confirms that the total issued/ paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.

r) Dividend Distribution Policy

In terms of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2016, the Company has formulated a Dividend Distribution Policy which has been uploaded on the website of the Company (https://www.makerslabs.com/Corporate_Policy.html).

s) Disclosure of certain types of agreements binding on listed entities

None


Annexure A

High/Low of Market price of the Company's shares traded on BSE Ltd. (BSE) during the financial year 2025-26 is furnished below:

Year	Month	Highest (₹)	Lowest (₹)	
2025	April	157.00	130.00	
	May	173.70	128.60	
	June	173.00	142.00	
	July	168.00	144.00	
	August	163.80	144.50	
	September	151.90	128.50	
	October	144.90	119.00	
	November	139.15	117.15	
	December	125.00	109.00	
	2026	January	129.00	112.10
		February	164.70	115.55
		March	171.00	133.60

Annexure B

Graph of Share Price/ BSE Sensex



Annexure C

The distribution of shareholding as on 31st March, 2026 is as follows :

No. of equity shares held			No. of shareholders	%	No. of shares	%
Upto		500	3311	85.18	377805	6.40
501	to	1000	257	6.61	194104	3.29
1001	to	2000	146	3.76	213406	3.62
2001	to	3000	57	1.47	145367	2.46
3001	to	4000	24	0.62	84990	1.44
4001	to	5000	10	0.26	45542	0.77
5001	to	10000	39	1.00	274426	4.65
10001	&	above	43	1.10	4564736	77.37
Grand Total			3887	100.00	5900376	100.00
No. of shareholders in Physical Mode			403	10.37	80582	1.37
No. of shareholders in Electronic Mode			3484	89.63	5819794	98.63

Shareholding pattern as on 31st March, 2026 is as follows :

Category	No. of shareholders	No. of shares	% holding
Indian Promoters	12	3615356	61.27
Banks and Insurance Companies	1	100	0.00
FIs and Mutual Funds	0	0	0.00
NRI	54	40640	0.69
Domestic Companies	27	104524	1.78
Resident Individuals / Others	3793	2139756	36.26
Total	3887	5900376	100.00

CEO CERTIFICATION26th May, 2026

To,
All the Members of
Makers Laboratories Ltd.

It is hereby certified and confirmed that as provided in terms of Regulation 26(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board members and the Senior Management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the financial year ended 31st March, 2026.

For Makers Laboratories Limited
Saahil Parikh
Wholetime Director / CEO

CEO/CFO CERTIFICATION26th May, 2026

The Board of Directors
Makers Laboratories Limited
54-D, Kandivli Industrial Estate,
Kandivli (West), Mumbai – 400 067

We hereby certify that:

- (a) We have reviewed financial statements and the cash flow statement for the year ended 31st March, 2026 and that to the best of our knowledge and belief;
 - i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii. these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- (b) No transaction is entered into by the Company during the year which is fraudulent, illegal or violative of the Company's code of conduct.
- (c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- (d) We have indicated to the Auditors and the Audit Committee:
 - i. significant changes in internal control over financial reporting during the year;
 - ii. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - iii. instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Makers Laboratories Ltd.

Saahil Parikh
Wholetime Director / CEO

For Makers Laboratories Ltd.

Sandeep Kadam
Sr. Manager (Accounts) / Chief Financial Officer

**PRACTISING COMPANY SECRETARIES' CERTIFICATE ON
CORPORATE GOVERNANCE**

TO THE MEMBERS OF

MAKERS LABORATORIES LIMITED

We have examined the compliance of the conditions of Corporate Governance by Makers Laboratories Limited ('the Company') for the year ended on March 31, 2026, as stipulated under Regulations 17 to 27, clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and para C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The compliance of the conditions of Corporate Governance is the responsibility of the management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2026.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Parikh & Associates
Practising Company Secretaries

Jeenal Jain
Partner
FCS: 13280 CP: 21246
UDIN: FO13280H000482419
PR No.: 7327/2025
Mumbai, May 26, 2026

DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

a)	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the year	No. of shares – 960 No. of shareholders - 10
b)	Number of shareholders who approached listed entity for transfer of shares from suspense account during the year	0
c)	Number of shareholders to whom shares were transferred from suspense account during the year	0
d)	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year	No. of shares – 540 No. of shareholders - 3
e)	That the voting rights on these shares shall remain frozen till the rightful owner of such shares claims the shares	Voting rights on these shares shall remain frozen till the rightful owner of such shares claims the shares

ANNEXURE 2**Form No. AOC-2**

(Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:
 - (a) Name(s) of the related party and nature of relationship: Not Applicable
 - (b) Nature of contracts/arrangements/transactions: Not Applicable
 - (c) Duration of the contracts / arrangements/transactions: Not Applicable
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Not Applicable
 - (e) Justification for entering into such contracts or arrangements or transactions: Not Applicable
 - (f) Date(s) of approval by the Board: Not Applicable
 - (g) Amount paid as advances, if any: Not Applicable
 - (h) Date on which the special resolution was passed in general meeting as required under first proviso to Section 188: Not Applicable
2. Details of material contracts or arrangement or transactions at arm's length basis:
 - (a) Name(s) of the related party and nature of relationship: M/s. Ipca Laboratories Ltd., companies promoted by same promoters.
 - (b) Nature of contracts/arrangements/transactions:
 - i. Purchase/ sale of materials, capital goods, plant & machineries, packing materials, etc. at a market determined price that would be generally agreed by the trade / industry for similar nature of transaction.
 - ii. Availing of/rendering of manufacturing and other services at a price that would be generally charged in the trade / industry for that particular type of service.
 - iii. Provision of common services at proportionate cost.
 - (c) Duration of the contracts / arrangements/transactions: Continuous transactions on an ongoing basis.
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Purchase/ sale of materials, capital goods, plant & machineries, packing materials, manufacturing on loan license basis, etc. on arm's length basis. Please see attached notes to Accounts for details.
 - (e) Date(s) of approval by the Board, if any: 26th May, 2025
 - (f) Date of approval of shareholders: 8th August, 2025 (Fresh approval of shareholders is also being obtained in the ensuing Annual General Meeting)
 - (g) Amount paid as advances, if any: None

Note: All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of Company's business. Details of the related party transactions are given in the notes to the Accounts attached herewith.

For and on behalf of the Board

Mumbai,
26th May, 2026

R. K. P. Verma
Chairman

ANNEXURE 3

DETAILS OF REMUNERATION AS REQUIRED UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5 (1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- i. The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2025-26, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2025-26 is as under:

Sr. No.	Name of the Director / Key Managerial Personnel and Designation	Remuneration of Director / KMP for the financial year 2025-26 (₹)	% increase/ (decrease) in remuneration in the financial year 2025-26	Ratio of remuneration of each Director to median remuneration of employees
1.	Mr. R. K. P. Verma (Chairman)	1,85,000	-	0.60
2.	Ms. Dipti Shah (Director)	1,65,000	-	0.53
3.	Mr. Vishal Jain (Director)	2,05,000	-	0.66
4.	Mr. Prashant Godha (Director)	75,000	-	0.24
5.	Mr. Saahil Parikh (Whole Time Director/CEO)	73,34,143	8.67%	23.66
6.	Mr. Nilesh Jain (Whole Time Director)	41,74,983	8.71%	13.47
7.	Mr. Sandeep Kadam (Sr. Manager Accounts / CFO)	14,60,688	8.82%	4.71
8.	Mr. Piyush Ajmera (Company Secretary)	4,20,000	17.19%	1.36

- ii. The median remuneration of the employees of the Company during the financial year was ₹ 3,09,936/-
- iii. In the financial year, there was an decrease of 12.22% in the median remuneration of employees.
- iv. There were 114 permanent employees on the rolls of Company as on 31st March, 2026.
- v. Average percentage increase made in the salaries of employees other than the managerial personnel in the financial year was 8.80% whereas the increase in the managerial remuneration for the financial year was 8.51%.
- vi. It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.

For and on behalf of the Board

Mumbai,
26th May, 2026

R. K. P. Verma
Chairman

ANNEXURE 4**1. CONSERVATION OF ENERGY****(i) The steps taken or impact on conservation of energy :**

During the year under review all possible efforts were made to ensure optimum conservation of electricity and fuel at the manufacturing plant of the Company.

(ii) The steps taken by the Company for utilizing alternate sources of energy :

Presently none.

(iii) The capital investment on energy conservation equipments :

The Company has not spent any material capital investment on energy conservation equipments except some investment on energy conservation consumables.

2. TECHNOLOGY ABSORPTION

Research & Development

(A) Specific areas in which R&D work was carried out by the Company:

The Company has started R&D activities at its Ahmedabad manufacturing unit. The Company is currently in the process of developing ophthalmic range of formulations.

(B) Benefits derived as a result of the above R&D:

The benefits of R&D activities will come in future years.

(C) Future Plan of Action :

Development of more range of ophthalmic range of formulations initially for the domestic market.

(D) Expenditure incurred on R&D:

	2025-26 (₹ lacs)	2024-25 (₹ lacs)
a) Capital	-	-
b) Revenue	21.27	12.20
c) Total	21.27	12.20
d) R & D expenditure as a percentage of turnover	0.42%	0.28%

(E) Imported technology (imported during last 5 years):

The Company has not imported any technology during the last 5 years.

3. FOREIGN EXCHANGE EARNINGS AND OUTGO

Foreign Exchange Earnings – Nil.

Foreign Exchange Expenditure – Nil.

For and on behalf of the Board

Mumbai,
26th May, 2026

R. K. P. Verma
Chairman

FORM No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

(Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To,
The Members,
Makers Laboratories Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Makers Laboratories Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, to the extent the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit, the explanations and clarifications given to us and the representations made by the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2026, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records made available to us and maintained by the Company for the financial year ended on March 31, 2026 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contract (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not applicable to the Company during the audit period)
 - d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (Not applicable to the Company during the audit period)
 - e) The Securities and Exchange Board of India (Issue and Listing of Non- Convertible Securities, 2021; (Not applicable to the Company during the audit period)
 - f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 and The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 2025 regarding the Companies Act and dealing with client;

- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (Not applicable to the Company during the audit period) and
 - h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not applicable to the Company during the audit period)
 - i) Other regulations of the Securities and Exchange Board of India as are applicable to the Company.
- (vi) Other laws applicable specifically to the Company namely:
- (1) Pharmacy Act, 1948,
 - (2) Drugs and Cosmetics Act, 1940,
 - (3) Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954,
 - (4) Narcotic Drugs and Psychotropic Substances Act, 1985,
 - (5) Drug Pricing Control Order, 2013

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings.
- (ii) The Listing Agreements entered into by the Company with BSE Limited read with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review, the Company has generally complied with the provisions of the Act, rules, regulations, guidelines, standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice was given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes, the decisions at the Board Meetings were taken unanimously.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit the period, no events occurred which had bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

For Parikh & Associates
Practising Company Secretaries

Jeenal Jain
Partner
FCS: 13280 CP: 21246
UDIN: F013280H000485433
PR No.: 7327/2025

Place: Mumbai
Date: May 26, 2026

This Report is to be read with our letter of even date which is annexed as Annexure A and Forms an integral part of this report.

'Annexure A'

To,
The Members
Makers Laboratories Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management Representation about the Compliance of laws, rules and regulations and happening of events, etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Parikh & Associates
Practising Company Secretaries

Jeenal Jain
Partner
FCS: 13280 CP: 21246
UDIN: F013280H000485433
PR No.: 7327/2025

Place: Mumbai
Date: May 26, 2026

INDEPENDENT AUDITORS' REPORT

To
The Members of
Makers Laboratories Limited
Mumbai

Report on the Audit of the Standalone Financial Statement

Opinion

We have audited the attached standalone financial statements of Makers Laboratories Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of Material Accounting Policy Information and other explanatory information (hereinafter referred to as "Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial Statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters:

Sr No	Key Audit Matters (KAM's)	How the KAM's were addressed in our audit
1.	<p>Inventory Valuation</p> <p>The Company manufactures and sells pharmaceutical products which carry shelf life. As a result, significant level of judgement is involved in estimating inventory valuation. Judgement is required to assess the appropriate net realisable value for short dated pharmaceutical products. Such judgements include management expectations for future sales and inventory liquidation plans.</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> • We attended stock counts to identify whether any inventory was obsolete, • We assessed the basis for the inventory valuation, the consistency in policy and the rationale in its application, • We tested the accuracy of the ageing of inventories based on system generated reports, • We tested the arithmetical accuracy of valuation files; and • We reviewed product-wise historical data relating to sales return etc. and also its impact on valuation. • We have assessed the adequacy of disclosure in the Standalone Financial Statements.

Sr No	Key Audit Matters (KAM's)	How the KAM's were addressed in our audit
2.	Revenue recognition as per INDAS 115 – Revenue from Contracts with customers.	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> • We have assessed the Company's accounting policies for revenue recognition by comparing with the applicable accounting standards i.e. Ind AS 115; • We have conducted testing of design, implementation and operating effectiveness of key internal financial controls over timing of recognition of revenue from sale of goods and subsequent adjustments made to the transaction price; • We have also performed substantive audit procedures on selected statistical samples of customer contracts. Verified terms and condition related to acceptance of goods, acknowledgement on delivery receipts and tested the transit time to deliver the goods and its revenue recognition. • We also assessed the issue of principal and agency arrangements in the transactions of sale of goods through Consignee Sales Distributors and accounted the revenue as per the principles of Ind AS 115. • Our tests of details focused on period end samples to verify only revenue pertaining to current year which satisfies the condition of revenue recognition is recognized based on terms and conditions set out in sale agreements/ contracts and delivery documents. • We have assessed the adequacy of disclosure in the Standalone Financial Statements.

Information Other than the Standalone Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the Other Information. The other information comprises the information included in the Board's Report but does not include the Standalone Financial Statements and our Independent Auditors' Report thereon. Our opinion on the Standalone Financial Statements does not cover the Other Information and we do not and will not express any form of assurance or conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the Other Information identified above and, in doing so, consider whether the Other Information is materially inconsistent with the Financial Statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this Other Information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy

and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, make it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the attached Annexure "A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid Financial Statements have been kept so far as it appears from our examination of those books except for the matters stated in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - c. The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the aforesaid Standalone Financial Statements comply with the Ind AS specified under Section 133 of the Act.
 - e. On the basis of the written representations received from the directors as on March 31, 2026, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With reference to maintenance of accounts and other matter therewith, reference is invited to paragraph 2(b) above on reporting under section 143(3)(b) and paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 as amended.
 - g. With respect to the adequacy of the internal financial controls system with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls system with reference to financial statements.
 - h. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is within the limits prescribed as per Schedule V read with the provisions of section 197 of the Act.
 - i. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 37 to the financial statements,
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were material foreseeable losses,
 - iii. The amount required to be transferred to the Investor Education and Protection Fund has been transferred by the Company within time.

- iv. a. The management has represented that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entities (“intermediaries”) with the understanding whether recorded in writing or otherwise, that the intermediary shall, whether directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (“Ultimate Beneficiaries”) or provide any guarantee, security, or the like on behalf of the Ultimate Beneficiaries.
- b. The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any person or entity including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- c. Based on such audit procedures considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (iv)(a) and (iv)(b) above contain any material misstatement.
- v. There are no events of dividend declared and paid by the Company during the year until the date of this report, hence compliance with provisions of section 123 of the Companies Act, 2013 is not required.
- vi. Based on our examination which included test checks, except for instances/ matters mentioned below, the Company, in respect of financial year commencing on 1 April 2025, has used an Inhouse developed accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further, audit trail feature is enabled for direct changes from November 24 onwards, 2024, to data when using certain access rights by the development team, as described in Note 43 to the financial statements. However, due to system constraints, the audit trail for direct database changes done by the Database administrator is retained only for a period of three days and therefore, audit trail for the direct access changes is available only for said period.

As regards the preservation of the audit trail as per the statutory requirements, at application level the same are retained for the period the edit log was enabled. In case of audit trail for direct database changes the audit trail prior to November 24, 2024 is not available since the direct database logs were enabled only from November 24, 2024 and due to system constrain the same are not retained for more than 3 days and thus to that extent the log retention are not retained by the Company.

For N V C & ASSOCIATES LLP
Chartered Accountants
FRN No: 106971W/ W101085

Nuzhat Khan
Partner
Membership No.124960
Mumbai, Dated: May 26, 2026
UDIN: 26124960YUCDKM6313

Annexure A to the Independent Auditor's Report

(Referred to in paragraph 1 under Report on Other Legal and Regulatory Requirements' section of our report to the Members of Makers Laboratories Limited of even date)

To the best of our knowledge and information, audit procedures followed by us, according to the information provided to us by the Company and the examination of the books of account and records in the normal course of audit, we state that:

- (i) a. (A) The Company has generally maintained proper records showing full particulars including quantitative details and situation of its Property, Plant and Equipment and relevant details of right of use assets.
(B) The company has generally maintained proper records showing full particulars of intangible assets.
- b. Property, Plant and Equipment and Right of Use assets have been physically verified by the management at reasonable intervals and no material discrepancies were noticed on such verification.
- c. We have verified the title deeds of all the immovable properties (other than properties where the company is the lessee, and the lease agreements are duly executed in favour of the lessee) disclosed in the Standalone Financial Statements and included under Property, Plant and Equipment and based on such verification, we confirm that the same are held in the name of the company. In case of Lease agreements for land, where the company is the lessee and the lease agreements are duly executed in favour of the company and on which building is constructed, we report that title in respect of self-constructed building is held in the Company's name.
- d. The company has not revalued its Property, Plant and Equipment (including Right of Use assets) and intangible assets during the year.
- e. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026, for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 as amended and rules made thereunder.
- (ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year. On the basis of examination of records, we are of the opinion that the coverage and procedure of such verification is appropriate and that no discrepancies of 10% or more in the aggregate for each class of inventory were noticed on such verification. The discrepancies wherever noted have been properly dealt with in the books of account of the Company.
(b) The Company has not been sanctioned working capital limits in excess of ₹ 5 crores in aggregate at any point of time during the year from banks or financial institutions on the basis of security of current assets and hence clause 3(ii)(b) of the Companies (Auditors Report) Order 2020 is not applicable to the Company.
- (iii) In our opinion and on the basis of examination of books and records and on the basis of information and explanation given to us the Company has not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence Clause 3(iii)(a), 3(iii)(b), 3(iii)(c), 3(iii)(d), 3(iii)(e) & 3(iii)(f) of the Companies (Auditor's Report) Order, 2020 are not applicable to the Company.
- (iv) The company has not given any loans, or made any investments, or given any guarantees and security to which section 185 or section 186 applies.

- (v) The Company has not accepted deposits from the public or amounts that are deemed to be deposits pursuant to sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and rules framed thereunder. As informed to us, there is no order that has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other tribunal in respect of the said sections.
- (vi) The maintenance of the cost records under the sub-section (1) of section 148 of the Companies Act, 2013 has been prescribed and we are of the opinion that prima facie, the prescribed accounts and records have been so maintained. We have not, however, carried out a detailed examination of the records to ascertain whether they are accurate.
- (vii) (a) The Company has been generally regular in depositing undisputed statutory dues including Goods and Services Act, Provident fund, Employees State Insurance, Income Tax, Sales Tax, Service Tax, duty of Customs, duty of Excise, Value Added Tax, Cess and other statutory dues to the appropriate authorities during the year. According to the information and explanations given to us, no undisputed amount payable in respect of the aforesaid dues were outstanding as at March 31, 2026, for a period of more than six months from the date they became payable.
- (b) There are no statutory dues referred to in sub-clause (a) which have not been deposited on account of any dispute except as given below:

Name of statute	Nature of dues	Period to which the amount relates	Amount (In lacs)	Amount paid under protest (In lacs)	Forum where dispute is pending
Income Tax	Order under section 143(3) r/w section 147	AY: 2010-11	14.54	2.90	CIT(Appeals)
Income Tax	Order under section 143(3) r/w section 147	AY: 2011-12	117.40	4.10	CIT(Appeals)
Income Tax	Order under section 143(3) r/w section 147	AY: 2012-13	22.97	-	CIT(Appeals)
Income Tax	order under section 147 r/w 144B.	AY: 2013-14	23.19	2.80	CIT(Appeals)
Income Tax	Order under section 143(3) r/w section 147	AY: 2014-15	24.94	3.01	CIT(Appeals)
Income Tax	Order under section 143(3) r/w section 147	AY: 2015-16	44.92	5.42	CIT(Appeals)
Indirect Taxes	Order u/s 73 of SGST/ CGST Act	FY 2020-21	1.34	0.06	State Tax Officer
Indirect Taxes	Order u/s 73 of SGST/ CGST Act	FY 2021-22	1.19	0.00 (Rs. 6)	State Tax Officer
Excise Duty	Order u/s 11 AB Central Excise Act, 1994.	FY 2003-04	17.93	-	Bombay High Court
Total			268.42	18.29	

- (viii) There are no transactions that were not recorded in the books of account, and which has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

- (ix) (a) The company has not defaulted in repayment of loans or borrowings or in the payment of interest thereon to any lender.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution.
- (c) No new term loan has availed during the year from any bank or financial institution. The Company however has obtained a long-term loan from group company which is applied for the purpose for which the same is raised.
- (d) On an overall examination of the financial statements of the company, we report that the Company has not raised funds on short-term basis which have been used for long-term purposes.
- (e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiary. The Company does not have any associates or joint ventures.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiary. The Company does not have any associates or joint ventures.
- (x) (a) The Company has not raised any money by way of initial public offer/further public offer (including debt instruments) during the year and hence clause 3(x)(a) of the Companies (Auditor's Report) Order, 2020 is not applicable to the Company.
- (b) The Company has not made any preferential allotment / private placement of shares / fully / partly / optionally convertible debentures during the year.
- (xi) (a) No fraud by the Company or any fraud on the Company has been noticed or reported during the year.
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed by us in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government and hence clause 3(xi)(b) of the Companies (Auditors Report) Order 2020 is not applicable to the Company.
- (c) No whistle-blower complaints have been received during the year by the Company.
- (xii) The Company is not a Nidhi Company and hence clauses 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Companies (Auditors Report) Order 2020 are not applicable to the Company.
- (xiii) All transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 in so far as our examination of the proceedings of the meetings of the Audit Committee and the Board of Directors are concerned. The details of related party transactions have been disclosed in the Financial Statements as required by the applicable Accounting Standards.
- (xiv) (a) The Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports of the company issued till date, for the period under audit.
- (xv) The company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence clause 3(xv) of the Companies (Auditor's Report) Order, 2020 is not applicable to the Company.

- (xvi) (a) The nature of business and the activities of the Company are such that the Company is not required to obtain registration under section 45-IA of the Reserve Bank of India Act 1934 and hence sub-clause 3(xvi)(a), 3(xvi)(b) and 3(xvi)(c) of the Companies (Auditors Report) Order, 2020 is not applicable to the company.
- (b) There are two core investment companies within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016).
- (xvii) On an examination of the Statement of Profit and Loss account, the Company has not incurred cash losses during the financial year and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year and accordingly clause (3) (xviii) of The Companies (Auditors Report) Order 2020 is not applicable to the Company.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements including management representations, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, we are of the opinion that there no exists material uncertainties in the management assumptions relating to the company's capability of meeting the financial liabilities existing as at the Balance sheet date as and when they fall due within next 12 months which casts significant doubts on the management ability to meet the liabilities as and when they fall due.
- (xx) Since the Company do not meet the applicability criteria for CSR as per section 135 of the Companies Act, 2013 and accordingly, reporting under clause 3(xx)(a) & 3(xx)(b) of the Order are not applicable for the year.

For N V C & ASSOCIATES LLP
Chartered Accountants
FRN No: 106971W/ W101085

Nuzhat Khan
Partner
Membership No.124960
Mumbai, Dated: May 26, 2026
UDIN: 26124960YUCDKM6313

Annexure - B to the Independent Auditors' Report

(Referred to in paragraph 2(g) under Report on Other Legal and Regulatory Requirements' section of our report to the Members of Makers Laboratories Limited of even date)

Report on the Internal Financial Controls with reference to Standalone Financial Statements under Clause Section 143(3)(i) of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls system with reference to Standalone Financial Statements of Makers Laboratories Limited ("the Company") as of March 31, 2026, in conjunction with our audit of the Standalone Financial Statement of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to Standalone Financial Statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to Standalone Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to Standalone Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Standalone Financial Statements included obtaining an understanding of internal financial controls with reference to Standalone Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to Standalone Financial Statements.

Meaning of Internal Financial Controls with reference to Standalone Financial Statements

A company's internal financial control with reference to Standalone Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to Standalone Financial Statements includes those

policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to Standalone Financial Statements.

Because of the inherent limitations of financial controls with reference to Standalone Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Standalone Financial Statements to future periods are subject to the risk that the internal financial control with reference to Standalone Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to Standalone Financial Statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For N V C & ASSOCIATES LLP

Chartered Accountants
FRN No: 106971W/ W101085

Nuzhat Khan

Partner
Membership No.124960
Mumbai, Dated: May 26, 2026
UDIN: 26124960YUCDKM6313

(All Figures are Rupees in Lacs unless otherwise stated)

Standalone Balance Sheet as at March 31, 2026

Particulars	Note	As at Mar 31, 2026	As at Mar 31, 2025
ASSETS			
(1) Non-current Assets			
(a) Property, Plant & Equipment	3	2,579.80	2,792.78
(b) Capital Work-in-Progress	3C	5.64	3.61
(c) Right Of Use Asset	3B	109.88	141.27
(d) Other Intangible Assets	3A	1.83	3.72
(e) Intangible Assets Under Development	3C	-	-
(f) Financial Assets			
(i) Investments	4	2,259.78	2,258.83
(ii) Loans	5	-	-
(iii) Others	6	88.21	87.29
(g) Deferred Tax Asset (Net)	16	-	-
(h) Other Non-current Assets	7	305.31	246.06
		5,350.45	5,533.56
(2) Current Assets			
(a) Inventories	8	1,064.03	780.99
(b) Financial Assets			
(i) Investments	4	-	-
(ii) Trade Receivables	9	596.88	567.05
(iii) Cash and Cash Equivalents	10	1.71	1.80
(iv) Bank Balances other than (iii) above	11	0.81	2.43
(v) Loans	5	-	0.17
(vi) Others	6	34.86	23.63
(c) Current Tax Assets (Net)		-	-
(d) Other Current Assets	7	304.99	229.90
		2,003.28	1,605.97
TOTAL ASSETS		7,353.73	7,139.53
EQUITY & LIABILITIES			
EQUITY			
(a) Equity Share Capital	12	590.04	590.04
(b) Other Equity	13	4,853.37	5,017.50
Total Equity		5,443.41	5,607.54
LIABILITIES			
(1) Non-current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	-	-	-
(ii) Lease Liability	32	87.65	118.06
(iii) Other Financial Liabilities	14	-	-
(b) Provisions	15	26.13	17.48
(c) Deferred Tax Liabilities (Net)	16	20.36	49.01
(d) Other Non-current Liabilities	17	-	-
		134.14	184.55
(2) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	18	270.28	29.64
(ii) Lease Liability	32	30.41	27.66
(iii) Trade Payables	19		
- Due to Micro and Small Enterprises		240.47	88.95
- Due to Other than Micro and Small Enterprises		515.80	537.52
(iv) Other Financial Liabilities	14	365.61	373.96
(b) Other Current Liabilities	17	258.76	178.46
(c) Provisions	15	94.85	111.25
(d) Current Tax Liabilities (Net)		-	-
		1,776.18	1,347.44
TOTAL EQUITY AND LIABILITIES		7,353.73	7,139.53

Statement of material accounting policy information and other explanatory notes form part of the balance sheet and statement of profit and loss

As per our report of even date attached

For N V C & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh

(DIN 00400079)

Wholetime Director & CEO

Nilesh Jain

(DIN 05263110)

Wholetime Director

Piyush Ajmera

ACS No : 58712

Company Secretary

Sandeep Kadam

Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Standalone Statement of Profit and Loss for the year ended March 31, 2026

Particulars	Note	Apr-Mar 26	Apr-Mar 25
I Revenue from Operations	20	5,034.73	4,294.46
II Other Income	21	59.28	1,092.35
III Total Income (I + II)		5,094.01	5,386.81
IV Expenses:			
Cost of Materials Consumed	22	546.49	481.56
Purchase of Stock in trade	23	2,220.36	1,459.64
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	24	(165.00)	393.29
Employee Benefit Expenses	25	968.92	904.80
Finance Cost	26	53.07	93.98
Depreciation and Amortisation	27	280.40	284.64
Other Expenses	28	1,390.90	1,276.04
Total Expenses (IV)		5,295.14	4,893.95
V Profit/ (Loss) Before exceptional items and Tax (III-IV)		(201.13)	492.86
VI Exceptional Items income/ (expenses)		-	-
VII Profit/ (Loss) Before Tax (V+VI)		(201.13)	492.86
VIII Tax Expense			
1. Current Tax	29	-	-
2. Short / (Excess) Provision of earlier years	29	-	(0.06)
3. Deferred Tax Liability / (Asset)	29	(29.15)	28.81
IX Profit/(Loss) for the period (VII-VIII)		(171.98)	464.11
X Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
(a) Actuarial gain / (loss)		7.40	(3.57)
Tax Effect thereon	30	-	-
(b) Fair Value change through Other Comprehensive Income		0.95	2.54
Tax Effect thereon	30	(0.50)	(0.26)
Other Comprehensive Income for the year, net of tax		7.85	(1.29)
Total Comprehensive Income for the year		(164.13)	462.82
XI Earnings per Equity Share :			
Par Value ₹10 each			
Basic (in ₹)	31	(2.91)	7.87
Diluted (in ₹)	31	(2.91)	7.87

Statement of material accounting policy information and other explanatory notes form part of the balance sheet and statement of profit and loss

As per our report of even date attached

For N V C & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh

(DIN 00400079)

Wholetime Director & CEO

Piyush Ajmera

ACS No : 58712

Company Secretary

Nilesh Jain

(DIN 05263110)

Wholetime Director

Sandeep Kadam

Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Standalone Cash Flow Statement for the year ended March 31, 2026

	April - March '26	April - March '25
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	(201.13)	492.86
Adjustments for :		
Depreciation	280.40	284.64
Bad debts w/off	13.14	23.51
Assets Scrap loss	-	2.04
Sundry balances written back	(1.11)	(0.34)
(Profit)/ Loss on sale of Property, Plant & Equipment	(0.77)	(1,010.34)
Unwinding of Lease rent Income	-	(0.07)
Unwinding of Lease rent Expenses	0.67	0.39
Reversal on Loss on Leasehold property	-	(56.95)
Interest income	(5.27)	(6.41)
Dividend income	(52.52)	(0.04)
Interest expense	46.51	90.88
2) Operating profit before working capital changes	79.92	(179.83)
Decrease / (Increase) in inventories	(283.04)	317.21
Decrease / (increase) in Trade Receivables	(42.97)	107.16
Decrease / (increase) in Other Financial assets	(11.39)	12.71
Decrease / (increase) in Other assets	(75.34)	15.07
Increase / (Decrease) in Trade Payables	130.91	(195.22)
Increase / (Decrease) in Other Financial liabilities	(20.47)	(159.96)
Increase / (Decrease) in Other liabilities	80.30	(16.37)
Increase / (Decrease) in Provisions	(0.35)	(15.22)
3) Cash generated from operation	(142.43)	(114.45)
Income Tax paid (net)	(59.68)	(44.23)
Net cash from operating activities	(202.11)	(158.68)
B. Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment including capital WIP & Intangibles	(31.14)	(242.39)
Proceeds from Sale of Plant, Property and Equipment	1.44	1,850.06
Movement in other bank balances	-	-
Interest received	4.68	5.86
Dividend received	52.52	0.04
Net cash from / (used in) investing activities	27.50	1,613.57
C. Cash Flow from Financing Activities		
Proceeds/ (Repayment) from short term borrowing (Net)	240.64	(689.63)
Repayment of Non-Current borrowing	-	(38.89)
Intercompany deposit repaid	-	(750.00)
Intercompany deposit received	-	150.00
Payment of lease Liability:		
- Interest	(12.34)	(19.10)
- Principal	(27.66)	(25.12)
Interest paid	(26.12)	(82.85)
Net cash from / (used in) financing activities	174.52	(1,455.59)
Net increase / (decrease) in cash and cash equivalents (A + B + C)	(0.09)	(0.70)
Cash and cash equivalents at beginning of year	1.80	2.50
Cash and cash equivalents at end of year	1.71	1.80
Components of Cash & Cash equivalents :		
Cash and cheques on hand	0.62	0.23
Balance with banks	1.09	1.57
	1.71	1.80

Refer note no. 18 (d) for reconciliation of liabilities from financing activities

As per our report of even date attached

For N V C & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh

(DIN 00400079)

Wholetime Director & CEO

Nilesh Jain

(DIN 05263110)

Wholetime Director

Piyush Ajmera

ACS No : 58712

Company Secretary

Sandeep Kadam

Chief Financial Officer

1. Standalone Statement of Changes in Equity for the year ended March 31, 2026

(All Figures are Rupees in Lacs unless otherwise stated)

Equity Share Capital	
Equity share capital of face value (₹) 10.00 each	
Balance as at March 31, 2024	59,00,376
Changes in equity share capital during the year	-
Balance as at March 31, 2025	59,00,376
Changes in equity share capital during the year	-
Balance as at March 31, 2026	59,00,376

Particulars	Other Equity				Total
	Reserves and Surplus		Other comprehensive income		
	Capital Reserve	Securities Premium	General Reserve	Not Reclassified to P&L Fair Value of Investment through OCI	
Balance as on March 31, 2024	302.76	1,449.43	1,200.00	1,598.71	4,554.68
Profit / (Loss) for the period	-	-	-	464.11	464.11
Gain/ (Loss) on Fair Value of Investment through OCI (Net of tax thereon)	-	-	-	-	2.28
Actuarial gain/(loss) on gratuity (Net of tax thereon)	-	-	-	(3.57)	(3.57)
Balance as on March 31, 2025	302.76	1,449.43	1,200.00	2,059.25	5,017.50
Profit / (Loss) for the period	-	-	-	(171.98)	(171.98)
Gain/ (Loss) on Fair Value of Investment through OCI (Net of tax thereon)	-	-	-	-	0.45
Actuarial gain/(loss) on gratuity (Net of tax thereon)	-	-	-	7.40	7.40
Balance as on March 31, 2026	302.76	1,449.43	1,200.00	1,894.67	4,853.37

Note:

- 1) Gain of ₹7.40 lacs and Loss of ₹ 3.57 lacs on remeasurement of defined employee benefit plans (net of tax) is recognized as a part of retained earnings for the year ended March 31, 2026 and year ended March 31, 2025, respectively.

As per our report of even date attached
For NVC & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 106971W / W101085

Nuzhat Khan
Partner
M.No. 124960
Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh (DIN 00400079) Wholtime Director & CEO	Nilesh Jain (DIN 05263110) Wholtime Director
Piyush Ajmera ACS No : 58712 Company Secretary	Sandeep Kadam Chief Financial Officer

Summary of Material accounting policy Information and other explanatory information to the Standalone Financial Statements for the year ended March 31, 2026

1. Corporate Information

Incorporated in the year 1984, Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company has one manufacturing units in India manufacturing formulations for the Indian market.

2. Statement of Compliance

The Standalone Financial Statements comply in all material aspects with Indian Accounting Standards (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013 (“the Act”), the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act.

The financial statements of the company for the year ended March 31, 2026 were authorised for issue in accordance with the resolution passed at the meeting of the Board of Directors held on May 26, 2026.

3. Basis of Preparation, Accounting judgements, estimates and assumptions and Material Accounting Policy information

3.1 Basis of Preparation

- These financial statements are prepared on a going concern basis, in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on the accrual basis, except for the following:
 - a) certain financial assets and liabilities (including derivative instruments) are measured at fair value, and
 - b) defined benefit plans - plan assets measured at fair value.
- Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.
- The Balance Sheet, the Statement of Profit and Loss and the Statement of Changes in Equity are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 (the Act). The Statement of Cash Flows has been prepared and presented in accordance with Ind AS 7 “Statement of Cash Flows”. The disclosures with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards as amended.
- Amounts in the financial statements are presented in Indian Rupees in Lakhs rounded off to two decimal places as permitted by Schedule III to the Companies Act, 2013. Per share data are presented in Indian Rupees to two decimals places.

3.2 Significant Accounting Judgements estimates and assumptions.

The financial statements require management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosures of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

3.2.1 Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates,

judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of circumstances surrounding the estimates. Changes in estimates are reflected in the financial statement in the period in which changes are made and if material, their effects are disclosed in the notes to the financial statements. During the year there were no Significant Judgements other than those stated hereinafter that were required to be exercised in the process of applying the entity's accounting policy and that have an impact on the amounts recognised in the Financial Statements.

3.2.2. Judgements

The Company's management has made the following judgements, which have the most significant effect on the amounts recognized in the separate financial statements, while formulating the Company's accounting policies:

a. Useful lives of Property, Plant and Equipment

The company reviews the useful life of property, plant and equipment at the end of each reporting period. This reassessment may result in change in depreciation expense in future periods.

b. Impairment of Property, Plant and Equipment

For property, plant and equipment and intangibles, an assessment is made at each reporting date to determine whether there is an indication that the carrying amount may not be recoverable or previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised.

c. Inventories

The Company estimates the net realisable value (NRV) of its inventories by taking into account estimated selling price, estimated cost of completion, estimated costs necessary to make the sale, obsolescence considering the past trend. Inventories are written down to NRV where such NRV is lower than their cost.

d. Recognition and measurement of other Provisions

The recognition and measurement of other provisions is based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the closing date. The actual outflow of resources at a future date may, therefore, vary from the amount included in other provisions.

e. Taxes

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

f. Defined benefit plans (Gratuity benefits)

The cost of the defined benefit plans, compensated absences and the present value of the defined benefit obligations are based on actuarial valuation using the projected unit

credit method. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These interalia include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

g. Leases

The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgement. The Company uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics.

3.2.3 Recent pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

1. In May 2025, MCA notified amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Company has reviewed the amendment and has determined that it does not have any impact in its financial statements.
2. In August 2025, MCA notified the following amendments to:
 - a. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 – The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The Company has no impact of these amendments in its classification criteria of current and non-current liabilities.
 - b. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments – Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and has determined that it does not have any impact in its financial statements.

- c. Ind AS 12, International Tax Reform – Pillar Two Model Rules applicable immediately - The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Company has no impact of these amendments in its Financial Statements

3.2.4 Material Accounting Policy Information

i. Current and non-current classification

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

The Company presents assets and liabilities in the balance sheet based on current/non-current classification.

An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle, or
- It is held primarily for the purpose of trading, or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle, or
- It is held primarily for the purpose of trading, or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

ii. Property, Plant and Equipment

- a) Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less depreciation. Cost of acquisition comprises its purchase price including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discount and rebates are deducted in arriving at the purchase price.
- b) Stores and spares which meet the definition of Property, Plant and Equipment and satisfy the recognition criteria of Ind AS 16 are capitalised as Property, Plant and Equipment.

- c) Capital Work In Progress represents expenditure incurred on capital assets that are under construction or are pending capitalisation and includes project expenses pending allocation. Project expenses pending allocation are apportioned to the Property, Plant and Equipment of the project proportionately on capitalization.
- d) Cost of borrowing for assets taking substantial time to be ready for use is capitalised for the period up to the time the asset is ready for its intended use.
- e) Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.
- f) The residual useful life of Property, Plant & Equipment is reviewed at each balance sheet date and adjusted if required in the depreciation rates.
- g) Depreciation methods, estimated useful lives and residual value

Depreciation on all assets of the Company is charged on straight line method over the useful life of assets mentioned in Schedule II to the Companies Act ,2013 or the useful life previously assessed by the management based on technical review whichever is lower for the proportionate period of use during the year. Intangible assets are amortised over the economic useful life estimated by the management.

The management's estimated useful life/useful life as per schedule II whichever is lower for the various tangible assets are as follows:

Assets	Estimated useful life (Years)
Leasehold Land	Period of Lease
Plant & Equipment	5 to 20 Years
Effluent Treatment Plant	15 Years
Vehicle	10 Years
Building	28 to 58 Years
Furniture & Fixtures	10 Years

iii. Intangible assets

The Company has elected to fair value its intangible assets on transition date. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The management has estimated the economic useful life for the various intangible assets as follows:

Particulars	Estimated useful life (Years)
Brands & Trademarks	4 years
Software for internal use	4 years

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

iv. Inventories

Items of inventories are valued at lower of cost or estimated net realisable value as given below:

Raw Materials and Packing Materials	Lower of cost and net realisable value. However materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost is determined on First In First Out basis.
Work-in-process and Finished Goods	At lower of cost (material cost net of refundable taxes, labour cost and all manufacturing overheads) and net realisable value.
Stores and Spares	Stores and spare parts are valued at lower of cost computed on First-in-First- out method and net realisable value.
Traded Goods	Traded Goods are valued at lower of cost and net realisable value.

The factors that the Company considers in determining the allowance for slow moving, obsolete and other non-saleable inventory in determining net realisable value include ageing of inventory, estimated shelf life, price changes, introduction of competitive new products and such other related factors.

Cost in case of Raw material and Packing material, Stores and Spare and Traded Goods include purchase cost net of refundable taxes and other overheads incurred in bringing such items of inventory to its present location and condition.

v. Borrowings

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the period in which they are incurred.

vi. Cash and cash equivalents.

Cash and cash equivalents include cash in hand, demand deposits in banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within bank borrowings in current liabilities in the balance sheet.

vii. Revenue recognition

- a. The Company derives revenues primarily from sale of products and services. Revenue from sale of goods is recognised net of returns, product expiry claims and discounts.

Revenue is recognized on satisfaction of performance obligations upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

To recognize revenues, the Company applies the following five step approach:

1. Identify the contract with a customer;
2. Identify the performance obligations in the contract;
3. Determine the transaction price;
4. Allocate the transaction price to the performance obligations in the contract;
5. Recognize revenues when a performance obligation is satisfied.

Performance obligation may be satisfied over time or at a point in time. Performance obligations are satisfied over time if any one of the following criteria is met. In such cases, revenue is recognized over time.

1. The customer simultaneously receives and consumes the benefits provided by the Company's performance; or
2. The Company's performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or
3. The Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date.

For performance obligations where one of the above conditions are not met, revenue is recognised at the point in time at which the performance obligation is satisfied.

Where Revenue is recognized over time, the amount of revenue is determined on the basis of contract costs incurred in relation to estimated contract expenses.

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties.

Revenue in respect of transactions through parties acting as agents is recognised only on completion of the performance obligation of the agent with corresponding accrual of agency commissions.

The Company presents revenues net of indirect taxes in its statement of profit and loss.

- b. In case of export benefits which are in the nature of neutralisation of duties and taxes are grouped under material costs. All other export incentives are grouped under other operating revenue.
- c. Revenue in respect of insurance/other claims, commission, etc. are recognised only when it is reasonably certain that the ultimate collection will be made.

- d. For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). Interest income is included in finance income in the statement of profit and loss.

viii. Impairment of assets

Carrying amount of Tangible assets, Intangible assets, Investments in Subsidiaries, Joint Venture and Associates (which are carried at cost) are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or Company's assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

ix. Leases

The Company, as a lessee, recognizes a right-of-use asset and a lease liability for its leasing arrangements, if the contract conveys the right to control the use of an identified asset.

The contract conveys the right to control the use of an identified asset, if it involves the use of an identified asset and the Company has substantially all of the economic benefits from use of the asset and has right to direct the use of the identified asset. The cost of the right-of-use asset shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date plus any initial direct costs incurred. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate.

For short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the lease term.

x. Provisions, contingent liabilities and contingent assets

Provision

A Provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

Contingent liabilities

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

xi. Retirement and other employee benefits**Provident fund**

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as an expense when an employee renders the related service.

Gratuity

The Company provides for the gratuity, a defined benefit retirement plan covering all employees. The plan provides for lump sum payments to employees upon death while in employment or on separation from employment after serving for the stipulated year mentioned under 'Code on Social Security, 2020' which has been notified and made effective from 21 November 2025, thereby replacing the erstwhile Payment of Gratuity Act, 1972. The Company also complies with provision of new labour codes 2025.

Gratuity, a post-employment defined benefit obligation is provided on the basis of an actuarial valuation made at the end of each year/period on projected unit credit method.

The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

Compensated absences

The Company has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet date using Projected Unit Credit method on the additional amount expected to be paid/ availed as a result of the unused entitlement that has accumulated at the balance sheet date. Expense on non-accumulating compensated absences is recognized in the period in which the absences occur.

Short-term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. Benefits such as salaries, wages etc. and the expected cost of ex-gratia, bonus and performance incentive are recognised in the period in which the employee renders the related service. A liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

xii. Foreign currencies**Transactions and balances:**

- i. The functional currency of the Company is the Indian rupee. These financial statements are presented in Indian rupees.
- ii. Transactions denominated in foreign currency are recorded at the exchange rate on the date of transaction where the settlement of such transactions are taking place at a later date. The exchange gain/loss on settlement / negotiation during the year is recognised in the statement of profit and loss. In case of advance payment for purchase of assets/ goods/services and advance receipt against sales of products/services, all such purchase/sales transaction are recorded at the rate at which such advances are paid/received.
- iii. Foreign currency monetary transactions remaining unsettled at the end of the year are converted at year-end rates. The resultant gain or loss is accounted for in the statement of profit and loss.
- iv. Non-monetary items that are measured at historical cost denominated in foreign currency are translated using exchange rate at the date of transaction.

xiii. Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

xiv. Financial instruments**a. Financial assets & financial liabilities****Initial recognition and measurement**

All financial assets and liabilities are recognised initially at fair value.

In the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset is treated as cost of acquisition. Purchases or sales of financial assets that require

delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 7 details how the entity determines whether there has been a significant increase in credit risk. For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

De-recognition of financial instruments

A financial asset is de-recognised only when

- The Company has transferred the rights to receive cash flows from the financial asset or
- Retains the contractual rights to receive the cash flows of the financial asset but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is de-recognised. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not de-recognised.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is de-recognised if the Company has not retained control of the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

A financial liability (or a part of a financial liability) is de-recognized from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

b. Derivative financial instruments and hedge accounting

Initial recognition and subsequent measurement

The Company uses derivative financial instruments such as forward currency contracts, interest rate swaps to hedge its foreign currency risks, interest rate risks, respectively.

Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The purchase contracts that meet the definition of a derivative under Ind AS 109 are recognised in the statement of profit and loss.

xv. Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

xvi. Goods and service tax input credit

Input tax credit is accounted for in the books in the period in which the underlying service received is accounted and when there is reasonable certainty in availing / utilising the credits.

xvii. Taxes

Tax expenses comprise Current Tax and Deferred Tax :

a. Current tax

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

b. Deferred tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the standalone financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill.

Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit (tax loss). Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

For items recognised in OCI or equity, deferred / current tax is also recognised in OCI or equity.

c. MAT credit

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and loss as current tax. The Company recognises MAT credit available as an asset only to the extent that there is reasonable certainty that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. The MAT credit to the extent there is reasonable certainty that the Company will utilize the credit is recognised in the statement of profit and loss and corresponding debit is done to the deferred tax asset as unused tax credit.

xviii. Earnings per share

Earnings per share is calculated by dividing the net profit or loss before OCI for the year by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss before OCI for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

(All Figures are Rupees in Lacs unless otherwise stated)

Notes to Standalone financial statements as at and for the year ended March 31, 2026

3. Property, Plant and Equipment

Particulars	Freehold Land	Building	Plant and Equipment	Office and Other Equipment	Effluent Treatment Plant	Furniture and Fixtures	Vehicles	R & D - Plant and Equipment	Total
Gross Block									
As on 31/03/2024	210.23	1,644.63	3,212.83	27.80	11.98	100.22	28.37	91.81	5,327.87
Additions	-	-	31.02	0.06	-	-	-	-	31.08
(Disposals) / Adjustments	(180.36)	(734.24)	(63.24)	(1.79)	-	-	-	-	(979.63)
As on 31/03/2025	29.87	910.39	3,180.61	26.07	11.98	100.22	28.37	91.81	4,379.32
Additions	-	0.93	32.99	0.27	-	0.63	-	-	34.81
(Disposals) / Adjustments	-	-	-	(0.17)	-	-	(3.15)	-	(3.32)
As on 31/03/2026	29.87	911.31	3,213.60	26.16	11.98	100.85	25.22	91.81	4,410.81
Accumulated Depreciation									
As on 31/03/2024	-	333.23	981.61	19.31	5.26	54.67	15.43	65.99	1,475.50
Charge for the year	-	28.55	203.70	3.02	0.59	5.85	2.29	4.91	248.91
(Disposals) / Adjustments	-	(99.16)	(37.56)	(1.15)	-	-	-	-	(137.87)
As on 31/03/2025	-	262.62	1,147.75	21.18	5.85	60.52	17.72	70.90	1,586.54
Charge for the year	-	26.80	205.29	1.80	0.59	5.84	1.88	4.91	247.12
(Disposals) / Adjustments	-	-	-	(0.16)	-	-	(2.49)	-	(2.65)
As on 31/03/2026	-	289.43	1,353.05	22.81	6.45	66.35	17.11	75.82	1,831.01
Net Block as on 31/03/2025	29.87	647.77	2,032.86	4.88	6.13	39.70	10.65	20.91	2,792.78
Net Block as on 31/03/2026	29.87	621.89	1,860.55	3.36	5.53	34.49	8.12	15.99	2,579.80

(All Figures are Rupees in Lacs unless otherwise stated)

3A. Other Intangible Assets

Particulars	Computer Software	Brand / Trade Mark	Total
Gross Block			
As on 31/03/2024	22.74	0.13	22.87
Additions	-	-	-
(Disposals) / Adjustments	-	-	-
As on 31/03/2025	22.74	0.13	22.87
Additions	-	-	-
(Disposals) / Adjustments	-	-	-
As on 31/03/2026	22.74	0.13	22.87
Accumulated Amortisation			
As on 31/03/2024	16.58	0.13	16.71
Charge for the year	2.44	-	2.44
(Disposals) / Adjustments	-	-	-
As on 31/03/2025	19.02	0.13	19.15
Charge for the year	1.89	-	1.89
(Disposals) / Adjustments	-	-	-
As on 31/03/2026	20.92	0.13	21.05
Net Block as on 31/03/2025	3.72	-	3.72
Net Block as on 31/03/2026	1.82	-	1.82

3B. Right to Use Asset

Particulars	Land	Building	Total
Gross Block			
As on 31/03/2024	257.03	-	257.03
Additions	-	159.58	159.58
(Disposals) / Adjustments	(257.03)	-	(257.03)
As on 31/03/2025	-	159.58	159.58
Additions	-	-	-
(Disposals) / Adjustments	-	-	-
As on 31/03/2026	-	159.58	159.58
Accumulated Amortisation			
As on 31/03/2024	127.73	-	127.73
Charge for the year	14.98	18.31	33.29
(Disposals) / Adjustments	(142.71)	-	(142.71)
As on 31/03/2025	(0.00)	18.31	18.31
Charge for the year	-	31.39	31.39
(Disposals) / Adjustments	-	-	-
As on 31/03/2026	(0.00)	49.70	49.70
Net Block as on 31/03/2025	0.00	141.27	141.27
Net Block as on 31/03/2026	0.00	109.88	109.88

(All Figures are Rupees in Lacs unless otherwise stated)

3C. Capital Work In Progress/ Intangible Assets Under Development

Particulars	Capital Work In Progress			Intangible Assets Under Development	
	Building	Proj Exp Pending Allocation	Plant and Equipment	Total	Software
As at 31st March 2024	-	-	-	-	-
Additions	-	-	3.61	3.61	-
Capitalization	-	-	-	-	-
As at 31st March 2025	-	-	3.61	3.61	-
Additions	-	-	5.64	5.64	-
Capitalization	-	-	3.61	3.61	-
As at 31st March 2026	-	-	5.64	5.64	-

CWIP and Intangible asset under development Ageing Schedule

As at Mar 31, 2026

CWIP for a period of	Projects in progress	Projects temporarily suspended	Total CWIP	Intangible Assets Under Development
Less than 1 year	5.64	-	5.64	-
1-2 years	-	-	-	-
2-3 years	-	-	-	-
More than 3 years	-	-	-	-
Total	5.64	-	5.64	-

As at Mar 31, 2025

CWIP for a period of	Projects in progress	Projects temporarily suspended	Total CWIP	Intangible Assets Under Development
Less than 1 year	3.61	-	3.61	-
1-2 years	-	-	-	-
2-3 years	-	-	-	-
More than 3 years	-	-	-	-
Total	3.61	-	3.61	-

Note : There are no cost or time overruns of CWIP as at March 31,2026 and March 31, 2025.

(All Figures are Rupees in Lacs unless otherwise stated)

4. Financial Assets - Investments

A. Summary of Non Current Investments

	As at 31/03/2026	As at 31/03/2025
Investment in Equity Instruments measured at Cost	2,244.41	2,244.41
Investment in Equity Instruments measured at Fair value through OCI	15.37	14.42
Total	2,259.78	2,258.83

B. Details of Non-current Investments

	Face Value per Equity Instrument (₹)	Number Of Equity Instruments		Amount	
		31-03-2026	31-03-2025	31-03-2026	31-03-2025
Investments measured at Cost fully paid					
Quoted equity shares					
1. Resonance Specialties Ltd - (Subsidiary)*	10	52,50,000	52,50,000	2,244.41	2,244.41
Investments measured at FVTOCI fully paid up					
Quoted equity shares					
1. Ipca Laboratories Ltd	1	960	960	15.37	14.42
Total				2,259.78	2,258.83

*Resonance Specialties Limited, an entity in which there is de facto control and in which the Company's interest is 45.48%. The Holding Company M/s Kaygee Investments Private Limited holds around 8.77% and is expected to vote towards the resolution in accordance with voting by the Holding Company and therefore the Company asserts that it has de facto control over Resonance Specialties Limited.

C. Aggregate Book value of investments

Particulars	31-03-2026	31-03-2025
Aggregate amount of quoted investments	2,259.78	2,258.83
Aggregate market value of quoted investments	4,106.70	3,535.07

D. Disclosure Under Section 186(4) of the Companies Act 2013

There are no transaction to be reported under 186(4).

5. Financial Assets - Loans

Particulars	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
(Unsecured, considered good)				
Loans given to Employees	-	-	-	0.17
Total	-	-	-	0.17

(All Figures are Rupees in Lacs unless otherwise stated)

6. Financial Assets - Others

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
(Unsecured, considered good)				
Gratuity reimbursements and other claims receivable	-	7.89	-	2.90
Interest Receivable	-	0.70	-	0.84
Other Receivable				
- Others	-	26.27	-	19.89
Deposits	88.21	-	87.29	-
Total	88.21	34.86	87.29	23.63

7. Other Non-Financial Assets

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
(Unsecured, considered good)				
Prepaid Expenses	3.24	12.45	2.98	10.44
Balance with Tax Authorities	-	152.20	-	172.50
Advance to suppliers	-	83.24	-	7.46
Advances to Employees	-	3.06	-	5.95
Advances to Others	-	6.50	-	0.49
Prepaid Taxes (Net of provisions)	300.65	-	240.98	-
Other Receivables	-	46.87	-	32.39
Prepaid Rent-Others	1.42	0.67	2.10	0.67
Total	305.31	304.99	246.06	229.90

8. Inventories (Valued at Lower of Cost and Net Realisable Value)

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
Raw Materials and components		235.68		153.70
Packing Materials and components		117.32		86.82
Work-in-progress		29.15		41.20
Finished goods:				
Manufactured	110.12		63.15	
Traded	538.17		409.70	
In transit	18.79	667.08	17.18	490.03
Consumable Stores and Spares		14.80		9.24
Total		1,064.03		780.99

(All Figures are Rupees in Lacs unless otherwise stated)

The disclosure of inventories recognised as an expense in accordance with paragraph 36 of Ind AS 2 is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Amount of inventories recognised as an expense	2,694.68	2,408.51
Total	2,694.68	2,408.51

9. Financial Assets - Trade Receivables (Unsecured, at amortised cost)

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables-Considered good	596.88	567.05
Trade Receivables-significant increase in credit risk	46.24	44.00
Trade Receivables-Credit impaired	-	-
	643.12	611.05
Less: Expected credit loss allowance	(46.24)	(44.00)
Total	596.88	567.05

Movement in the expected credit loss allowance

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the period	44.00	22.89
Adjustment during the year (Net)	2.24	21.11
Provision at the end of the period	46.24	44.00

Since the Company calculates impairment under the simplified approach the Company does not track the changes in credit risk of trade receivables. The impairment amount represents lifetime expected credit loss. Hence the additional disclosures in trade receivables for changes in credit risk and credit impaired trade receivables are not disclosed.

As at March 31, 2026 (Ageing from due date of payment)

Range of O/s period	Undisputed			Total
	Considered Good	Significant increase in credit risk	Credit Impaired	
Unbilled	19.16	-	-	19.16
Not Due	519.20	-	-	519.20
less than 6 months	51.05	5.32	-	56.37
6 months - 1 year	7.47	0.77	-	8.24
1-2 year	-	9.80	-	9.80
2-3 year	-	19.89	-	19.89
> 3 years	-	10.46	-	10.46
Total	596.88	46.24	-	643.12

(All Figures are Rupees in Lacs unless otherwise stated)

As at March 31, 2025 (Ageing from due date of payment)

Range of O/s period	Undisputed			Total
	Considered Good	Significant increase in credit risk	Credit Impaired	
Unbilled	40.60	-	-	40.60
Not Due	447.20	-	-	447.20
less than 6 months	67.77	5.91	-	73.68
6 months - 1 year	11.48	1.50	-	12.98
1-2 year	-	25.53	-	25.53
2-3 year	-	11.06	-	11.06
> 3 years	-	-	-	-
Total	567.05	44.00	-	611.05

There are no disputed Trade receivable as at March 2026 and March 2025.

10. Financial Assets - Cash & Cash Equivalents

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Balances with banks	1.09	1.57
Cash on hand	0.62	0.23
Total	<u>1.71</u>	<u>1.80</u>

11. Financial Assets - Bank Balances other than (10) above

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Unpaid dividend accounts	0.81	2.43
Total	<u>0.81</u>	<u>2.43</u>

Note: Amounts required to be transferred to Investor Education Protection Fund are transferred.

12. Equity Share Capital

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>No. of Shares</u>	<u>Amount</u>	<u>No. of Shares</u>	<u>Amount</u>
Face Value per share (₹)		10		10
Authorised Capital	75,00,000	750.00	75,00,000	750.00
Issued, Subscribed and Paid up Capital				
Issued & Subscribed	59,00,376	590.04	59,00,376	590.04
Paid up	59,00,376	590.04	59,00,376	590.04
Total		<u>590.04</u>		<u>590.04</u>

(All Figures are Rupees in Lacs unless otherwise stated)

Disclosures:

i) Reconciliation of Shares

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Numbers</u>	<u>Amount</u>	<u>Numbers</u>	<u>Amount</u>
Shares outstanding at the beginning of the period	59,00,376	590.04	59,00,376	590.04
Shares Issued during the period	-	-	-	-
Shares outstanding at the end of the peirod	59,00,376	590.04	59,00,376	590.04

ii) Details of Shareholding in excess of 5%

<u>Name of Shareholder</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Number of shares held</u>	<u>%</u>	<u>Number of shares held</u>	<u>%</u>
Kaygee Laboratories Private Limited	8,46,720	14.35%	8,46,720	14.35%
Kaygee Investments Private Limited (refer note iia)	21,75,859	36.88%	10,25,280	17.38%
Paschim Chemicals Private Limited (refer note iia)	-	-	9,66,672	16.38%

ii a) During the year, pursuant to the Scheme of Merger ('the Scheme') of Paschim Chemicals Private Limited, Mexin Medicaments Private Limited and Kaygee Investments Private Limited under the provisions of Sections 233 of the Companies Act, 2013 which has been approved by the Hon'ble Regional Director, North Western Region, Mumbai vide their order delivered on June 26, 2025, which has been filed with the Registrar of Companies on July 15, 2025, to make the Scheme effective. Paschim Chemicals Private Limited and Mexin Medicaments Private Limited are merged with Kaygee Investments Private Limited and therefore the shares of Paschim and Mexin have got added to the share holding of Kaygee Investments as at March 31, 2026.

iii) Rights and obligations of shareholders

The Company has only one class of share referred as Equity shares having a par value of ₹10/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after payment of external liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders. The dividend is recommended by management which is subject to shareholder's approval at the General Meeting.

(All Figures are Rupees in Lacs unless otherwise stated)

iv) Shareholding of Promoters

Shares held by promoters as at March 31, 2026

Sr no	Promoter name	Shares held by promoters		Change in Promoter Shareholding
		No of shares	% of total shares	
1	Kaygee Investments Pvt Ltd (refer note iia)	21,75,859	36.88%	19.50%
2	Paschim Chemicals Pvt Ltd (refer note iia)	-	0.00%	-16.38%
3	Kaygee Laboratories Pvt Ltd	8,46,720	14.35%	-
4	Mexin Medicaments Pvt Ltd (refer note iia)	-	0.00%	-3.12%
5	Chandurkar investments Pvt Ltd	84,411	1.43%	-
6	Premchand Godha	1,27,033	2.15%	-
7	Prashant Godha	1,22,937	2.08%	-
8	Nirmal Jain	95,875	1.62%	-
9	Usha Godha	57,315	0.97%	-
10	Usha Chandurkar	41,000	0.69%	-
11	Bhawna Godha	42,206	0.72%	-
12	Sameer Chandurkar	22,000	0.37%	-
	Total	36,15,356	61.27%	
		59,00,376	100.00%	

Shares held by promoters at March 31, 2025

Sr no	Promoter name	Shares held by promoters		Change in Promoter Shareholding
		No of shares	% of total shares	
1	Kaygee Investments Pvt Ltd	10,25,280	17.38%	-
2	Paschim Chemicals Pvt Ltd	9,66,672	16.38%	-
3	Kaygee Laboratories Pvt Ltd	8,46,720	14.35%	-
4	Mexin Medicaments Pvt Ltd	1,83,907	3.12%	-
5	Chandurkar investments Pvt Ltd	84,411	1.43%	-
6	Premchand Godha	1,27,033	2.15%	-
7	Prashant Godha	1,22,937	2.08%	-
8	Nirmal Jain	95,875	1.62%	-
9	Usha Godha	57,315	0.97%	-
10	Usha Chandurkar	41,000	0.69%	-
11	Bhawna Godha	42,206	0.72%	-
12	Sameer Chandurkar	22,000	0.37%	-
	Total	36,15,356	61.27%	
		59,00,376	100.00%	

(All Figures are Rupees in Lacs unless otherwise stated)

13. Other Equity

<u>Particulars</u>	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Capital Reserve	-	302.76	-	302.76
Securities Premium	-	1,449.43	-	1,449.43
General Reserve	-	1,200.00	-	1,200.00
Retained Earnings	-	1,894.67	-	2,059.25
Other Comprehensive Reserve				
- Remeasurement of Investment through FVOCI	-	6.51	-	6.06
Total	-	4,853.37	-	5,017.50

a) Security Premium Reserve:

Securities premium account comprises of premium on issue of shares. The reserve is utilised in accordance with the specific provision of the Companies Act, 2013.

b) General Reserve :

The General reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. As the General reserve is created by a transfer from one component of equity to another and is not an item of other comprehensive income, items included in the General reserve will not be reclassified subsequently to the statement of profit and loss.

14. Other Financial Liabilities

<u>Particulars</u>	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Security Deposits from				
- Dealers	-	261.00	-	271.00
- Others	-	0.50	-	0.50
Unpaid dividends	-	0.81	-	2.43
Payable for Capital Goods	-	18.88	-	13.18
Interest accrued	-	48.78	-	40.74
Payable to Employees	-	35.64	-	46.11
Total	-	365.61	-	373.96

(All Figures are Rupees in Lacs unless otherwise stated)

15. Provisions

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
Provision for breakage/damage	-	-	-	0.01
Provision for product expiry	-	11.61	-	29.76
Provision for sales return	-	42.29	-	38.04
Provision for Gratuity	-	-	-	2.11
Provision for leave encashment	26.13	8.53	17.48	9.24
Provision for leave travel assistance (LTA)	-	7.30	-	6.97
Provision for Tax (Net of prepaid)	-	25.12	-	25.12
Total	26.13	94.85	17.48	111.25

The disclosure of provisions movement as required by Ind AS 37 is as follows:-

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
(i) Provision for breakage/damage		
Balance at the beginning of the period	0.01	0.01
Provisions/ Reversal during the year.	(0.01)	-
Utilisations during the period	-	-
Provision at the end of the period	-	0.01
(ii) Provision for product expiry		
Balance at the beginning of the period	29.76	26.43
Provisions/ Reversal during the year.	(18.15)	3.33
Utilisations during the period	-	-
Provision at the end of the period	11.61	29.76
(iii) Provision for sales return		
Balance at the beginning of the period	38.04	54.70
Provisions/ Reversal during the year.	4.25	(16.66)
Utilisations during the period	-	-
Provision at the end of the period	42.29	38.04

(All Figures are Rupees in Lacs unless otherwise stated)

(iv) Disclosure in accordance with Ind AS – 19 “Employee Benefits”, of the Companies (Indian Accounting Standards) Rules, 2015.

Gratuity

The Company's liabilities under 'Code on Social Security, 2020' which has been notified and made effective from November 21, 2025, thereby replacing the erstwhile Payment of Gratuity Act, 1972 are determined on the basis of actuarial valuation made at the end of each financial year using the projected unit credit method. The Gratuity liabilities of the Company is funded.

The following table summarizes the components of net benefit expense recognized in the statement of profit and loss and the funded status and amounts recognized in the balance sheet.

Particulars	31/03/2026	31/03/2025
Expense recognised in Statement of Profit & Loss		
Current Service cost	8.72	7.54
Interest expense	6.68	6.64
Expected Return on Plan Assets	(7.88)	(8.32)
Benefit paid but pending claim	-	-
Past Service cost	6.45	-
Total	13.97	5.86
Expense recognised in Other Comprehensive Income		
Return on plan assets (Greater)/Less than Discount Rate	1.44	0.47
Actuarial (Gain)/Loss due to Experience on DBO	5.95	(4.04)
Total	7.39	(3.57)
Present value of funded defined benefit obligation	129.03	122.56
Fair value of Plan assets	(135.51)	(120.45)
Funded Status	(6.48)	2.11
Net defined benefit (Asset) / Liability	(6.48)	2.11
Movements in present value of defined benefit obligation		
Present value of defined benefit obligation at the beginning of the year	122.56	109.13
Current Service Cost	8.72	7.54
Interest Cost	6.68	6.64
Actuarial (Gain)/Loss	(5.95)	4.04
Benefits paid	(9.43)	(4.79)
Past Service Cost	6.45	-
Present value of defined benefit obligation at the end of the year	129.03	122.56
Movements in fair value of the plan assets are as follows		
Opening fair value of plan assets	120.45	115.86
Adjustment to opening fair value	-	-
Expected returns on Plan Assets	7.88	8.32
Remeasurement (Gains)/Losses:	-	-
Actuarial (Gain)/Loss on Plan assets	1.44	0.47

(All Figures are Rupees in Lacs unless otherwise stated)

Contribution from Employer	15.16	-
Benefits paid	-	-
Fund Charges	-	-
Benefit paid but pending claim	(9.43)	(4.19)
Closing fair value of the plan asset	135.50	120.46

Remeasurement effect recognised on Other Comprehensive Income

Actuarial (Gain)/Loss arising from experience adjustments	(5.95)	4.04
Actuarial (Gain)/Loss on Plan assets	(1.44)	(0.47)
Total Actuarial (Gain)/Loss included in OCI	(7.39)	3.57

The principal assumptions used as at the balance sheet date are used for purpose of actuarial valuations were as follow:

(v) Financial Assumptions

Discount Rate	6.71%	6.54%
Salary Increase Rate	6.00%	6.00%

(vi) Demographic Assumptions

Mortality Rate	IALM (2012-14) Ultimate	IALM (2012-14) Ultimate
Withdrawal Rate	25%	25%
Retirement age	58 Years	58 Years

The rate used to discount post-employment benefit obligations is determined by reference to market yields at the end of the reporting period on government bonds.

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and mortality.

The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of reporting period, while holding all other assumptions constant.

(vii) Defined Benefit Obligation

Discount rate

a. Discount rate - 50 basis points	130.71	124.11
b. Discount rate + 50 basis points	127.40	121.06

Salary increase rate

a. Rate - 50 basis points	127.08	120.77
b. Rate + 50 basis points	131.02	124.39

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would clear in isolation of one another as some of the assumptions may be correlated.

Further more, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

(All Figures are Rupees in Lacs unless otherwise stated)

(viii) Risk Characteristics of the Defined Benefit Plan

Valuations are based on certain assumptions, which are dynamic in nature and vary over time. As such company is exposed to various risks as follow

- (i) Investment Risk :** For funded plans that rely on insurers for managing the assets, the value of assets certified by the insurer may not be the fair value of instruments backing the liability. In such cases, the present value of the assets is independent of the future discount rate. This can result in wide fluctuations in the net liability or the funded status if there are significant changes in the discount rate during the inter-valuation period.
- (ii) Market Risk (Discount Rate) :** Market risk is a collective term for risks that are related to the changes and fluctuations of the financial markets. The discount rate reflects the time value of money. An increase in discount rate leads to decrease in Defined Benefit Obligation of the plan benefits & vice versa. This assumption depends on the yields on the corporate/government bonds and hence the valuation of liability is exposed to fluctuations in the yields as at the valuation date.
- (iii) Longevity Risk :** The impact of longevity risk will depend on whether the benefits are paid before retirement age or after. Typically for the benefits paid on or before the retirement age , the longevity risk is not very material.
- (iv) Actuarial Risk :**
 Salary Increase Assumption: Actual Salary increase that are higher than the assumed salary escalation , will result in increase to the Obligation at a rate that is higher than expected
 Attrition / Withdrawal Assumption: If actual withdrawal rates are higher than assumed withdrawal rate assumption, then the benefits will be paid earlier than expected. The impact of this will depend on whether the benefits are vested as at the resignation date.
- (v) Regulatory Risk :**
 Any Changes to the current Regulations by the Government, will increase (in most cases) or Decrease the obligation which is not anticipated. Sometimes, the increase is many fold which will impact the financials quite significantly.

16. Deferred Tax Liabilities (Net)

Particulars	As at March 31, 2026		As at March 31, 2025	
(a) Deferred tax liabilities on account of				
PPE including ROU Assets(Net)	313.04		316.79	
Fair Value Change of Investment through OCI	1.80	314.84	1.30	318.09
(b) Deferred tax asset on account of				
Compensated Absences	(9.23)		(9.24)	
Carried forward losses	-		(7.13)	
Unabsorbed depreciation*	(273.60)		(241.63)	
Other tax disallowance	(11.65)	(294.48)	(11.08)	(269.08)
Net deferred tax liability		20.36		49.01

*The company continues to create deferred asset on unabsorbed depreciation on the estimations that the Company will be having sufficient profit to absorb the depreciation losses.

(All Figures are Rupees in Lacs unless otherwise stated)

17. Other Non-financial Liabilities

<u>Particulars</u>	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Advance from Customers- Contract Liabilities				
-Related Party *	-	238.62	-	150.00
-Others	-	0.99	-	9.62
Duties & Taxes Payable	-	12.91	-	12.47
Statutory dues payable	-	6.24	-	6.37
Total	-	258.76	-	178.46

* Ipca Laboratories Ltd

18. Short Term Borrowings

<u>Particulars</u>	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Secured				
Working Capital Facility from Yes bank	-	270.28	-	29.64
Total	-	270.28	-	29.64

(a) **Security:**

Exclusive charge on present and future current asset of the Company.

Negative Lien on Plot No. 30/4, Makers Laboratories Ltd., Nr. Sovereign Metals Limited, Lane 3, Phase -3, Naroda GIDC, Naroda, GIDC Road, Ahmedabad- 382330.

(b) The rate of interest on short term borrowings is Repo Rate plus Spread 3%.

(c) **Charge creation / satisfaction with Registrar of companies:**

Charge Creation: The Company has created on the existing working capital facility on present and future current asset of the Company.

Charge Satisfaction: There are charges appearing on MCA portal amounting to ₹ 1,332.01 Lacs as at March 31, 2026 in respect of borrowings which have been already repaid by the Company. The Company is unable to close the satisfaction for lack of requisite documentation. The matter is being followed up by the Company.

(d) **Changes in liabilities arising out of Financing Activities as per IndAS 7**

<u>Particulars</u>	As at March 31, 2026	
	Non-Current Borrowings	Current Maturities and Current Borrowings
Opening Balances	-	29.64
Changes from Financing Cash Flows	-	240.64
Effect of changes in foreign currency	-	-
Transfer to Current Maturities	-	-
Other Changes	-	-
Closing Balances	-	270.28

(All Figures are Rupees in Lacs unless otherwise stated)

Particulars	As at March 31, 2025	
	Non-Current Borrowings	Current Maturities and Current Borrowings
Opening Balances	600.00	758.16
Changes from Financing Cash Flows	(600.00)	(728.52)
Effect of changes in foreign currency	-	-
Transfer to Current Maturities	-	-
Other Changes	-	-
Closing Balances	-	29.64

19. Financial Liabilities - Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Payables for goods and services:		
- Total outstanding dues of Micro and small enterprise	240.47	88.95
- Others	515.80	537.52
Total	756.27	626.47

Trade payables and acceptances are non-interest bearing and are normally settled between 0-120 days.

Details of dues to micro and small enterprises as defined under MSMED Act, 2006

Particulars	As at March 31, 2026	As at March 31, 2025
Principal amount due	240.47	88.95
Interest due on above	0.79	0.17
Amount paid in terms of Sec 16 of the Micro, Small and Medium Enterprise Development Act, 2006		
- Principal amount paid beyond appointed day	250.89	156.45
- Interest paid thereon	-	-
Amount of interest due and payable for the period of delay	5.77	3.13
Amount of interest accrued and remaining unpaid as at year end	47.30	40.74
Amount of further interest remaining due and payable in the succeeding year	-	-

The company has compiled the above information based on written confirmations from suppliers and have been determined to the extent such parties have been identified on the basis of the information available with the company.

(All Figures are Rupees in Lacs unless otherwise stated)

(a) As at March 31, 2026 (Ageing from due date of payment)

Range of O/s period	MSME		Others	
	Undisputed	Disputed	Undisputed	Disputed
Unbilled	-	-	153.79	-
Not Due	201.59	-	285.97	-
Less than 1 year	38.88	-	76.04	-
1-2 years	-	-	-	-
2-3 year	-	-	-	-
> 3 years	-	-	-	-
Total	240.47	-	515.80	-

(b) As at March 31, 2025 (Ageing from due date of payment)

Range of O/s period	MSME		Others	
	Undisputed	Disputed	Undisputed	Disputed
Unbilled	-	-	136.49	-
Not Due	71.79	-	324.29	-
Less than 1 year	17.16	-	75.63	-
1-2 years	-	-	1.11	-
2-3 year	-	-	-	-
> 3 years	-	-	-	-
Total	88.95	-	537.52	-

20. Revenue from Operations

Particulars	Apr-Mar 26	Apr-Mar 25
Sale of Products	3,679.21	3,465.20
Sale of Services	1,052.96	827.13
Other operating revenues		
Sundry Creditors Balances written back	1.11	0.34
Compensation received	300.00	-
Miscellaneous income	1.45	1.79
Total	5,034.73	4,294.46

A. Disclosure in accordance with Ind AS - 115 "Revenue Recognition Disclosures", of the Companies (Indian Accounting Standards) Rules, 2015

(a) Disclosure relating to disaggregation of revenue in terms of Ind AS 115	Apr-Mar 26	Apr-Mar 25
Sale of Generic formulations	3,679.21	3,465.20
Sale of Services	1,052.96	827.13

(b) There is one party (PY two parties) which individually account for more that 10% of sales of the company. Aggregate revenue from these parties is ₹ 1,626.59 Lacs (PY ₹ 1,521.65 lacs). Of the above ₹ 1,626.59 Lacs (PY ₹ 1,070.98 Lacs) pertains to related party- Ipca Laboratories Ltd.

B. Movement of Contract Balances

(a) Contractual Liabilities	Apr-Mar 26	Apr-Mar 25
Opening Balance	159.62	172.29
Addition during the year	239.61	159.62
Billed/Received during the Year	(159.62)	(172.29)
Closing Balance	239.61	159.62

The outstanding performance obligation is expected to be discharged in next one year.

(All Figures are Rupees in Lacs unless otherwise stated)

(b) Unbilled Revenue (part of trade receivable)	Apr-Mar 26	Apr-Mar 25
Opening Balance	40.60	25.01
Addition during the year	19.16	40.60
Billed/Received during the Year	(40.60)	(25.01)
Closing Balance	19.16	40.60

21. Other Income

Particulars	Apr-Mar 26	Apr-Mar 25
Interest income	4.54	5.69
Interest income on financial asset on EIR basis	0.73	0.72
Reversal of Loss on leasehold Property Ind As	-	56.95
Dividend income - from investments	52.52	0.04
Profit on sale of property, plant & equipment	0.77	1,010.34
Rent Income	-	18.13
Miscellaneous Income	0.72	0.41
Remeasurement of Financial Assets (IND AS)	-	0.07
Total	59.28	1,092.35

22. Cost of Materials Consumed

Particulars	Apr-Mar 26	Apr-Mar 25
Raw Materials Consumed		
Opening stock	153.70	65.77
Add : Purchases (Net of discount)	463.64	426.30
	617.34	492.07
Less : Closing stock	235.68	153.70
	381.66	338.37
Packing Materials Consumed		
Opening stock	86.82	92.22
Add : Purchases (Net of discount)	195.33	137.79
	282.15	230.01
Less : Closing stock	117.32	86.82
	164.83	143.19
Total	546.49	481.56

23. Purchases of Traded Goods

Particulars	Apr-Mar 26	Apr-Mar 25
Formulations	2,147.09	1,432.98
Others	73.27	26.66
Total	2,220.36	1,459.64

(All Figures are Rupees in Lacs unless otherwise stated)

24. Changes in inventories of Finished Goods(FG), Work-in-progress(WIP) and Traded Goods

Particulars	Apr-Mar 26		Apr-Mar 25	
Inventory Adjustments - WIP				
Stock at commencement	41.20		23.72	
Less: - Stock at closing	29.15	12.05	41.20	(17.48)
Inventory Adjustments - FG				
Stock at commencement	63.15		177.26	
Less : Stock at closing	110.12	(46.97)	63.15	114.11
Inventory Adjustments - FG In transit				
Stock at commencement	17.18		29.23	
Less : Stock at closing	18.79	(1.61)	17.18	12.05
Inventory Adjustments - Traded Goods				
Stock at commencement	409.70		694.32	
Less : Stock at closing	538.17	(128.47)	409.70	284.62
Total		(165.00)		393.29

25. Employee Benefits Expenses

Particulars	Apr-Mar 26		Apr-Mar 25	
Salaries, bonus, perquisites , etc.	863.67		828.28	
Contribution to provident and other funds	43.73		40.94	
Leave encashment*	16.21		9.63	
Leave travel assistance	7.96		7.10	
Gratuity fund contributions*	13.97		5.87	
Staff welfare expenses	22.58		11.17	
Recruitment & training	0.80		1.81	
Total		968.92		904.80

*On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 which consolidate 29 existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to the new Labour Codes. The Company has assessed and disclosed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Labour Codes, amongst other things, introduce changes, including a uniform definition of wages. These changes have resulted in increase in gratuity and Leave liability arising from past service by ₹ 10.92 lacs which is recognised in the Statement of Profit & loss.

26. Finance Cost

Particulars	Apr-Mar 26		Apr-Mar 25	
Interest on loan	17.91		53.80	
Unwinding of Financial Liabilities	12.35		19.17	
Interest on Dealer's Deposit	16.24		17.86	
Interest on MSME Creditors	6.56		3.10	
Interest on Direct tax	0.01		0.05	
Total		53.07		93.98

(All Figures are Rupees in Lacs unless otherwise stated)

27. Depreciation & Amortisation

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Depreciation on Property, plant & equipment	247.12	248.91
Amortisation on Intangible Assets	1.89	2.44
Depreciation on Right of Use Assets	31.39	33.29
Total	280.40	284.64

28. Other Expenses

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Commission & Distribution Charges	134.71	117.81
Outside manufacturing charges	44.72	47.29
Power and fuel	413.68	420.62
Consumption of stores and spares	92.83	74.01
Freight, forwarding and transportation	113.12	84.84
Field staff expenses	78.89	70.97
Repairs and maintenance - Refer note 1 below	90.72	98.73
Water charges	10.00	7.91
Assets scrapped	-	2.04
Sales and marketing expenses	46.88	17.03
Brand Recall Expenses - Domestic Marketing	21.69	24.45
Product information catalogue	-	2.75
Laboratory expenses and analytical Charges	77.05	66.19
Expenditure on research & development	15.78	6.76
Rent	111.85	74.03
Rates and taxes	7.77	11.92
Travelling expenses	6.20	10.61
Professional charges	15.66	18.96
Printing and stationery	14.04	13.68
Books, subscription and software	2.74	0.65
GST expenses	4.64	7.31
Communication expenses	4.28	4.27
Insurance	14.05	10.16
Intellectual property right expenses	0.92	1.48
Remuneration to auditors - Refer note 2 below	10.23	8.97
Bank charges	0.25	0.23
Bad debts and other balance w/off	13.14	23.51
Security Charges	32.03	35.59
Miscellaneous expenses (none of which individually forms more than 1% of the operating revenue)	13.03	13.28
Total	1,390.90	1,276.04

(All Figures are Rupees in Lacs unless otherwise stated)

Details of:

1. Repairs and Maintenance:

- Building	4.51	6.05
- Machinery	84.95	90.89
- Others	1.26	1.79
	<u>90.72</u>	<u>98.73</u>

2. Remuneration To Auditors:

- Audit fees including Limited Review and Tax Audit	9.10	7.85
- Tax matters	1.13	1.12
	<u>10.23</u>	<u>8.97</u>

i) Total expenditure on R & D is included in respective heads of accounts as under:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Employee benefits expenses	0.58	0.53
Laboratory Expenses	15.78	6.76
Depreciation	4.91	4.91
Total	<u>21.27</u>	<u>12.20</u>

29. Tax Expense- Profit and Loss Account

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Current Tax	-	-
Short / Excess Provision of earlier years	-	(0.06)
Deferred Tax	(29.15)	28.81
Total	<u>(29.15)</u>	<u>28.75</u>

30. Tax Expense- Other Comprehensive Income

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Taxes on Other Comprehensive Income	0.50	0.26
Total	<u>0.50</u>	<u>0.26</u>

(i) Reconciliation of current rate of tax and effective rate of tax:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Profit/ (Loss) before Income taxes	(201.13)	492.86
Enacted tax rates in India (%)- Business	25.17%	25.17%
Enacted tax rates in India (%)- Long term Capital Gain	22.88%	22.88%
Computed expected tax expenses	(50.62)	119.84
Effect of deductible expenses	(78.15)	(312.77)
Effect of non- deductible expenses	94.69	94.90
Carry forward / (Set off) of losses	34.10	98.03
Income tax expenses	<u>0.00</u>	<u>0.00</u>
Tax on OCI	<u>(0.50)</u>	<u>(0.26)</u>

(All Figures are Rupees in Lacs unless otherwise stated)

(ii) **Reconciliation of Deferred Tax of Profit and loss account and Other Comprehensive Income**

Deferred tax (assets) / liabilities in relation to statement of profit and loss:

<u>Particulars</u>	<u>Opening (Asset)/ Liability</u>	<u>Recognized in P & L (Asset)/ Liability</u>	<u>Recognized in OCI (Asset)/ Liability</u>	<u>Closing (Asset)/ Liability</u>
PPE including ROU Assets(Net)	316.79	(3.75)	-	313.04
Compensated Absences	(9.24)	0.01	-	(9.23)
Unabsorbed Depreciation	(241.63)	(31.97)	-	(273.60)
Other tax disallowance	(11.08)	(0.57)	-	(11.65)
Unabsorbed Tax Loss	(7.13)	7.13	-	-
Fair Value Changes of Investment held through OCI	1.30	-	0.50	1.80
As at March 31, 2026	49.01	(29.15)	0.50	20.36
PPE including ROU Assets(Net)	241.39	75.40	-	316.79
Compensated Absences	(6.28)	(2.96)	-	(9.24)
Unabsorbed Depreciation	(199.03)	(42.60)	-	(241.63)
Other tax disallowance	(5.77)	(5.31)	-	(11.08)
Unabsorbed Tax Loss	(11.41)	4.28	-	(7.13)
Fair Value Changes of Investment held through OCI	1.04	-	0.26	1.30
As at March 31, 2025	19.94	28.81	0.26	49.01

31. Disclosure as required by Accounting Standard – IND AS 33 “Earning Per Share” of the Companies (Indian Accounting Standards) Rules 2015.

The earning per share is calculated by dividing the profit after tax by weighted average no. of shares outstanding for basic & diluted EPS.

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Profit/ (Loss) after tax	(171.98)	464.11
Closing equity shares outstanding (Nos.)	59,00,376	59,00,376
Opening equity shares outstanding (Nos.)	59,00,376	59,00,376
Add:- issued during the year (Nos.)	-	-
Closing equity shares outstanding (Nos.)	59,00,376	59,00,376
Weighted avg no. of shares outstanding (Nos.) (Basic)	59,00,376	59,00,376
Weighted avg no. of shares outstanding (Nos.) (Diluted)	59,00,376	59,00,376
Nominal value of equity share (₹)	10.00	10.00
Basic EPS (₹)	(2.91)	7.87
Diluted EPS (₹)	(2.91)	7.87

(All Figures are Rupees in Lacs unless otherwise stated)

32. Disclosure in accordance with Ind AS – 116 “Leases”, of the Companies (Indian Accounting Standards) Rules, 2015.

i) The following is the carrying value of lease liability:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Opening Liability	145.72	179.47
Additions during the year	-	159.59
Finance cost accrued during the year	12.34	19.10
Deletions	-	(168.24)
Payment of lease liabilities	(40.00)	(44.20)
Balance	118.06	145.72
Breakup:	Apr-Mar 26	Apr-Mar 25
Current portion of Lease liability	30.41	27.66
Non Current portion of Lease liability	87.65	118.06
	118.06	145.72

ii) Amounts recognised in the statement of cash flows

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Total cash outflow for leases	40.00	44.20

iii) The details of the contractual maturities(on undiscounted basis) of lease liabilities:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Less than one year	40.01	40.01
One to five years	97.80	137.81
More than five years	0.00	0.00
Total	137.81	177.82

The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

33. Disclosure as required by IND AS 108 "Operating Segment", of the Companies (Indian Accounting Standards) Rules, 2015.

Based on the "management approach" as defined in Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Company's performance In accordance with IND AS "Operating Segment", The Company has only one reportable operating segment i.e. Pharmaceuticals.

34. Disclosure in accordance with Ind AS - 24 "Related Party Disclosures", of the Companies (Indian Accounting Standards) Rules, 2015

A) List of related parties

Relationships

(i) Entities having control over the Company

Kaygee Investments Pvt.Ltd.

(Promoter holding together with its subsidiary holding more than 51%)

(All Figures are Rupees in Lacs unless otherwise stated)

(ii) Entities where Holding Company is having control

Kaygee Laboratories Private Limited Fellow Subsidiary

(iii) Entities where Control Exists

Resonance Specialties Limited Subsidiary

(iv) Key Management Personnel

Mr. Saahil Parikh	Whole time Director and CEO
Mr. Nilesh Jain	Whole time Director
Ms. Dipti Shah	Independent Director
Mr. R K P Verma	Independent Director
Mr. Prashant Godha	Additional Director
Mr. Vishal Jain	Additional Director

(v) Entities in which promoters have significant influence

Ipca Laboratories Ltd.

(vi) Other Related parties

Relative of Key Management Personnel
Mr. Umesh Parikh

B) Details of related party transaction are given in statement 1 attached to the financial statement.

35. Analytical Ratios as per requirements of Schedule III are given in Statement 2

36. CSR Expenditure:

Gross amount required to be spent by the Company during the year Nil (previous year Nil).

37. Contingent Liabilities and Commitments

A) Contingent Liabilities

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Other moneys for which the Company is contingently liable for tax and other matters not accepted by the Company (Out of total, ₹18.29 lacs has been paid under protest)	268.41	224.58
Total	<u>268.41</u>	<u>224.58</u>

B) Commitments

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
(a) Estimated amount of contracts remaining to be executed on capital account. (Net of Capital Advances)	-	28.70
	<u>-</u>	<u>28.70</u>

38. Financial Instruments

The carrying value and fair value of financial instruments by categories is as follows:

<u>Particulars</u>	<u>Carrying Value</u>		<u>Fair Value</u>	
	<u>31/03/2026</u>	<u>31/03/2025</u>	<u>31/03/2026</u>	<u>31/03/2025</u>
Financial Assets				
Amortised Cost				
Loans	-	0.17	-	0.17
Others	123.07	110.92	123.07	110.92
Trade receivables	596.88	567.05	596.88	567.05
Cash and cash equivalents	2.52	4.23	2.52	4.23
FVTOCI				
Equity Instruments	15.37	14.42	15.37	14.42
Total Financial Assets	<u>737.84</u>	<u>696.79</u>	<u>737.84</u>	<u>696.79</u>
Financial liabilities				
Amortised Cost				
Borrowings	270.28	29.64	270.28	29.64
Trade payables	756.27	626.47	756.27	626.47
Others	365.61	373.96	365.61	373.96
Lease Liability	118.06	145.72	118.06	145.72
Total Financial Liabilities	<u>1,510.22</u>	<u>1,175.79</u>	<u>1,510.22</u>	<u>1,175.79</u>

The management assessed that fair value of cash and short-term deposits, trade receivables, trade payables, cash credit and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

39. Fair Value Hierarchy

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

<u>Particulars</u>	<u>Date of Valuation</u>	<u>Quoted prices inactive-markets</u>	<u>Significant observable inputs</u>	<u>Significant unobservable inputs</u>	<u>Total</u>
		<u>(Level 1)</u>	<u>(Level 2)</u>	<u>(Level 3)</u>	
For the year ended March 31, 2026					
Financial assets measured at fair value through OCI					
Listed Equity Investments	31/03/2026	15.37	-	-	15.37
		15.37	-	-	15.37
For the year ended March 31, 2025					
Financial assets measured at fair value through OCI					
Listed Equity Investments	31/03/2025	14.42	-	-	14.42
		14.42	-	-	14.42

All the assets and liabilities carried at amortized cost and are equal to its fair value.

40. Financial Risk Factors

The Company's business activities are exposed to a variety of financial risks: Market/Business risk, credit risk, Exchange risk, etc. The Company's focus is to foresee the unpredictability of financial and business risks and seek to minimize potential adverse effects of these risks on its business and financial performance.

(i) Business/Market Risk

The primary business/market risk to the company is the price risk on account of the drug pricing regime in the country. The Indian generic formulations market is currently in the growth phase. It is expected that use of generic formulations will gradually increase in India. However, cut throat competition, quality issues of generics manufactured in the country and non existence of organised generic formulations distribution and retailing system are a cause of concern and is hampering the growth of generic formulations market.

(ii) Credit Risk

The Company has exposure to credit risks associated with sales to various Customers. To mitigate these credit risks arising out of this, the Company on a regular basis evaluates the credit risk associated with a customer. Customer where no credit insurance is available, the Company monitors such risk by continuously monitoring its exposure to such customer. Based on the historical data, the Company has made adequate provisions for expected loss because of credit risk, which is neither significant nor material.

41. Capital Management

For the purpose of the Company's capital management, capital includes paid-up equity share capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximize the shareholders' value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust its dividend payment ratio to shareholders, return capital to shareholders or issue fresh shares. The Company monitors capital using a gearing ratio, which is net debt divided by its total capital. The Company includes within its net debt the cash credit facilities, trade, lease and other payables less cash and cash equivalents.

<u>Particulars</u>	<u>31/03/2026</u>	<u>31/03/2025</u>
Borrowings	270.28	29.64
Less: Cash and Cash Equivalents	(1.71)	(1.80)
Net debt	268.57	27.84
Total Equity Capital and net debt	5,443.41	5,607.54
Gearing Ratio	0.05	0.00

42. Relationship with Struck off Companies

The information about transaction with struck off Companies (defined under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956) has been determined to the extent such parties have been identified on the basis of the information available with the Company and the same is relied upon by the auditors.

43. Audit Trail

The Ministry of Corporate Affairs (MCA) by the Companies (Accounts) Amendment Rules 2021 and vide notification dated 24 March, 2021 has issued the "Companies (Audit and Auditors) Amendment Rules, 2021" has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

As required under above rules, the company uses in-house developed software for its financial accounting and MIS which works along with Database – Oracle as accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all transactions recorded and the audit trail feature has not been tampered with. Further, audit trail feature is enabled for direct changes on November 24, 2024, to data when using certain access rights by the development team. However, due to system constraints, the audit trail for direct database changes done by the Database administrator is retained only for a period of three days and therefore, audit trail for the direct access changes is available only for said period.

Further, As regards the preservation of the audit trail as per the statutory requirements, at application level the same are retained for the period the edit log was enabled. In case of audit trail for direct database changes the audit trail prior to November 24, 2024 is not available since the direct database logs were enabled only from November 24, 2024 and due to system constrain the same are not retained for more than 3 days and thus to that extent the log retention are not retained by the Company.

44. Figures of the previous year have been regrouped to conform to the requirements of Schedule III.

45. The balance sheet, statement of profit and loss, cash flow statement, statement of changes in equity, statement of material accounting policy information and the other explanatory notes forms an integral part of the financial statements of the Company for the year ended March 31,2026.

As per our report of even date attached**For N V C & ASSOCIATES LLP**

Chartered Accountants

Firm Registration No. 106971W / W101085

For and on behalf of the Board of Directors**Saahil Parikh**

(DIN 00400079)

Wholetime Director & CEO

Nilesh Jain

(DIN 05263110)

Wholetime Director

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

Piyush Ajmera

ACS No : 58712

Company Secretary

Sandeep Kadam

Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Statement - 1

Related Party Disclosure as required by Indian Accounting Standard – IND AS 24 "Related Party Transactions" of the Companies (Accounting Standards) Rule 2015.

Transactions with Related Parties

Description	Entities having control over the Company		Subsidiary		Key Management Personnel		Entities in which promoters have significant influence		Other Related Parties		Total	
	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25
Purchase of goods and services												
Ipca Laboratories Ltd	-	-	-	-	-	-	72.45	99.68	-	-	72.45	99.68
TOTAL	-	-	-	-	-	-	72.45	99.68	-	-	72.45	99.68
Purchase of assets												
Ipca Laboratories Ltd	-	-	-	-	-	-	1.81	-	-	-	1.81	-
TOTAL	-	-	-	-	-	-	1.81	-	-	-	1.81	-
Sale of Assets												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	1,850.00	-	-	-	1,850.00
TOTAL	-	-	-	-	-	-	-	1,850.00	-	-	-	1,850.00
Sales of goods and services												
Ipca Laboratories Ltd	-	-	-	-	-	-	1,626.59	1,070.98	-	-	1,626.59	1,070.98
TOTAL	-	-	-	-	-	-	1,626.59	1,070.98	-	-	1,626.59	1,070.98
Rent income Received												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	16.80	-	-	-	16.80
Resonance Specialties Ltd	-	-	-	1.33	-	-	-	-	-	-	-	1.33
TOTAL	-	-	-	1.33	-	-	-	16.80	-	-	-	18.13
Dividend Income:												
Ipca Laboratories Ltd	-	-	-	-	-	-	0.02	0.04	-	-	0.02	0.04
Resonance Specialties Ltd	-	-	52.50	-	-	-	-	-	-	-	52.50	-
TOTAL	-	-	52.50	-	-	-	0.02	0.04	-	-	52.52	0.04
Other expenses paid:												
Ipca Laboratories Ltd	-	-	-	-	-	-	40.01	29.02	-	-	40.01	29.02
TOTAL	-	-	-	-	-	-	40.01	29.02	-	-	40.01	29.02
Other expenses recovered:												
Ipca Laboratories Ltd	-	-	-	-	-	-	0.03	6.91	-	-	0.03	6.91
TOTAL	-	-	-	-	-	-	0.03	6.91	-	-	0.03	6.91
Advance received												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	150.00	-	-	-	150.00
TOTAL	-	-	-	-	-	-	-	150.00	-	-	-	150.00
ICD received												
Kaygee Investments Pvt Ltd	-	150.00	-	-	-	-	-	-	-	-	-	150.00
TOTAL	-	150.00	-	-	-	-	-	-	-	-	-	150.00
ICD Paid												
Kaygee Investments Pvt Ltd	-	750.00	-	-	-	-	-	-	-	-	-	750.00
TOTAL	-	750.00	-	-	-	-	-	-	-	-	-	750.00

Description	Entities having control over the Company		Subsidiary		Key Management Personnel		Entities in which promoters have significant influence		Other Related Parties		Total	
	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25
ICD interest paid												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	-	-	-	-	-
Kaygee Investments Pvt Ltd	-	25.18	-	-	-	-	-	-	-	-	-	25.18
TOTAL	-	25.18	-	-	-	-	-	-	-	-	-	25.18
Rent Deposit Refund												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	-	-	-	-	-
Resonance Specialties Ltd	-	-	-	1.50	-	-	-	-	-	-	-	1.50
TOTAL	-	-	-	1.50	-	-	-	-	-	-	-	1.50
Remuneration to Directors												
Mr. Saahil Parikh	-	-	-	-	67.98	62.49	-	-	-	-	67.98	62.49
Mr. Nilesh Jain	-	-	-	-	38.50	35.37	-	-	-	-	38.50	35.37
TOTAL	-	-	-	-	106.48	97.86	-	-	-	-	106.48	97.86
Provident Fund												
Mr. Saahil Parikh	-	-	-	-	5.36	4.99	-	-	-	-	5.36	4.99
Mr. Nilesh Jain	-	-	-	-	3.25	3.03	-	-	-	-	3.25	3.03
TOTAL	-	-	-	-	8.61	8.02	-	-	-	-	8.61	8.02
Sitting Fee to Non-executive Directors												
Mrs. Dipti Shah	-	-	-	-	1.65	1.65	-	-	-	-	1.65	1.65
Mr. R K P Verma	-	-	-	-	1.85	1.85	-	-	-	-	1.85	1.85
Mr. Prashant Godha	-	-	-	-	0.75	0.75	-	-	-	-	0.75	0.75
Mr. Vishal Jain	-	-	-	-	2.05	2.05	-	-	-	-	2.05	2.05
TOTAL	-	-	-	-	6.30	6.30	-	-	-	-	6.30	6.30
Salaries Paid												
Mr. Umesh Parikh	-	-	-	-	-	-	-	-	23.61	23.88	23.61	23.88
TOTAL	-	-	-	-	-	-	-	-	23.61	23.88	23.61	23.88
Closing Balances of Related Parties												
Balance at year end												
Payables												
Ipca Laboratories Ltd	-	-	-	-	-	-	216.75	147.94	-	-	216.75	147.94
TOTAL	-	-	-	-	-	-	216.75	147.94	-	-	216.75	147.94

- 1 The above disclosure of Related Party Transaction is without considering the impacts of IND AS Adjustments and are based on the actual transaction values.
- 2 Managerial remuneration excludes provision for short term benefits as the incremental liability has been accounted by the Company as a whole

(All Figures are Rupees in Lacs unless otherwise stated)

Statement - 2 : Ratios

Sr. No.	Ratio	Numerator/ Denominator	Ratio (2025-26)	Ratio (2024-25)	% of Variation	Reason for variance
1.	Current ratio	Current Assets / Current Liabilities	1.13	1.19	-5.37%	
2.	Debt-Equity ratio	Total Debts / Shareholders Equity	0.07	0.03	128.13%	Increase in borrowings from WCTL.
3.	Debt Service Coverage ratio # Debts includes Lease Liability	Earnings available for debt service / Debt Service#	1.87	-0.16	-1253.55%	Reduction in debt due to repayment & increase in other equity due to profit.
4.	Return on Equity ratio (ROE)	Net Profits after taxes – Preference Dividend / Average Shareholder's Equity	-3.11%	8.63%	-136.05%	Loss during the year against profit in last year.
5.	Inventory Turnover Ratio	Cost of goods sold / Average Inventory	2.92	2.56	13.95%	
6.	Trade Receivables turnover ratio	Sales / Average Accounts Receivables	8.13	7.01	15.95%	
7.	Trade payables turnover ratio	Net Credit Purchases / Average Trade Payables	4.16	2.44	70.88%	Increase in credit purchases.
8.	Net capital turnover ratio	Revenue / Average Working Capital	19.49	-37.30	-152.25%	Increase in Revenue and Improvement in working capital
9.	Net profit ratio	Net Profit after Tax / Net Sales	-3.63%	10.81%	-133.61%	Loss during the year against profit in last year.
10.	Return on Capital employed (ROCE)	Earning before interest and taxes / Capital Employed	-2.58%	10.32%	-125.02%	Loss during the year against profit in last year.
11.	Return on Investment (ROI)	{MV(T1) – MV(T0) – Sum [C(t)]} / {MV(T0) + Sum [W(t) * C(t)]}	0.00%	0.00%	0.00%	

Where:

T1 = End of time period

T0 = Beginning of time period

t = Specific date falling between T1 and T0

MV(T1) = Market Value at T1

MV(T0) = Market Value at T0

C(t) = Cash inflow, cash outflow on specific date

W(t) = Weight of the net cash flow (i.e. either net inflow or net outflow) on day 't', calculated as $[T1 - t] / T1$

Companies may provide ROI separately for each asset class (e.g., equity, fixed income, money market, etc.).

INDEPENDENT AUDITORS' REPORT

To
The Members of
Makers Laboratories Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of Makers Laboratories Limited (hereinafter referred to as the "Holding Company") and its Subsidiary (The Holding Company and its Subsidiary together referred to as "the Group") which comprise the Consolidated Balance Sheet as at March 31, 2026, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income) and the Consolidated Statement of Changes in Equity for the year then ended, and notes to the consolidated financial statements, and a summary of material accounting policy information and other explanatory information (hereinafter referred to as the "Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended ("Ind AS") and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2026, their consolidated profit, their consolidated total Comprehensive income, their consolidated changes in equity and their consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Consolidated Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence by us is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters:

Sr No	Key Audit Matters (KAM's)	How the KAM's were addressed in our audit
1.	<p>Inventory Valuation The Company manufactures and sells pharmaceutical products which carry shelf life. As a result, significant level of judgement is involved in estimating inventory valuation. Judgement is required to assess the appropriate net realisable value for short dated pharmaceutical products. Such judgements include management expectations for future sales and inventory liquidation plans.</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> • We attended stock counts to identify whether any inventory was obsolete, • We assessed the basis for the inventory valuation, the consistency in policy and the rationale in its application, • We tested the accuracy of the ageing of inventories based on system generated reports, • We tested the arithmetical accuracy of valuation files; and • We reviewed product-wise historical data relating to sales return etc. and also its impact on valuation. • We have assessed the adequacy of disclosure in the Standalone Financial Statements.

Sr No	Key Audit Matters (KAM's)	How the KAM's were addressed in our audit
2.	Revenue recognition as per INDAS 115 – Revenue from Contracts with customers.	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> • We have assessed the Company's accounting policies for revenue recognition by comparing with the applicable accounting standards i.e. Ind AS 115; • We have conducted testing of design, implementation and operating effectiveness of key internal financial controls over timing of recognition of revenue from sale of goods and subsequent adjustments made to the transaction price; • We have also performed substantive audit procedures on selected statistical samples of customer contracts. Verified terms and condition related to acceptance of goods, acknowledgement on delivery receipts and tested the transit time to deliver the goods and its revenue recognition. • We also assessed the issue of principal and agency arrangements in the transactions of sale of goods through Consignee Sales Distributors and accounted the revenue as per the principles of Ind AS 115. • Our tests of details focused on period end samples to verify only revenue pertaining to current year which satisfies the condition of revenue recognition is recognized based on terms and conditions set out in sale agreements/ contracts and delivery documents. • We have assessed the adequacy of disclosure in the Standalone Financial Statements.
3.	<p>In the case of Subsidiary, the component auditor additionally has addressed the following Key Audit Matters:</p> <p>(Refer note 37- "Contingent Liabilities")</p> <p>There are number of material regulatory and tax cases against the Company. Significant judgement is required in estimating/ reassessing the level of provisioning and/or disclosures. The management's assessment is supported by advice from independent legal/tax consultants. We considered this as a Key Audit Matter as the eventual outcome of litigations is uncertain and the positions taken by the Management are based on the application of significant judgement and estimation. Any unexpected adverse outcomes could significantly impact the Company's results and financial position.</p>	<p>Auditors Response</p> <p>Our procedures included, Discussing with the management and tax and regulatory department heads to understand matters under litigation; Reading external legal opinions obtained by management, where available; Assessing management's conclusions;</p> <p>For Direct tax litigations, involving internal tax experts to understand the current status of tax cases and monitoring changes in the disputes by reading details received by the Company; Performing detailed procedures on the underlying calculations supporting the provisions recorded and ensuring adequacy of disclosures made.</p> <p>Based on the above procedures performed, we have not identified any significant exceptions relating to disclosure of contingent liabilities and accounting for provisions for litigations.</p>

Information Other than the Consolidated Financial Statements and Auditors' Report Thereon

The Holding Company's Board of Directors is responsible for the Other Information. The Other Information comprises the information included in the Holding Company's Annual Report excluding the Consolidated and Standalone Financial Statements and our Independent Auditors' Report thereon.

Our opinion on the Consolidated Financial Statements does not cover the Other Information and we do not and will not express any form of assurance or conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the Other Information identified above and, in doing so, consider whether the Other Information is materially inconsistent with the consolidated financial statements, or our knowledge obtained during the course of our audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this Auditor's Report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in terms of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
3. evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the Consolidated Financial Statements and other financial information of the Group to express an opinion on the Consolidated Financial Statement. We are responsible for the direction, supervision and performance of the audit of financial information of the Holding Company included in the Statement of which we are the independent auditors. For the other entity included in the Consolidated Financial Statement, which have been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, make it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation

precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We did not audit the financial statements of Resonance Specialties Limited, whose financial statements reflect total assets of ₹ 9,246.73 lacs as at March 31, 2026, total revenue of ₹ 9,188.93 lacs and net cash inflow/(outflow) amounting to ₹ (4.52) lacs for the year ended on that date, as considered in the preparation of the consolidated financial statements. The said financial statements have been audited by their respective independent auditor whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of the other auditor and the procedures stated by us in paragraph above. Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.

Report on Other Legal and Regulatory Requirements

1. With respect to the matters specified in paragraphs 3(xxii) and 4 of the Companies (Auditor's Report) Order, 2020 (the "Order"/ "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO report issued by us for the Company and received from the auditor of the subsidiary included in the consolidated financial statements of the Company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.
 - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books except for the matters stated in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 and the reports of the other auditors.
 - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement relevant books of account and other relevant records maintained for the purpose of preparation of the Consolidated Financial Statements.
 - d. In our opinion, the aforesaid Consolidated Financial Statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2026 taken on record by the Board of Directors of the Holding Company and the report of the statutory auditor of its subsidiary company incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164(2) of the Act.
 - f. With reference to maintenance of accounts and other matter therewith, reference is invited to paragraph 2(b) above on reporting under section 143(3)(b) and paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 as amended.

- g. With respect to the adequacy of internal financial controls with reference to Financial Statements of the Holding Company and its subsidiary incorporated in India and the operating effectiveness of such controls, refer to our separate report in “Annexure A”. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company’s internal financial controls with reference to Consolidated Financial Statements.
- h. With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended:
- In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Group Company to its directors during the year is within the limits prescribed as per Schedule V read with the provisions of section 197 of the Act.
- i. With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Consolidated Financial Statements disclose the impact of pending litigations on the consolidated financial position of the Group, its associates – Refer Note 37 to the Consolidated Financial Statements.
 - ii. The Group did not have any long-term contracts including derivative contracts for which there were material foreseeable losses.
 - iii. There are no amounts which are required to be transferred to Investor Education and Protection Fund by the Holding Company and its subsidiary companies incorporated in India.
 - iv. (a) The respective Managements of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company or any of such subsidiaries to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company or any of such subsidiaries (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (b) The respective Managements of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company or any of such subsidiaries from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company or any of such subsidiaries shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us on the Company, and based on the report received from the subsidiary auditor, whose financial statements have been audited under the Act, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

- v. There are no events of dividend declared and paid by the Holding Company during the year until the date of this report, hence compliance with provisions of section 123 of the Companies Act, 2013 is not required.

On the basis of the report of the auditor of the subsidiary company we report that the subsidiary has complied with the provisions of section 123 in respect of the dividends declared and paid during the year.

vi. **In Case of Holding Company,**

Based on our examination which included test checks, except for instances/ matters mentioned below, the Company, in respect of financial year commencing on 1 April 2025, has used an inhouse developed accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further, audit trail feature is enabled for direct changes from November 24, 2024 onwards, to data when using certain access rights by the development team, as described in Note 43 to the financial statements. However, due to system constraints, the audit trail for direct database changes done by the Database administrator is retained only for a period of three days and therefore, audit trail for the direct access changes is available only for said period.

As regards the preservation of the audit trail as per the statutory requirements, at application level the same are retained for the period the edit log was enabled. In case of audit trail for direct database changes the audit trail prior to November 24, 2024 is not available since the direct database logs were enabled only from November 24, 2024 and due to system constrain the same are not retained for more than 3 days and thus to that extent the log retention are not retained by the Company.

In Case of Subsidiary

Based on their examination which included test checks, the company has used an accounting software for maintaining its books of account for the financial year March 31, 2026 which have the feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software systems. Further, during the course our audit we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For N V C & Associates LLP

Chartered Accountants

FRN No: 106971W/ W101085

Nuzhat Khan

Partner

Membership No.124960

Mumbai, Dated: May 26, 2026

UDIN: 26124960IOMNAP6637

Annexure - A to the Auditors' Report

(Referred to in paragraph 2(g) under Report on Other Legal and Regulatory Requirements' section of our report to the Members of Makers Laboratories Limited of even date)

Report on the Internal Financial Controls with reference to Consolidated Financial Statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the Consolidated Financial Statements of the Holding Company as of and for the year ended March 31, 2026, we have audited the internal financial controls with reference to Consolidated Financial Statements of **Makers Laboratories Limited** (hereinafter referred to as "the Holding Company") and its subsidiary which is incorporated in India, as on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the companies included in the Group is responsible for establishing and maintaining internal financial controls based on the internal control with reference to Consolidated Financial Statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to Consolidated Financial Statements of the Holding Company and Subsidiary which is company incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Consolidated Financial Statements included obtaining an understanding of internal financial controls with reference to Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence and the audit evidence obtained by the other auditor in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Holding Company's internal financial controls system with reference to Consolidated Financial Statements.

Meaning of Internal Financial Controls with reference to Consolidated Financial Statements

A company's internal financial control with reference to Consolidated Financial Statements is a process

designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with reference to Consolidated Financial Statements.

Because of the inherent limitations of financial controls with reference to Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Consolidated Financial Statements to future periods are subject to the risk that the internal financial control with reference to Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary, which is company incorporated in India, have, in all material respects, an adequate internal financial controls system with reference to Financial Statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matters

Our aforesaid reports under section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements in so far as it relates to financial statements of subsidiary, which is company incorporated in India, are based on the corresponding report of the auditor of such companies incorporated in India.

For N V C & Associates LLP

Chartered Accountants

FRN No: 106971W/ W101085

Nuzhat Khan

Partner

Membership No.124960

Mumbai, Dated: May 26, 2026

UDIN: 26124960IOMNAP6637

(All Figures are Rupees in Lacs unless otherwise stated)

Consolidated Balance Sheet as at March 31, 2026

Particulars	Note	As at Mar 31, 2026	As at Mar 31, 2025
ASSETS			
(1) Non-current Assets			
(a) Property, Plant & Equipment	3	6,834.95	7,147.89
(b) Capital Work-in-Progress	3C	364.37	59.34
(c) Right Of Use Asset	3B	128.94	165.22
(d) Other Intangible Assets	3A	89.74	102.14
(e) Intangible Assets Under Development	3C	9.00	-
(f) Financial Assets			
(i) Investments	4	15.37	14.42
(ii) Loans	5	-	-
(iii) Others	6	158.10	157.18
(g) Deferred Tax Asset (Net)		-	-
(h) Other Non-current Assets	7	366.58	321.62
		<u>7,967.05</u>	<u>7,967.81</u>
(2) Current Assets			
(a) Inventories	8	4,494.07	3,403.65
(b) Financial Assets			
(i) Investments	4	1,157.40	-
(ii) Trade Receivables	9	1,986.35	2,803.59
(iii) Cash and Cash Equivalents	10	19.68	24.29
(iv) Bank Balances other than (iii) above	11	43.15	40.30
(v) Loans	5	-	0.17
(vi) Others	6	34.90	27.01
(c) Current Tax Assets (Net)		-	-
(d) Other Current Assets	7	959.32	528.00
		<u>8,694.87</u>	<u>6,827.01</u>
TOTAL ASSETS		<u>16,661.92</u>	<u>14,794.82</u>
EQUITY & LIABILITIES			
EQUITY			
(a) Equity Share Capital	12	590.04	590.04
(b) Other Equity	13	6,702.37	6,460.55
Equity attributable to the shareholders of the Holding company		<u>7,292.41</u>	<u>7,050.59</u>
Non Controlling Interest		4,955.23	4,468.60
LIABILITIES			
(1) Non-current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	14	102.90	205.74
(ii) Lease Liability	34	100.79	135.82
(iii) Other Financial Liabilities	15	-	-
(b) Provisions	16	41.65	26.68
(c) Deferred Tax Liabilities (Net)	17	766.77	787.34
(d) Other Non-current Liabilities	18	-	-
		<u>1,012.11</u>	<u>1,155.58</u>
(2) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	19	373.39	132.75
(ii) Lease Liability	34	35.03	31.90
(iii) Trade Payables	20	-	-
- Due to Micro Enterprises and Small Enterprises		334.86	176.92
- Due to Other than Micro Enterprises and Small Enterprises		1,632.60	992.94
(iv) Other Financial Liabilities	15	566.35	433.70
(b) Other Current Liabilities	18	272.10	219.08
(c) Provisions	16	98.17	118.13
(d) Current Tax Liabilities (Net)		89.67	14.63
		<u>3,402.17</u>	<u>2,120.05</u>
TOTAL EQUITY AND LIABILITIES		<u>16,661.92</u>	<u>14,794.82</u>

Statement of material accounting policy information and other explanatory notes form part of the balance sheet and statement of profit and loss

As per our report of even date attached
For N V C & Associates LLP
Chartered Accountants
Firm Registration No. 106971W / W101085

Nuzhat Khan
Partner
M.No. 124960
Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh
(DIN 00400079)
Wholtime Director & CEO

Piyush Ajmera
ACS No : 58712
Company Secretary

Nilesh Jain
(DIN 05263110)
Wholtime Director

Sandeep Kadam
Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Consolidated Statement of Profit and Loss for the period ended March 31, 2026

Particulars	Note	Apr-Mar 26	Apr-Mar 25
I Revenue from Operations	21	14,059.48	12,075.12
II Other Income	22	170.96	1,188.64
III Total Income (I + II)		14,230.44	13,263.76
IV Expenses:			
Cost of Materials Consumed	23	4,453.55	4,237.73
Purchase of Stock in trade	24	2,220.36	1,459.64
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	25	(116.51)	(290.74)
Employee Benefit Expenses	26	1,558.58	1,405.18
Finance Cost	27	77.12	128.50
Depreciation & Amortisation	28	452.77	478.59
Other Expenses	29	4,469.64	4,424.70
Total Expenses (IV)		13,115.51	11,843.60
V Profit/ (Loss) Before exceptional items and Tax (III-IV)		1,114.93	1,420.16
VI Exceptional Items income/ (expenses)	30	-	(79.10)
VII Profit/ (Loss) Before Tax (V+VI)		1,114.93	1,341.06
VIII Tax Expense			
1. Current Tax	31	353.40	243.57
2. Short / (Excess) Provision of earlier years	31	(4.39)	(0.06)
3. Deferred Tax Liability / (Asset) incl. MAT Credit	31	(20.16)	6.80
IX Profit/ (Loss) for the period (VII-VIII)		786.08	1,090.75
X Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
(a) Actuarial gain and loss		3.97	(9.04)
Tax Effect thereon	32	0.89	1.42
(b) Fair Value change through Other Comprehensive Income		0.95	2.54
Tax Effect thereon	32	(0.50)	(0.26)
Other Comprehensive Income for the year, net of tax		5.31	(5.34)
Total Comprehensive Income for the year		791.39	1,085.41
Profit/ (Loss) for the period attributable to :			
Owners of the parent		235.13	749.07
Non-controlling interest - profit / (loss)		550.95	341.68
		786.08	1,090.75
Other Comprehensive Income for the period attributable to :			
Owners of the parent		6.69	(3.13)
Non-controlling interest - profit / (loss)		(1.38)	(2.21)
		5.31	(5.34)
Total Comprehensive Income for the period attributable to :			
Owners of the parent		241.82	745.94
Non-controlling interest - profit / (loss)		549.57	339.47
		791.39	1,085.41
XI Earnings per Equity Share :			
Par Value ₹ 10 each			
Basic (in ₹)	33	3.99	12.70
Diluted (in ₹)	33	3.99	12.70

Statement of material accounting policy information and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our report of even date attached
For N V C & Associates LLP
Chartered Accountants
Firm Registration No. 106971W / W101085

Nuzhat Khan
Partner
M.No. 124960
Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh
(DIN 00400079)
Wholetime Director & CEO

Piyush Ajmera
ACS No : 58712
Company Secretary

Nilesh Jain
(DIN 05263110)
Wholetime Director

Sandeep Kadam
Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Consolidated Cash Flow Statement for the period ended March 31, 2026

	April - March '26	April - March '25
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	1,114.93	1,341.06
Adjustments for :		
Depreciation	452.77	478.59
Bad debts w/off	13.14	39.77
Assets Scrap loss	-	81.14
Sundry balances written back	(1.11)	(0.34)
(Profit)/ Loss on sale of Property, Plant & Equipment	-	(991.83)
Unwinding of Lease rent Expenses	-	0.39
Reversal of Loss on Leasehold property	-	(56.95)
(Profit)/Loss on sale of Mutual funds	(15.54)	(27.22)
MTM (Gain) / Loss on Mutual fund	(8.41)	-
Rent	0.67	-
Interest income	(28.56)	(37.97)
Dividend income	(0.02)	(0.04)
Interest expense	70.56	125.40
	<u>1,598.43</u>	<u>952.00</u>
2) Operating profit before working capital changes	(1,090.42)	(23.18)
Decrease / (Increase) in inventories	804.10	(813.28)
Decrease / (increase) in Trade Receivables	(8.05)	9.60
Decrease / (increase) in Other Financial assets	(425.85)	496.62
Decrease / (increase) in Other assets	798.71	(500.18)
Increase / (Decrease) in Trade Payables	90.36	(271.96)
Increase / (Decrease) in Other Financial liabilities	(9.94)	6.26
Increase / (Decrease) in Other liabilities	3.34	(23.62)
Increase / (Decrease) in Provisions		
3) Cash generated from operation	1,760.68	(167.74)
Income Tax paid (net)	(332.11)	(240.15)
Net cash from operating activities	<u>1,428.57</u>	<u>(407.89)</u>
B. Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment including capital WIP & Intangibles	(370.72)	(394.11)
Proceeds from Sale of Plant, Property and Equipment	8.50	1,882.14
(Purchase)/Sale of Mutual Funds	(1,133.45)	308.20
Movement in other bank balances	(0.85)	139.29
Interest received	27.97	39.14
Dividend received	0.02	0.04
Net cash from / (used) in investing activities	<u>(1,468.53)</u>	<u>1,974.70</u>
C. Cash Flow from Financing Activities		
Proceeds/(Repayment) from short term borrowings	240.64	(689.63)
Repayment of Non-Current borrowing	(102.84)	(141.63)
Intercompany deposit repaid	-	(750.00)
Intercompany deposit received	-	150.00
Payment of lease Liability		
- Interest	(14.10)	(20.23)
- Principal	(31.90)	(27.31)
Interest paid	(56.45)	(105.12)
Net cash from/(used in) financing activities	<u>35.35</u>	<u>(1,583.92)</u>
Net increase / (decrease) in cash and cash equivalents (A + B + C)	<u>(4.61)</u>	<u>(17.11)</u>
Cash and cash equivalents at beginning of year	24.29	41.40
Cash and cash equivalents at end of year	<u>19.68</u>	<u>24.29</u>
Components of Cash & Cash equivalents :		
Cash and cheques on hand	1.08	0.37
Balance with banks	18.60	23.92
	<u>19.68</u>	<u>24.29</u>

Refer note no. 14 (d) for reconciliation of liabilities from financing activities

As per our report of even date attached

For N V C & Associates LLP

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh

(DIN 00400079)

Wholetime Director & CEO

Piyush Ajmera

ACS No : 58712

Company Secretary

Nilesh Jain

(DIN 05263110)

Wholetime Director

Sandeep Kadam

Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

1. Consolidated Statement of Changes in Equity for the period ended March 31, 2026

Equity Share Capital

	No. of shares	Amount
Equity share capital of face value (₹) 10.00 each		
Balance as at March 31, 2024	59,00,376	590.04
Changes in equity share capital during the year	-	-
Balance as at March 31, 2025	59,00,376	590.04
Changes in equity share capital during the year	-	-
Balance as at March 31, 2026	59,00,376	590.04

Other Equity

Particulars	Other Equity					Equity Attributed to the Shareholders of the Company	Non Controlling Interest	Total	
	Reserves and Surplus		Other comprehensive income Not Reclassified to P&L	Fair Value of Investment through OCI	Retained Earnings				
	Capital Reserve	Securities Premium	General Reserve	Capital Reserve on Bargain purchase					
Balance as on April 1, 2024	302.76	1,449.43	1,200.00	322.70	2,435.95	3.77	5,714.61	4,129.13	9,843.74
Profit for the period	-	-	-	-	749.07	-	749.07	341.68	1,090.75
Gain/ (Loss) on Fair Value of Investment through OCI (Net of tax thereon)	-	-	-	-	-	2.28	2.28	-	2.28
Actuarial gain/(loss) on gratuity (Net of tax thereon)	-	-	-	-	(5.41)	-	(5.41)	(2.21)	(7.62)
Balance as on Mar 31, 2025	302.76	1,449.43	1,200.00	322.70	3,179.61	6.05	6,460.55	4,468.60	10,929.15

(All Figures are Rupees in Lacs unless otherwise stated)

Particulars	Other Equity				Equity Attributed to the Shareholders of the Company	Non Controlling Interest	Total
	Reserves and Surplus	Capital Reserve on Bargain purchase	Retained Earnings	Fair Value of Investment through OCI			
Profit for the period	-	-	235.13	-	235.13	550.95	786.08
Less : Dividend paid	-	-	-	-	-	(62.94)	(62.94)
Gain/ (Loss) on Fair Value of Investment through OCI (Net of tax thereon)	-	-	-	0.45	0.45	(1.38)	(0.93)
Actuarial gain/(loss) on gratuity (Net of tax thereon)	-	-	6.24	-	6.24	-	6.24
Balance as on March 31, 2026	302.76	1,449.43	1,200.00	322.70	3,420.98	6,702.37	11,657.60

Note:

- i) Gain of ₹ 6.24 lacs and Loss of ₹ 5.41 lacs on remeasurement of defined employee benefit plans (net of tax) is recognized as a part of retained earnings for the years ended March 31, 2026 and 2025, respectively.

As per our report of even date attached

For NVC & Associates LLP

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors

Saahil Parikh
(DIN 00400079)

Wholetime Director & CEO

Nilesh Jain
(DIN 05263110)

Wholetime Director

Piyush Ajmera

ACS No : 58712

Company Secretary

Sandeep Kadam

Chief Financial Officer

Summary of Material accounting policy Information and other explanatory information to the Consolidated Financial Statements for the year ended March 31, 2026

1. Corporate Information

Incorporated in the year 1984, Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company has one manufacturing units in India manufacturing formulations for the Indian market.

2. Statement of Compliance

The Consolidated Financial Statements comply in all material aspects with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act"), the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act.

The consolidated financial statements of the company for the year ended March 31, 2026 were authorised for issue in accordance with the resolution passed at the meeting of the Board of Directors held on May 26, 2026.

3. Basis and Principles of Consolidation

The consolidated financial statements relate to the Company, and its aforesaid Subsidiary (the holding and subsidiary together referred to as "The Group"). The consolidated financial statements have been prepared in accordance with Indian Accounting Standard - 110 "Consolidated Financial Statement" of the Companies (Indian Accounting Standards) Rules 2015 as amended by the Companies (Indian Accounting Standards) Amendment) Rules, 2016 and other relevant provisions of the Act. The consolidated financial statements have been prepared on the following basis:

The consolidated financial statements of the Group are consolidated on a line-by-line basis and intra-group balances and transactions including unrealized gain/loss from such transactions are eliminated upon consolidation. These consolidated financial statements are prepared by applying uniform accounting policies in use at the Group. Non-controlling interests which represent part of the net profit or loss and net assets of subsidiaries that are not, directly or indirectly, owned or controlled by the company, are excluded. The financial statements of the Subsidiary used in consolidation are drawn up to the same reporting date as that of the Company i.e. 31st March. The difference between the cost to the Company of its investments in the subsidiary over the Company's portion of equity computed on acquisition date based on fair value of assets and liabilities are recognized in the financial statement as Goodwill / Capital Reserve on consolidation.

The Subsidiary included in the Consolidation and the Company's holding therein is as follows:

1. Resonance Specialties Limited, an entity in which there is de facto control and in which the Company's interest is 45.48%. The Ultimate Holding Company M/s Kaygee Investments Private Limited holds around 8.77% and is expected to vote towards the resolution in accordance with voting by the Holding Company and therefore the Company asserts that it has de facto control over Resonance Specialties Limited.

4. Basis of Preparation, Accounting judgements, estimates and assumptions and Material Accounting Policy information

4.1 Basis of Preparation

- These consolidated financial statements are prepared on a going concern basis, in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on the accrual basis, except for the following:
 - a) certain financial assets and liabilities (including derivative instruments) are measured at fair value, and
 - b) defined benefit plans - plan assets measured at fair value.

- Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.
- The Balance Sheet, the Statement of Profit and Loss and the Statement of Changes in Equity are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 (the Act). The Statement of Cash Flows has been prepared and presented in accordance with Ind AS 7 “Statement of Cash Flows”. The disclosures with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards as amended.
- Amounts in the consolidated financial statements are presented in Indian Rupees in Lacs rounded off to two decimal places as permitted by Schedule III to the Companies Act, 2013. Per share data are presented in Indian Rupees to two decimals places.

4.2 Significant Accounting Judgements estimates and assumptions.

The consolidated financial statements require management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosures of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

4.2.1. Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of circumstances surrounding the estimates. Changes in estimates are reflected in the financial statement in the period in which changes are made and if material, their effects are disclosed in the notes to the financial statements. During the year there were no Significant Judgements other than those stated hereinafter that were required to be exercised in the process of applying the entity’s accounting policy and that have an impact on the amounts recognised in the Consolidated Financial Statements.

4.2.2. Judgements

The Company's management has made the following judgements, which have the most significant effect on the amounts recognized in the separate financial statements, while formulating the Company's accounting policies:

a. Useful lives of Property, Plant and Equipment

The company reviews the useful life of property, plant and equipment at the end of each reporting period. This reassessment may result in change in depreciation expense in future periods.

b. Impairment of Property, Plant and Equipment

For property, plant and equipment and intangibles, an assessment is made at each reporting date to determine whether there is an indication that the carrying amount may not be recoverable or previously recognised impairment losses no longer exist

or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised.

c. Inventories

The Company estimates the net realisable value (NRV) of its inventories by taking into account estimated selling price, estimated cost of completion, estimated costs necessary to make the sale, obsolescence considering the past trend. Inventories are written down to NRV where such NRV is lower than their cost.

d. Recognition and measurement of other Provisions

The recognition and measurement of other provisions is based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the closing date. The actual outflow of resources at a future date may, therefore, vary from the amount included in other provisions.

e. Taxes

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

f. Defined benefit plans (Gratuity benefits)

The cost of the defined benefit plans, compensated absences and the present value of the defined benefit obligations are based on actuarial valuation using the projected unit credit method. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These interalia include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

g. Leases

The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgement. The Company uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics.

4.2.3. Recent pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

1. In May 2025, MCA notified amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Company has reviewed the amendment and has determined that it does not have any impact in its financial statements.
2. In August 2025, MCA notified the following amendments to:
 - a. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 – The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The Company has no impact of these amendments in its classification criteria of current and non-current liabilities.
 - b. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments – Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and has determined that it does not have any impact in its financial statements.
 - c. Ind AS 12, International Tax Reform – Pillar Two Model Rules applicable immediately - The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Company has no impact of these amendments in its Financial Statements.

4.2.4. Material Accounting Policy Information

i. Current and non-current classification

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

The Company presents assets and liabilities in the balance sheet based on current/non-current classification.

An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle, or
- It is held primarily for the purpose of trading, or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle, or
- It is held primarily for the purpose of trading, or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

ii. Property, Plant and Equipment

- a) Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less depreciation. Cost of acquisition comprises its purchase price including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discount and rebates are deducted in arriving at the purchase price.
- b) Stores and spares which meet the definition of Property, Plant and Equipment and satisfy the recognition criteria of Ind AS 16 are capitalised as Property, Plant and Equipment.
- c) Capital Work In Progress represents expenditure incurred on capital assets that are under construction or are pending capitalisation and includes project expenses pending allocation. Project expenses pending allocation are apportioned to the Property, Plant and Equipment of the project proportionately on capitalization.
- d) Cost of borrowing for assets taking substantial time to be ready for use is capitalised for the period up to the time the asset is ready for its intended use.
- e) Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.
- f) The residual useful life of Property, Plant & Equipment is reviewed at each balance sheet date and adjusted if required in the depreciation rates.
- g) Depreciation methods, estimated useful lives and residual value

Depreciation on all assets of the Company is charged on straight line method over the useful life of assets mentioned in Schedule II to the Companies Act ,2013 or the useful life previously assessed by the management based on technical review whichever is lower for the proportionate period of use during the year. Intangible assets are amortised over the economic useful life estimated by the management.

The management's estimated useful life/useful life as per schedule II whichever is lower for the various tangible assets are as follows:

Assets	Estimated useful life (Years)
Leasehold Land	Period of Lease
Plant & Equipment	5 to 20 Years
Effluent Treatment Plant	15 Years
Vehicle	10 Years
Building	28 to 58 Years
Furniture & Fixtures	10 Years

iii. Intangible assets

The Company has elected to fair value its intangible assets on transition date. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The management has estimated the economic useful life for the various intangible assets as follows:

Particulars	Estimated useful life (Years)
Brands & Trademarks	4 years
Software for internal use	4 years

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

iv. Inventories

Items of inventories are valued at lower of cost or estimated net realisable value as given below:

Raw Materials and Packing Materials	Lower of cost and net realisable value. However materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost is determined on First In First Out basis.
Work-in-process and Finished Goods	At lower of cost (material cost net of refundable taxes, labour cost and all manufacturing overheads) and net realisable value.
Stores and Spares	Stores and spare parts are valued at lower of cost computed on First-in-First-out method and net realisable value.
Traded Goods	Traded Goods are valued at lower of cost and net realisable value.

The factors that the Company considers in determining the allowance for slow moving, obsolete and other non-saleable inventory in determining net realisable value include ageing of inventory, estimated shelf life, price changes, introduction of competitive new products and such other related factors.

Cost in case of Raw material and Packing material, Stores and Spare and Traded Goods include purchase cost net of refundable taxes and other overheads incurred in bringing such items of inventory to its present location and condition.

v. Borrowings

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the period in which they are incurred.

vi. Cash and cash equivalents.

Cash and cash equivalents include cash in hand, demand deposits in banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within bank borrowings in current liabilities in the balance sheet.

vii. Revenue recognition

a. The Company derives revenues primarily from sale of products and services. Revenue from sale of goods is recognised net of returns, product expiry claims and discounts.

Revenue is recognized on satisfaction of performance obligations upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

To recognize revenues, the Company applies the following five step approach:

1. Identify the contract with a customer;
2. Identify the performance obligations in the contract;
3. Determine the transaction price;
4. Allocate the transaction price to the performance obligations in the contract;
5. Recognize revenues when a performance obligation is satisfied.

Performance obligation may be satisfied over time or at a point in time. Performance obligations are satisfied over time if any one of the following criteria is met. In such cases, revenue is recognized over time.

1. The customer simultaneously receives and consumes the benefits provided by the Company's performance; or
2. The Company's performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or
3. The Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date.

For performance obligations where one of the above conditions are not met, revenue is recognised at the point in time at which the performance obligation is satisfied.

Where Revenue is recognized over time, the amount of revenue is determined on the basis of contract costs incurred in relation to estimated contract expenses.

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties.

Revenue in respect of transactions through parties acting as agents is recognised only on completion of the performance obligation of the agent with corresponding accrual of agency commissions.

The Company presents revenues net of indirect taxes in its statement of profit and loss.

- b. In case of export benefits which are in the nature of neutralisation of duties and taxes are grouped under material costs. All other export incentives are grouped under other operating revenue.
- c. Revenue in respect of insurance/other claims, commission, etc. are recognised only when it is reasonably certain that the ultimate collection will be made.
- d. For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR) Interest income is included in finance income in the statement of profit and loss.

viii. Impairment of assets

Carrying amount of Tangible assets, Intangible assets, Investments in Subsidiaries, Joint Venture and Associates (which are carried at cost) are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or Company's assets (cash-generating units). Non- financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

ix. Leases

The Company, as a lessee, recognizes a right-of-use asset and a lease liability for its leasing arrangements, if the contract conveys the right to control the use of an identified asset.

The contract conveys the right to control the use of an identified asset, if it involves the use of an identified asset and the Company has substantially all of the economic benefits from use of the asset and has right to direct the use of the identified asset. The cost of the right-of-use asset shall comprise of the amount of the initial

measurement of the lease liability adjusted for any lease payments made at or before the commencement date plus any initial direct costs incurred. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate.

For short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the lease term.

x. Provisions, contingent liabilities and contingent assets

Provision

A Provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

Contingent liabilities

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

xi. Retirement and other employee benefits

Provident fund

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as an expense when an employee renders the related service.

Gratuity

The Company provides for the Gratuity, a defined benefit retirement plan covering all employees. The plan provides for lump sum payments to employees upon death while in employment or on separation from employment after serving for the stipulated year mentioned under 'Code on Social Security, 2020' which has been notified and made effective from November 21, 2025, thereby replacing the erstwhile Payment of Gratuity Act, 1972. The Company also complies with provision of new labour codes 2025.

Gratuity, a post-employment defined benefit obligation is provided on the basis of an actuarial valuation made at the end of each year/period on projected unit credit method.

The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognized immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

Compensated absences

The Company has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet date using Projected Unit Credit method on the additional amount expected to be paid/ availed as a result of the unused entitlement that has accumulated at the balance sheet date. Expense on non-accumulating compensated absences is recognized in the period in which the absences occur.

Short-term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. Benefits such as salaries, wages etc. and the expected cost of ex-gratia, bonus and performance incentive are recognised in the period in which the employee renders the related service. A liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

xii. Foreign currencies**Transactions and balances:**

- i. The functional currency of the Company is the Indian rupee. These financial statements are presented in Indian rupees.
- ii. Transactions denominated in foreign currency are recorded at the exchange rate on the date of transaction where the settlement of such transactions are taking place at a later date. The exchange gain/loss on settlement / negotiation during the year is recognised in the statement of profit and loss. In case of advance payment for purchase of assets/ goods/services and advance receipt against sales of products/services, all such purchase/sales transaction are recorded at the rate at which such advances are paid/received.
- iii. Foreign currency monetary transactions remaining unsettled at the end of the year are converted at year-end rates. The resultant gain or loss is accounted for in the statement of profit and loss.
- iv. Non-monetary items that are measured at historical cost denominated in foreign currency are translated using exchange rate at the date of transaction.

xiii. Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset

or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

xiv. Financial instruments

a. Financial assets & financial liabilities

Initial recognition and measurement

All financial assets and liabilities are recognised initially at fair value.

In the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset is treated as cost of acquisition. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 7 details how the entity determines whether there has been a significant increase in credit risk. For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

De-recognition of financial instruments

A financial asset is de-recognised only when

- The Company has transferred the rights to receive cash flows from the financial asset or
- Retains the contractual rights to receive the cash flows of the financial asset but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is de-recognised. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not de-recognised.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is de-recognised if the Company has not retained control of the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

A financial liability (or a part of a financial liability) is de-recognized from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

b. Derivative financial instruments and hedge accounting**Initial recognition and subsequent measurement**

The Company uses derivative financial instruments such as forward currency contracts, interest rate swaps to hedge its foreign currency risks, interest rate risks, respectively.

Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The purchase contracts that meet the definition of a derivative under Ind AS 109 are recognised in the statement of profit and loss.

xv. Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

xvi. Goods and service tax input credit

Input tax credit is accounted for in the books in the period in which the underlying service received is accounted and when there is reasonable certainty in availing / utilising the credits.

xvii. Taxes

Tax expenses comprise Current Tax and Deferred Tax :

a. Current tax

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

b. Deferred tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit (tax loss). Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

For items recognised in OCI or equity, deferred / current tax is also recognised in OCI or equity.

c. MAT credit

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and loss as current tax. The Company recognises MAT credit available as an asset only to the extent that there is reasonable certainty that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. The MAT credit to the extent there is reasonable certainty that the Company will utilize the credit is recognised in the statement of profit and loss and corresponding debit is done to the deferred tax asset as unused tax credit.

xviii. Earnings per share

Earnings per share is calculated by dividing the net profit or loss before OCI for the year by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss before OCI for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

(All Figures are Rupees in Lacs unless otherwise stated)

Notes to Consolidated financial statements as at and for the year ended March 31, 2026

3. Property, Plant and Equipment

Particulars	Freehold Land	Leasehold Land	Building	Plant and Equipment	Office and Other Equipment	Effluent Treatment Plant	Furniture and Fixtures	Vehicles	R & D - Plant and Equipment	Total
Gross Block										
As on 01/04/2024	210.23	2,816.82	1,921.04	7,676.74	53.51	11.98	109.59	37.36	238.03	13,075.30
Additions	-	-	22.24	104.82	4.00	-	2.57	-	3.65	137.28
Disposals / Adjustments	(180.36)	-	(748.09)	(737.07)	(2.41)	-	(0.94)	-	(56.48)	(1,725.35)
As on 31/03/2025	29.87	2,816.82	1,195.19	7,044.49	55.10	11.98	111.22	37.36	185.20	11,487.23
Additions	-	-	4.02	74.52	6.61	-	1.83	5.31	7.36	99.65
Disposals / Adjustments	-	-	-	(12.71)	(0.18)	-	-	(9.65)	-	(22.54)
As on 31/03/2026	29.87	2,816.82	1,199.21	7,106.30	61.53	11.98	113.05	33.02	192.56	11,564.34
Accumulated Depreciation										
As on 01/04/2024	-	143.68	544.80	3,677.37	30.49	5.26	57.65	20.86	180.60	4,660.71
Charge for the year	-	43.49	31.40	329.99	7.22	0.59	6.80	3.16	9.88	432.53
Disposals / Adjustments	-	-	(107.05)	(596.46)	(1.64)	-	(0.38)	-	(48.37)	(753.90)
As on 31/03/2025	-	187.17	469.15	3,410.90	36.07	5.85	64.07	24.02	142.11	4,339.34
Charge for the year	-	43.49	27.87	306.23	6.50	0.59	6.98	2.34	10.09	404.09
Disposals / Adjustments	-	-	-	(5.64)	(0.16)	-	-	(8.24)	-	(14.04)
As on 31/03/2026	-	230.66	497.02	3,711.49	42.41	6.44	71.05	18.12	152.20	4,729.39
Net Block as on 31/03/2025	29.87	2,629.65	726.04	3,633.59	19.03	6.13	47.15	13.34	43.09	7,147.89
Net Block as on 31/03/2026	29.87	2,586.16	702.19	3,394.81	19.12	5.54	42.00	14.90	40.36	6,834.95

(All Figures are Rupees in Lacs unless otherwise stated)

3A. Other Intangible Assets

Particulars	Computer Software	Brand / Trade Mark	Inhouse developed technology	Total
Gross Block				
As on 01/04/2024	22.74	0.13	238.93	261.80
Additions	-	-	1.84	1.84
Disposals / Adjustments	-	-	-	-
As on 31/03/2025	22.74	0.13	240.77	263.64
Additions	-	-	-	-
Disposals / Adjustments	-	-	-	-
As on 31/03/2026	22.74	0.13	240.77	263.64
Accumulated Amortisation				
As on 01/04/2024	16.58	0.13	132.29	149.00
Charge for the year	2.44	-	10.06	12.50
Disposals / Adjustments	-	-	-	-
As on 31/03/2025	19.02	0.13	142.35	161.50
Charge for the year	1.89	-	10.51	12.40
Disposals / Adjustments	-	-	-	-
As on 31/03/2026	20.91	0.13	152.86	173.90
Net Block as on 31/03/2025	3.72	-	98.42	102.14
Net Block as on 31/03/2026	1.83	-	87.91	89.74

3B. Right to Use Asset

Particulars	Land	Building	Total
Gross Block			
As on 01/04/2024	257.03	-	257.03
Additions	159.58	24.21	183.79
Disposals / Adjustments	(257.03)	-	(257.03)
As on 31/03/2025	159.58	24.21	183.79
Additions	-	-	-
Disposals / Adjustments	-	-	-
As on 31/03/2026	159.58	24.21	183.79
Accumulated Amortisation			
As on 01/04/2024	127.73	-	127.73
Charge for the year	33.29	0.26	33.55
Disposals / Adjustments	(142.71)	-	(142.71)
As on 31/03/2025	18.31	0.26	18.57
Charge for the year	31.39	4.89	36.28
Disposals / Adjustments	-	-	-
As on 31/03/2026	49.70	5.15	54.85
Net Block as on 31/03/2025	141.27	23.95	165.22
Net Block as on 31/03/2026	109.88	19.06	128.94

(All Figures are Rupees in Lacs unless otherwise stated)

3C. Capital Work In Progress/ Intangible Assets Under Development

Particulars	Capital Work In Progress			Intangible Assets Under Development
	Building	Plant and Equipment	Total	Software
As at 31st March 2024	0.17	31.38	31.55	-
Additions	-	126.05	126.05	-
Capitalization	0.17	98.09	98.26	-
As at 31st March 2025	-	59.34	59.34	-
Additions	24.25	358.87	383.12	9.00
Capitalization	-	78.09	78.09	-
As at 31st March 2026	24.25	340.12	364.37	9.00

CWIP Ageing Schedule

As at March 31, 2026

CWIP for a period of	Projects in progress	Projects temporarily suspended	Total	Intangible Assets Under Development
Less than 1 year	322.86	-	322.86	9.00
1-2 years	41.51	-	41.51	-
2-3 years	-	-	-	-
More than 3 years	-	-	-	-
Total	364.37	-	364.37	9.00

Note : There are no cost or time overruns of CWIP as at March 31,2026.

As at March 31, 2025

CWIP for a period of	Projects in progress	Projects temporarily suspended	Total	Intangible Assets Under Development
Less than 1 year	56.37	-	56.37	-
1-2 years	2.97	-	2.97	-
2-3 years	-	-	-	-
More than 3 years	-	-	-	-
Total	59.34	-	59.34	-

Note : There are no cost or time overruns of CWIP as at March 31, 2026.

- i) The Group has carried out the exercise of assessment of any indication of impairment to its property plant and equipment as on the Balance Sheet date. Pursuant to such exercise it is determined that there has been no impairment to its property, plant and equipment during the current financial year. (PY net impact of ₹ 79.10 lacs was given in exceptional items)
- ii) There are no changes proposed to the previously assessed residual useful life of the assets.

(All Figures are Rupees in Lacs unless otherwise stated)

4. Financial Assets - Investments

A. Summary of Non Current Investments

	<u>As at 31/03/2026</u>	<u>As at 31/03/2025</u>
Investment in Equity Instruments measured at Fair value through OCI	15.37	14.42
Total	15.37	14.42

B. Details of Non-current Investments

	Face Value per Equity Instrument (₹)	Number Of Equity Instruments		Amount	
		<u>31-03-2026</u>	<u>31-03-2025</u>	<u>31-03-2026</u>	<u>31-03-2025</u>
Investments measured at fair value through OCI (fully paid)					
Quoted equity shares					
1. Ipca Laboratories Ltd	1	960	960	15.37	14.42
Total				15.37	14.42

C. Aggregate value of investments

<u>Particulars</u>	<u>31-03-2026</u>	<u>31-03-2025</u>
Aggregate amount of quoted investments	15.37	14.42
Aggregate market value of quoted investments	15.37	14.42

D. Summary of Current Investments

	<u>31-03-2026</u>	<u>31-03-2025</u>
Investment in Mutual Funds		
At Fair Value through Profit & Loss		
Kotak Liquid Fund (CY Units Purchased 14,819.143 NAV 5,508.5837)	816.32	-
Axis Liquid Fund - Reg Growth (CY Units Purchased 11,233.053 NAV 3,036.4134)	341.08	-
	1,157.40	-

E. Disclosure Under Section 186(4) of the Companies Act 2013

There are no transaction to be reported under 186(4).

5. Financial Assets - Loans

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
(Unsecured, considered good)				
Inter Corporate Deposits	-	-	-	-
Loans given to Employees	-	-	-	0.17
Total	-	-	-	0.17

(All Figures are Rupees in Lacs unless otherwise stated)

6. Financial Assets - Others

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
(Unsecured, considered good)				
Gratuity reimbursements and other claims receivable	-	7.89	-	6.24
Interest Receivable	-	0.74	-	0.88
Other Receivable				
- Related Parties	-	-	-	-
- Other Parties	-	26.27	-	19.89
Maharashtra Pollution Control Board Advance	52.13	-	52.13	-
Deposits	105.97	-	105.05	-
Total	158.10	34.90	157.18	27.01

7. Other Non-Financial Assets

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
(Unsecured, considered good)				
Capital Advances	13.73	-	16.38	-
Prepaid Expenses	3.24	47.99	2.98	43.76
Prepaid Rent Others	1.42	0.67	2.10	0.67
Balance with Tax Authorities	-	473.50	-	322.33
Export Incentive Receivable	-	-	-	22.02
Advance to suppliers				
-Related Party*	-	275.36	-	82.71
-Other	-	105.37	-	17.68
Advances to Employees	-	3.06	-	5.95
Advances to Others	-	6.50	-	0.49
Prepaid Taxes (Net of provisions)	348.19	-	294.44	-
Other Receivables	-	46.87	5.72	32.39
Total	366.58	959.32	321.62	528.00

* Kaygee Laboratories Pvt Ltd- Interest at 10.5% p.a. is levied on the advance given.

8. Inventories (Valued at Lower of Cost or Net Realisable Value)

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
Raw Materials and components		1,244.24		487.01
Packing Materials and components		125.93		90.82
Work-in-progress		364.24		355.67
Finished goods:				
Manufactured	1,880.28		1,902.42	
Traded	538.17		409.70	
In transit	18.79	2,437.24	17.18	2,329.30
Consumable Stores and Spares		322.42		140.85
Total		4,494.07		3,403.65

(All Figures are Rupees in Lacs unless otherwise stated)

The disclosure of inventories recognised as an expense in accordance with paragraph 36 of Ind AS 2 is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Amount of inventories recognised as an expense	6,706.00	5,620.09
Total	6,706.00	5,620.09

9. Financial Assets - Trade Receivables (Unsecured, at amortised cost)

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables considered good :	1,969.85	2,803.59
Trade Receivables-significant increase in credit risk	79.24	60.26
Credit impaired	-	-
	2,049.09	2,863.85
Less : Expected credit loss allowance	(62.74)	(60.26)
Total	1,986.35	2,803.59

Trade receivable considered good includes ₹19.16 lacs (PY- ₹40.60 lacs) from related party- Ipca Laboratories Limited.

The Holding Company calculates impairment under the simplified approach the Company does not track the changes in credit risk of trade receivables. The impairment amount represents lifetime expected credit loss. Hence the additional disclosures in trade receivables for changes in credit risk and credit impaired trade receivables are not disclosed.

Movement in the expected credit loss allowance

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the period	60.26	22.89
Adjustment during the year (Net)	2.48	37.37
Provision at the end of the period	62.74	60.26

As at March 31, 2026

Range of O/s period	Undisputed			Total
	Considered Good	Significant increase in credit risk	Credit Impaired	
Unbilled	19.16	-	-	19.16
Not Due	1,654.64	-	-	1,654.64
less than 6 months	226.60	5.32	-	231.92
6 months - 1 year	8.80	0.77	-	9.57
1-2 year	60.65	42.80	-	103.45
2-3 year	-	19.89	-	19.89
> 3 years	-	10.46	-	10.46
Total	1,969.85	79.24	-	2,049.09

(All Figures are Rupees in Lacs unless otherwise stated)

As at March 31, 2025

Range of O/s period	Undisputed			Total
	Considered Good	Significant increase in credit risk	Credit Impaired	
Unbilled	40.60	-	-	40.60
Not Due	1,851.17	-	-	1,851.17
less than 6 months	854.39	19.92	-	874.31
6 months - 1 year	56.39	3.75	-	60.14
1-2 year	0.98	25.53	-	26.51
2-3 year	0.07	11.06	-	11.13
> 3 years	-	-	-	-
Total	2,803.59	60.26	-	2,863.85

There are no disputed Trade Receivables as at March 2026 and March 2025

10. Financial Assets - Cash & Cash Equivalents

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Balances with banks	18.60	23.92
Cash on hand	1.08	0.37
Total	19.68	24.29

11. Financial Assets - Bank Balances other than (10) above

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Unpaid dividend accounts- Refer Note (a) below	29.61	27.61
In Fixed Deposits		
- Margin Money*	13.54	12.69
- Other Deposits	-	-
Total	43.15	40.30

(a) Unpaid Dividend

Amounts required to be transferred to Investor Education and Protection Fund during the year are transferred.

*(Under Lien towards margin of Letter of Credit and Bank Guarantees)

12. Equity Share Capital

<u>Particulars</u>	<u>As at Mar 31, 2026</u>		<u>As at Mar 31, 2025</u>	
	<u>No. of Shares</u>	<u>₹ in Lacs</u>	<u>No. of Shares</u>	<u>₹ in Lacs</u>
Face Value per share (₹)		10.00		10.00
Class of Shares- Equity				
Authorised Capital	75,00,000	750.00	75,00,000	750.00
Issued, Subscribed and Paid up Capital				
Issued & Subscribed	59,00,376	590.04	59,00,376	590.04
Paid up	59,00,376	590.04	59,00,376	590.04
Total		590.04		590.04

(All Figures are Rupees in Lacs unless otherwise stated)

Disclosures:

i) Reconciliation of Shares

Particulars	As at Mar 31, 2026		As at Mar 31, 2025	
	Numbers	₹ in Lacs	Numbers	₹ in Lacs
Shares outstanding at the beginning of the period	59,00,376	590.04	59,00,376	590.04
Shares Issued during the period	-	-	-	-
Shares outstanding at the end of the period	59,00,376	590.04	59,00,376	590.04

ii) Details of Shareholding in excess of 5%

Name of Shareholder	As at March 31, 2026		As at March 31, 2025	
	Number of shares held	%	Number of shares held	%
Kaygee Laboratories Private Limited	8,46,720	14.35%	8,46,720	14.35%
Kaygee Investments Private Limited (refer note iia)	21,75,859	36.88%	10,25,280	17.38%
Paschim Chemicals Private Limited (refer note iia)	-	-	9,66,672	16.38%

iiia) During the year, pursuant to the Scheme of Merger ('the Scheme') of Paschim Chemicals Private Limited, Mexin Medicaments Private Limited and Kaygee Investments Private Limited under the provisions of Sections 233 of the Companies Act, 2013 which has been approved by the Hon'ble Regional Director, North Western Region, Mumbai vide their order delivered on June 26, 2025, which has been filed with the Registrar of Companies on July 15, 2025, to make the Scheme effective. Paschim Chemicals Private Limited and Mexin Medicaments Private Limited are merged with Kaygee Investments Private Limited and therefore the shares of Paschim and Mexin have got added to the share holding of Kaygee Investments as at March 31, 2026.

iii) Rights and obligations of shareholders

The Company has only one class of share referred as Equity shares having a par value of ₹10/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after payment of external liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders. The dividend is recommended by management which is subject to shareholder's approval at the General Meeting.

iv) Shareholding of Promoters

Shares held by promoters as at March 31, 2026

Sr no	Promoter name	Shares held by promoters		% of change during the year
		No of shares	% of total shares	
1	Kaygee Investments Pvt Ltd (refer note iia)	21,75,859	36.88%	19.50%
2	Paschim Chemicals Pvt Ltd (refer note iia)	-	0.00%	-16.38%
3	Kaygee Laboratories Pvt Ltd	8,46,720	14.35%	-
4	Mexin Medicaments Pvt Ltd (refer note iia)	-	0.00%	-3.12%
5	Chandurkar investments Pvt Ltd	84,411	1.43%	-
6	Premchand Godha	1,27,033	2.15%	-
7	Prashant Godha	1,22,937	2.08%	-
8	Nirmal Jain	95,875	1.62%	-
9	Usha Godha	57,315	0.97%	-
10	Usha Chandurkar	41,000	0.69%	-
11	Bhawna Godha	42,206	0.72%	-
12	Sameer Chandurkar	22,000	0.37%	-
	Total	36,15,356	61.27%	
		59,00,376	100.00%	

(All Figures are Rupees in Lacs unless otherwise stated)

Shares held by promoters as at March 31, 2025

Sr no	Promoter name	Shares held by promoters		% of change during the year
		No of shares	% of total shares	
1	Kaygee Investments Pvt Ltd	10,25,280	17.38%	-
2	Paschim Chemicals Pvt Ltd	9,66,672	16.38%	-
3	Kaygee Laboratories Pvt Ltd	8,46,720	14.35%	-
4	Mexin Medicaments Pvt Ltd	1,83,907	3.12%	-
5	Chandurkar investments Pvt Ltd	84,411	1.43%	-
6	Premchand Godha	1,27,033	2.15%	-
7	Prashant Godha	1,22,937	2.08%	-
8	Nirmal Jain	95,875	1.62%	-
9	Usha Godha	57,315	0.97%	-
10	Usha Chandurkar	41,000	0.69%	-
11	Bhawna Godha	42,206	0.72%	-
12	Sameer Chandurkar	22,000	0.37%	-
	Total	36,15,356	61.27%	
		59,00,376	100.00%	

13. Other Equity

<u>Particulars</u>	<u>As at March 31, 2026</u>	<u>As at March 31, 2025</u>
Capital Reserve	302.76	302.76
Capital Reserve on Bargain Purchase	322.70	322.70
Securities Premium	1,449.43	1,449.43
General Reserve	1,200.00	1,200.00
Retained Earnings	3,420.98	3,179.61
Other Comprehensive Reserve		
- Remeasurement of Investment through FVOCI	6.50	6.05
Total	<u>6,702.37</u>	<u>6,460.55</u>

a) Security Premium Reserve:

Securities premium account comprises of premium on issue of shares. The reserve is utilised in accordance with the specific provision of the Companies Act, 2013.

b) General Reserve :

The General reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. As the General reserve is created by a transfer from one component of equity to another and is not an item of other comprehensive income, items included in the General reserve will not be reclassified subsequently to the statement of profit and loss.

c) Capital Reserve on Bargain Purchase:

Capital Reserve on Bargain Purchase represents the excess of the fair value of Assets less Liabilities over the purchase consideration in accordance with Ind AS 103.

(All Figures are Rupees in Lacs unless otherwise stated)

14. Financial Liabilities - Borrowings

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
Term Loan - Yes bank	102.90	103.11	205.74	103.11
Less : Current Maturities shown under short term borrowings	-	(103.11)	-	(103.11)
Total	102.90	-	205.74	-
Secured Borrowing	102.90	103.11	205.74	103.11
Unsecured Borrowing	-	-	-	-

a) Details of Term Loan

<u>Name of the Instruments/ Institutions</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
Term Loan From Yes Bank	102.90	103.11	205.74	103.11
	102.90	103.11	205.74	103.11

b) In case of Subsidiary Company

Details of securities and repayment terms of secured loans stated above

- i) Term Loan of ₹ 4.64Cr is taken from YES bank secured by sole charge by way of hypothecation on all movable fixed assets and second charge by way of hypothecation on current assets of the company
- ii) Term loan carry interest rate between 7.5% to 8.5% p.a. - Linked to repo rate (PY 8.5% - Linked to repo rate)

Utilization of Borrowing taken from bank

The subsidiary has taken the borrowing for a specific purpose and it will be utilized for the same purpose only.

c) Maturity Profile of Borrowings is as per the original sanction terms.

(The maturity profile is as per the repayment schedule without any Ind AS adjustment)

<u>Particulars</u>	<u>31-03-2026</u>	<u>31-03-2025</u>
Instalment payable between 0 to 1 years	103.11	103.11
Instalment payable between 1 to 2 years	103.11	103.11
Instalment payable between 2 to 5 years	-	103.11
Instalment payable beyond 5 years	-	-
Total	206.22	309.33

(All Figures are Rupees in Lacs unless otherwise stated)

d) Changes in liabilities arising out of financing activities

<u>Particulars</u>	As at March 31, 2026	
	Non-Current Borrowings	Current Maturities and Current Borrowings
Opening Balances	205.74	132.75
Changes from Financing Cash Flows	-	137.80
Transfer to Current Maturities	(103.11)	103.11
Other Changes	0.27	(0.27)
Closing Balances	102.90	373.39

<u>Particulars</u>	As at March 31, 2025	
	Non-Current Borrowings	Current Maturities and Current Borrowings
Opening Balances	908.48	861.27
Changes from Financing Cash Flows	(599.63)	(831.63)
Transfer to Current Maturities	(103.11)	103.11
Other Charges	-	-
Closing Balances	205.74	132.75

15. Other Financial Liabilities

<u>Particulars</u>	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Security Deposits from				
- Dealers	-	261.00	-	271.00
- Others	-	0.50	-	0.50
Unpaid dividends- Refer Note 11(a)	-	29.61	-	27.61
Payable for Capital Goods	-	55.22	-	14.93
Interest accrued	-	50.14	-	43.03
Payable to Employees	-	49.67	-	69.11
Other Payable	-	120.21	-	7.52
Total	-	566.35	-	433.70

(All Figures are Rupees in Lacs unless otherwise stated)

16. Provisions

Particulars	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Provision for breakage/damage	-	-	-	0.01
Provision for product expiry	-	11.61	-	29.76
Provision for sales return	-	42.29	-	38.04
Provision for Gratuity	2.77	-	-	2.11
Provision for leave encashment	38.88	10.98	26.68	11.08
Provision for leave travel assistance (LTA)	-	8.17	-	7.65
Provision for Tax (Net of prepaid)	-	25.12	-	29.48
Total	41.65	98.17	26.68	118.13

The disclosure of provisions movement as required by Ind AS 37 is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
(i) Provision for breakage/damage		
Balance at the beginning of the period	0.01	0.01
Provisions/ Reversal during the year.	(0.01)	-
Utilisations during the period	-	-
Provision at the end of the period	-	0.01
(ii) Provision for product expiry		
Balance at the beginning of the period	29.76	26.43
Provisions/ Reversal during the year.	(18.15)	3.33
Utilisations during the period	-	-
Provision at the end of the period	11.61	29.76
(iii) Provision for sales return		
Balance at the beginning of the period	38.04	54.70
Provisions/ Reversal during the year.	4.25	(16.66)
Utilisations during the period	-	-
Provision at the end of the period	42.29	38.04

(iv) Disclosure in accordance with Ind AS – 19 “Employee Benefits”, of the Companies (Indian Accounting Standards) Rules, 2015.

Gratuity

The Company's liabilities under 'Code on Social Security, 2020' which has been notified and made effective from November 21, 2025, thereby replacing the erstwhile Payment of Gratuity Act, 1972 are determined on the basis of actuarial valuation made at the end of each financial year using the projected unit credit method. The Gratuity liabilities of the Company is funded.

(All Figures are Rupees in Lacs unless otherwise stated)

The following table summarizes the components of net benefit expense recognized in the statement of profit and loss and the funded status and amounts recognized in the balance sheet.

Particulars	31-03-2026	31-03-2025
Expense recognised in Statement of Profit & Loss		
Current Service cost	15.18	12.27
Interest expense	6.53	6.01
Expected Return on Plan Assets	(7.88)	(8.32)
Benefit paid but pending claim	-	-
Past Service cost	14.56	-
Total	28.39	9.96
Expense recognised in Other Comprehensive Income		
Return on plan assets (Greater)/Less than Discount Rate	5.63	1.00
Actuarial (Gain)/Loss due to Experience on DBO	5.19	(10.04)
Total	10.82	(9.04)
Present value of funded defined benefit obligation	197.87	173.96
Fair value of Plan assets	(201.60)	(177.58)
Funded Status	(3.73)	(3.62)
Net defined benefit (Asset) / Liability*	(3.73)	(3.62)

* Includes Defined benefit asset of ₹6.48 lacs and Defined benefit liability of ₹2.75 lacs

Movements in present value of defined benefit obligation

Present value of defined benefit obligation at the beginning of the period	173.97	150.58
Liability raised due to acquisition through business combination	-	7.54
Current Service Cost	15.18	11.37
Interest Cost	10.31	6.61
Actuarial (Gain)/Loss	(6.71)	1.21
Benefits paid	(9.43)	(3.34)
Past Service Cost	14.56	-
Present value of defined benefit obligation at the end of the period	197.88	173.97

Movements in fair value of the plan assets are as follows.

Opening fair value of plan assets	177.58	160.43
Adjustment to opening fair value	-	-
Expected returns on Plan Assets	11.66	11.52
Remeasurement Gains/(Losses):	-	-
Actuarial Gain/(Loss) on Plan assets	6.61	1.00
Contribution from Employer	15.16	12.16
Benefits paid	-	(3.34)
Fund Charges	-	-
Benefit paid but pending claim	(9.43)	(4.19)
Closing fair value of the plan asset	201.58	177.58

Remeasurement effect recognised on Other Comprehensive Income

Actuarial (Gain)/Loss arising from experience adjustments	(6.71)	10.04
Actuarial (Gain)/Loss on Plan assets	2.75	(1.00)
Total Actuarial (Gain)/Loss included in OCI	(3.96)	9.04

(All Figures are Rupees in Lacs unless otherwise stated)

The principal assumptions used as at the balance sheet date are used for purpose of actuarial valuations were as follow

(v) Financial Assumptions

Discount Rate	6.71% & 7.20%	6.54% & 6.62%
Salary Increase Rate	6.00% & 8.00%	6.00% & 7.00%

(vi) Demographic Assumptions

Mortality Rate	IALM (2012-14) Ultimate	IALM (2012-14) Ultimate
Withdrawal Rate	25% & 14%	25% & 14%
Retirement age	58 Years	58 Years

The rate used to discount post-employment benefit obligations is determined by reference to market yields at the end of the reporting period on government bonds.

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and mortality.

The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of reporting period, while holding all other assumptions constant.

(vii) Defined Benefit Obligation

Discount rate

a. Discount rate - 50 basis points	196.13	172.90
b. Discount rate + 50 basis points	200.06	175.37

Salary increase rate

a. Rate - 50 basis points	199.63	175.03
b. Rate + 50 basis points	196.44	173.16

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would clear in isolation of one another as some of the assumptions may be correlated.

Further more, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

(viii) Risk Characteristics of the Defined Benefit Plan

Valuations are based on certain assumptions, which are dynamic in nature and vary over time. As such company is exposed to various risks as follow.

(i) Investment Risk :

For funded plans that rely on insurers for managing the assets, the value of assets certified by the insurer may not be the fair value of instruments backing the liability. In such cases, the present value of the assets is independent of the future discount rate. This can result in wide fluctuations in the net liability or the funded status if there are significant changes in the discount rate during the inter-valuation period.

(All Figures are Rupees in Lacs unless otherwise stated)

(ii) Market Risk (Discount Rate) :

Market risk is a collective term for risks that are related to the changes and fluctuations of the financial markets. The discount rate reflects the time value of money. An increase in discount rate leads to decrease in Defined Benefit Obligation of the plan benefits & vice versa. This assumption depends on the yields on the corporate/government bonds and hence the valuation of liability is exposed to fluctuations in the yields as at the valuation date.

(iii) Longevity Risk :

The impact of longevity risk will depend on whether the benefits are paid before retirement age or after . Typically for the benefits paid on or before the retirement age , the longevity risk is not very material.

(iv) Actuarial Risk:

Salary Increase Assumption: Actual Salary increase that are higher than the assumed salary escalation , will result in increase to the Obligation at a rate that is higher than expected.

Attrition / Withdrawal Assumption: If actual withdrawal rates are higher than assumed withdrawal rate assumption ,than the benefits will be paid earlier than expected. The impact of this will depend on whether the benefits are vested as at the resignation date.

(v) Regulatory Risk:

Any Changes to the current Regulations by the Government, will increase (in most cases) or Decrease the obligation which is not anticipated. Sometimes, the increase is many fold which will impact the financials quite significantly.

17. Deferred Tax Liabilities (Net)

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
(a) Deferred tax liabilities on account of				
PPE including ROU Assets and R & D Assets	489.58		479.28	
Fair Value changes on Business Combination	580.59		590.36	
Fair Value Change of Investment through PL	2.12		-	
Fair Value Change of Investment through OCI	1.80	1,074.09	1.30	1,070.94
(b) Deferred tax asset on account of				
Compensated Absences	(10.95)		(11.93)	
Unabsorbed depreciation*	(273.62)		(241.64)	
Carried forward losses	-		(7.13)	
Other tax disallowance	(22.75)	(307.32)	(22.90)	(283.60)
Net deferred tax liability		766.77		787.34

*The company continues to create deferred asset on unabsorbed depreciation on the estimations that the Company will be having sufficient profit to absorb the depreciation losses.

18. Other Non-financial Liabilities

<u>Particulars</u>	<u>As at March 31, 2026</u>		<u>As at March 31, 2025</u>	
	<u>Non Current</u>	<u>Current</u>	<u>Non Current</u>	<u>Current</u>
Advance from Customers- Contract Liabilities				
- Related Party *	-	238.62	-	150.00
- Others	-	0.99	-	41.06
Statutory Dues Payable	-	19.58	-	15.55
Duties & Taxes Payable		12.91		12.47
Other Payables	-	-	-	-
Total	-	272.10	-	219.08
* Ipca Laboratories Ltd				

(All Figures are Rupees in Lacs unless otherwise stated)

19. Short Term Borrowings

Particulars	As at March 31, 2026		As at March 31, 2025	
	Non Current	Current	Non Current	Current
Current Maturities of long term Borrowings	-	103.11	-	103.11
Working Capital Loan from Yes bank	-	270.28	-	29.64
Total	-	373.39	-	132.75
Secured Borrowing	-	373.39	-	132.75
Unsecured Borrowing	-	-	-	-

Holding Company

(a) Security:

Exclusive charge on present and future current asset of the Company.

Negative Lien on Plot No. 30/4, Makers Laboratories Ltd., Nr. Sovereign Metals Limited, Lane 3, Phase -3, Naroda GIDC, Naroda, GIDC Road, Ahmedabad- 382330.

(b) The rate of interest on short term borrowings is Repo Rate plus Spread 3%.

(c) Charge creation / satisfaction with Registrar of companies:

Charge Creation : The Company has created on the existing working capital facility on present and future current asset of the Company.

Charge Satisfaction : There are charges appearing on MCA portal amounting to ₹ 1,332.01 Lacs as at March 31, 2026 in respect of borrowings which have been already repaid by the Company. The Company is unable to close the satisfaction for lack of requisite documentation. The matter is being followed up by the Company.

Subsidiary Company

Current period reporting as on 31.03.2026

(d) Working Capital facility of ₹ 8Cr is taken from YES bank secured by first pari pasu charge on all present and future current assets and second charge on movable fixed assets of the company.

(e) Working capital borrowing carry interest of Repo Rate + 2.25%

Previous period reporting as on 31.03.2025

(f) Working Capital facility of ₹ 8Cr is taken from YES bank secured by first pari pasu charge on all present and future current assets and second charge on movable fixed assets of the company

(g) Working capital borrowing carry interest of Repo Rate + 2.25%

20. Financial Liabilities - Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Payables for goods and services:		
- Total outstanding dues of Micro and small enterprise	334.86	176.92
- Others	1,632.60	992.94
Total	1,967.46	1,169.86

Trade payables and acceptances are non-interest bearing and are normally settled between 0-120 days.

(All Figures are Rupees in Lacs unless otherwise stated)

(a) As at March 31, 2026

Range of O/s period	MSME		Others	
	Undisputed	Disputed	Undisputed	Disputed
Unbilled	-	-	153.79	-
Not Due	295.98	-	1,393.08	-
Less than 1 year	38.88	-	85.73	-
1-2 years	-	-	-	-
2-3 year	-	-	-	-
> 3 years	-	-	-	-
Total	334.86	-	1,632.60	-

(b) As at March 31, 2025

Range of O/s period	MSME		Others	
	Undisputed	Disputed	Undisputed	Disputed
Unbilled	-	-	136.49	-
Not Due	159.64	-	653.62	-
Less than 1 year	17.28	-	201.70	-
1-2 years	-	-	1.13	-
2-3 year	-	-	-	-
> 3 years	-	-	-	-
Total	176.92	-	992.94	-

21. Revenue from Operations

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Sale of Products	12,599.54	11,175.55
Sale of Services	1,052.96	827.13
Other operating revenues:		
Rodtep Income	-	-
Export Benefit/Duty Drawback	103.94	69.22
Packing and forwarding on sales	0.48	1.09
Sundry Creditors Balances written back	1.11	0.34
Compensation received	300.00	-
Miscellaneous income	1.45	1.79
Total	14,059.48	12,075.12

A. Disclosure in accordance with Ind AS - 115 "Revenue Recognition Disclosures", of the Companies (Indian Accounting Standards) Rules, 2015

(a) Disclosure relating to disaggregation of revenue in terms of Ind AS 115	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Sale of Generic formulations	3,679.21	3,465.20
Sale of Chemicals	8,920.33	7,710.35
Sale of Services	1,052.96	827.13

(b) There is one party (PY Nil) which individually account for more that 10% of sales of the company. Aggregate revenue from one party is ₹ 1,626.59 Lacs (PY NIL)

(All Figures are Rupees in Lacs unless otherwise stated)

(c) Disclosure relating to disaggregation of revenue in terms of Ind AS-115	Apr-Mar 26	Apr-Mar 25
Domestic	8,704.42	8,664.04
Exports	5,355.06	3,411.08
	14,059.48	12,075.12

B. Movement of Contract Balances

(a) Contractual Liabilities	Apr-Mar 26	Apr-Mar 25
Opening Balance	191.06	183.30
Addition during the year	208.17	180.05
Billed/Received during the Year	(159.62)	(172.29)
Closing Balance	239.61	191.06

The outstanding performance obligation is expected to be discharged in next one year.

(b) Unbilled Revenue (part of trade receivable)

Opening Balance	40.60	25.01
Addition during the year	19.16	40.60
Billed/Received during the Year	(40.60)	(25.01)
Closing Balance	19.16	40.60

22. Other Income

Particulars	Apr-Mar 26	Apr-Mar 25
Interest income	27.83	37.48
Interest income on financial asset on EIR basis	0.73	0.49
Reversal of Loss on leasehold Property Ind As	-	56.95
Dividend income - from investments	0.02	0.04
Profit on sale of property, plant & equipment	0.77	1,010.34
Rent Income	-	16.75
Profit on Sale of MF	15.54	27.22
Fair Valuation of Investments	8.41	-
Foreign Exchange Loss/ (Gain)	116.94	38.57
Miscellaneous Income	0.72	0.80
Total	170.96	1,188.64

23. Cost of Materials Consumed

Particulars	Apr-Mar 26	Apr-Mar 25
Raw Materials Consumed		
Opening stock	487.01	695.39
Add : Purchases (Net of discount)	5,009.85	3,843.58
	5,496.86	4,538.97
Less : Closing stock	1,244.24	487.01
	4,252.62	4,051.96
Packing Materials Consumed		
Opening stock	90.82	95.57
Add : Purchases (Net of discount)	236.04	181.02
	326.86	276.59
Less : Closing stock	125.93	90.82
	200.93	185.77
Total	4,453.55	4,237.73

24. Purchases of Traded Goods

Particulars	Apr-Mar 26	Apr-Mar 25
Formulations	2,147.09	1,432.98
Others	73.27	26.66
Total	2,220.36	1,459.64

(All Figures are Rupees in Lacs unless otherwise stated)

25. Changes in inventories of Finished Goods(FG), Work-in-progress(WIP) and Traded Goods

<u>Particulars</u>	<u>Apr-Mar 26</u>		<u>Apr-Mar 25</u>	
Inventory Adjustments - WIP				
Stock at commencement	355.67		411.57	
Less: - Stock at closing	<u>364.24</u>	(8.57)	<u>355.67</u>	55.90
Inventory Adjustments - FG				
Stock at commencement	1,902.42		1,259.11	
Less : Stock at closing	<u>1,880.28</u>	22.14	<u>1,902.42</u>	(643.31)
Inventory Adjustments - FG In transit				
Stock at commencement	17.18		29.23	
Less : Stock at closing	<u>18.79</u>	(1.61)	<u>17.18</u>	12.05
Inventory Adjustments - Traded Goods				
Stock at commencement	409.70		694.32	
Less : Stock at closing	<u>538.17</u>	(128.47)	<u>409.70</u>	284.62
Total		<u>(116.51)</u>		<u>(290.74)</u>

26. Employee Benefit Expenses

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Salaries , bonus , perquisites , etc.	1,393.17	1,290.36
Contribution to provident and other funds	66.79	63.37
Leave encashment *	20.98	11.04
Leave travel assistance	10.96	6.51
Gratuity fund contributions*	28.40	9.97
Staff welfare expenses	37.48	22.12
Recruitment & training	0.80	1.81
Total	<u>1,558.58</u>	<u>1,405.18</u>

*On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 which consolidate 29 existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to the new Labour Codes. The Company has assessed and disclosed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Labour Codes, amongst other things, introduce changes, including a uniform definition of wages. These changes have resulted in increase in gratuity and Leave liability arising from past service by ₹ 21.32 lacs which is recognised in the Statement of Profit & loss.

27. Finance Cost

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Interest on loan	40.20	87.26
Unwinding of Financial Liabilities	12.35	20.23
Interest on Lease Liability	1.76	-
Interest on Dealer's Deposit	16.24	17.86
Interest on MSME Creditors	6.56	3.10
Interest on Direct Tax	0.01	0.05
Total	<u>77.12</u>	<u>128.50</u>

(All Figures are Rupees in Lacs unless otherwise stated)

28. Depreciation & Amortisation

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Depreciation on Property, plant & equipment	404.09	432.54
Amortisation on Intangible Assets	12.40	12.50
Depreciation on Right of Use Assets	36.28	33.55
Total	452.77	478.59

29. Other Expenses

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Commission & Distribution Charges	134.71	117.81
Outside manufacturing charges	1,722.63	1,777.12
Power and fuel	1,008.69	1,080.12
Consumption of stores and spares	148.60	213.46
Freight, forwarding and transportation	356.29	264.17
Field staff expenses	78.89	70.97
Repairs and maintenance (Refer note 1 below)	282.09	250.09
Water charges	10.00	7.91
Assets scrapped	-	2.04
Sales and marketing expenses	65.65	44.26
Brand Recall Expenses - Domestic Marketing	21.69	24.45
Product information catalogue	-	2.75
Laboratory expenses and analytical Charges	77.05	66.19
Expenditure on research & development	29.50	18.10
Rent	120.55	80.94
Rates and taxes	36.54	57.08
Travelling expenses	68.67	15.72
Professional charges	53.28	46.16
Printing and stationery	21.60	13.68
Books, subscription and software	2.74	0.65
GST expenses	4.64	7.71
Communication expenses	4.28	10.63
Insurance	69.69	60.78
Intellectual property right expenses	0.92	1.48
Remuneration to auditors (Refer note 2 below)	10.23	8.97
Remuneration to Component Auditors	9.10	6.55
Bank charges	7.95	0.23
Bad debts and other balance w/off	13.14	39.77
Security Charges	32.03	35.59
Loss on Sale of property, plant & equipment	4.89	18.51
Director Sitting Fee	8.05	-
Interest on late filing	-	0.03
CSR Expenses	13.00	17.85
Membership Fees	10.01	7.77
Effluent Treatment & Desludging Charges	24.95	23.66
Miscellaneous expenses (none of which individually forms more than 1% of the operating revenue)	17.59	31.50
Total	4,469.64	4,424.70

(All Figures are Rupees in Lacs unless otherwise stated)

Details of:		
1. Repairs and Maintenance:		
- Building	54.30	42.08
- Machinery	168.22	199.61
- Others	59.57	8.40
	<u>282.09</u>	<u>250.09</u>
2. Remuneration To Auditors:		
	Apr-Mar 26	Apr-Mar 25
- Audit fees including Limited Review and Tax Audit	9.10	7.85
- Tax matters	1.13	1.12
	<u>10.23</u>	<u>8.97</u>
i) Total expenditure on R & D is included in respective heads of accounts as under:		
Particulars	Apr-Mar 26	Apr-Mar 25
Employee benefits expenses	0.58	0.53
Laboratory Expenses	29.50	18.10
Depreciation	4.91	4.91
Total	<u>34.99</u>	<u>23.54</u>
30. Exceptional Items income/ (expenses)		
Particulars	Apr-Mar 26	Apr-Mar 25
Fixed assets Written off	-	79.10
Total	<u>-</u>	<u>79.10</u>
31. Tax Expense- Profit and Loss Account		
Particulars	Apr-Mar 26	Apr-Mar 25
Current Tax	353.40	243.57
Short / Excess Provision of earlier years	(4.39)	(0.06)
Deferred Tax	(20.16)	6.80
Total	<u>328.85</u>	<u>250.31</u>
32. Tax Expense- Other Comprehensive Income		
Particulars	Apr-Mar 26	Apr-Mar 25
Current Tax	-	-
Short / Excess Provision of earlier years	-	-
Deferred Tax	(0.39)	(1.16)
Total	<u>(0.39)</u>	<u>(1.16)</u>
(i) Reconciliation of current rate of tax and effective rate of tax:		
Particulars	Apr-Mar 26	Apr-Mar 25
Profit/ (Loss) before Income taxes	1,114.93	1,341.06
Enacted tax rates in India (%)	25.17%	25.17%
Enacted tax rates in India on Capital Gains (%)	22.88%	22.88%
Computed expected tax expenses	303.58	332.67
Effect of non- deductible expenses	152.60	196.80
Effect of deductible expenses	(136.88)	(384.00)
Carry forward / (Set off) of losses	34.10	98.03
Others	-	0.07
Income tax expenses - Net	<u>353.40</u>	<u>243.57</u>
Tax on OCI	<u>(0.39)</u>	<u>(1.16)</u>

(All Figures are Rupees in Lacs unless otherwise stated)

(ii) **Reconciliation of Deferred Tax of Profit and loss account and Other Comprehensive Income**

Deferred tax (assets) / liabilities in relation to statement of profit and loss:

<u>Particulars</u>	<u>Opening March</u>	<u>Recognized in P & L</u>	<u>Recognized in OCI</u>	<u>Closing March</u>
Depreciation including on ROU , R&D Assets , Amortisation and impairment	479.28	10.30	-	489.58
Fair Value change on Business Combination	590.36	(9.77)	-	580.59
Compensated Absences	(11.93)	0.98	-	(10.95)
Unabsorbed Depreciation	(241.64)	(31.98)	-	(273.62)
Other tax disallowance	(22.90)	0.15	-	(22.75)
Unabsorbed Tax Loss	(7.13)	7.13	-	-
Fair Value Changes of Investment held through PL	-	2.12	-	2.12
Fair Value Changes of Investment held through OCI	1.30	-	0.50	1.80
As at March 31, 2026	787.34	(21.07)	0.50	766.77

Depreciation including on ROU, R&D Assets, Amortisation and impairment	412.99	66.29	-	479.28
Fair Value change on Business Combination	600.13	(9.77)	-	590.36
Compensated Absences	(9.69)	(2.24)	-	(11.93)
Unabsorbed Depreciation	(199.03)	(42.61)	-	(241.64)
Other tax disallowance	(12.58)	(10.32)	-	(22.90)
Unabsorbed Tax Loss	(11.41)	4.28	-	(7.13)
Fair Value Changes of Investment held through PL	0.25	(0.25)	-	-
Fair Value Changes of Investment held through OCI	1.04	-	0.26	1.30
As at March 31, 2025	781.70	5.38	0.26	787.34

33. Disclosure as required by Accounting Standard – IND AS 33 “Earning Per Share” of the Companies (Indian Accounting Standards) Rules 2015.

The earning per share is calculated by dividing the profit after tax by weighted average no. of shares outstanding for basic & diluted EPS.

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Profit/ (Loss) after tax	235.13	749.07
Closing equity shares outstanding (Nos.)	59,00,376	59,00,376
Opening equity shares outstanding (Nos.)	59,00,376	59,00,376
Add:- issued during the year (Nos.)	-	-
Closing equity shares outstanding (Nos.)	59,00,376	59,00,376
Weighted avg no. of shares outstanding (Nos.) (Basic)	59,00,376	59,00,376
Weighted avg no. of shares outstanding (Nos.) (Diluted)	59,00,376	59,00,376
Nominal value of equity share (₹)	10.00	10.00
Basic EPS (₹)	3.99	12.70
Diluted EPS (₹)	3.99	12.70

(All Figures are Rupees in Lacs unless otherwise stated)

34. Disclosure in accordance with Ind AS – 116 “Leases”, of the Companies (Indian Accounting Standards) Rules, 2015.

i) The following is the carrying value of lease liability:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Opening Liability	167.72	179.46
Additions during the year	-	183.80
Finance cost accrued during the year	14.10	20.16
Deletions	-	(168.26)
Payment of lease liabilities	(46.00)	(47.44)
Balance	135.82	167.72
Breakup:	Apr-Mar 26	Apr-Mar 25
Current portion of Lease liability	35.03	31.90
Non Current portion of Lease liability	100.79	135.82
	135.82	167.72

ii) Amounts recognised in the statement of cash flows

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Total cash outflow for leases	46.00	47.44

iii) The details of the contractual maturities(on undiscounted basis) of lease liabilities:

<u>Particulars</u>	<u>Apr-Mar 26</u>	<u>Apr-Mar 25</u>
Less than one year	46.01	46.01
One to five years	112.97	158.48
More than five years	-	-
Total	158.98	204.49

The Group does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

35. Disclosure as required by IND AS 108 "Operating Segment", of the Companies (Indian Accounting Standards) Rules, 2015.

The disclosure for Segment Reporting is made on the information reviewed by the "Chief Operating Decision Maker (CODM)", or which are otherwise regularly provided to the CODM.

Pursuant to acquisition of Resonance Specialties Limited (Resonance), the group has two reportable segments viz. "Pharmaceutical" (Makers) and " Chemical Manufacturing" (Resonance) as per Indian Accounting Standard "Operating Segment (Ind AS- 108). Segment information is given here in below:

<u>Particulars</u>	<u>Apr-Mar 26</u>		
	<u>Pharmaceutical</u>	<u>Chemical Manufacturing</u>	<u>Total</u>
Revenue from External Customers	5,034.73	9,024.75	14,059.48
Other Income	6.78	164.18	170.96
Total Revenue	5,041.51	9,188.93	14,230.44

(All Figures are Rupees in Lacs unless otherwise stated)

Interest Expenses	53.07	24.05	77.12
Depreciation and Amortisation	280.40	172.37	452.77
Other Expenses	4,961.67	7,623.95	12,585.62
Total Expenses	5,295.14	7,820.37	13,115.51
Extraordinary item	-	-	-
Segment Results - PBT	(253.63)	1,368.56	1,114.93
Tax	(29.15)	358.00	328.85
Segment Results - PAT	(224.48)	1,010.56	786.08
Segment Assets	5,109.32	11,552.60	16,661.92
Segment Liabilities	1,910.32	2,503.96	4,414.28
<u>Particulars</u>	<u>Apr-Mar 25</u>		
	Pharmaceutical	Chemical Manufacturing	Total
Revenue from External Customers	4,294.46	7,780.66	12,075.12
Other Income	1,090.90	97.74	1,188.64
Total Revenue	5,385.36	7,878.40	13,263.76
Interest Expenses	93.92	34.58	128.50
Depreciation and Amortisation	284.64	193.95	478.59
Other Expenses	4,515.34	6,721.17	11,236.51
Total Expenses	4,893.90	6,949.70	11,843.60
Extraordinary item	-	(79.10)	(79.10)
Segment Results - PBT	491.46	849.60	1,341.06
Tax	28.75	221.56	250.31
Segment Results - PAT	462.71	628.04	1,090.75
Segment Assets	4,895.12	9,899.70	14,794.82
Segment Liabilities	1,533.32	1,742.30	3,275.62

36. Disclosure in accordance with Ind AS - 24 "Related Party Disclosures", of the Companies (Indian Accounting Standards) Rules, 2015

A) List of related parties

Relationships

(i) Entities having control over the Company

Kaygee Investments Pvt.Ltd.

(Promoter holding together with its subsidiary holding more than 51%)

(ii) Entities where Holding Company is having control

Kaygee Laboratories Private Limited

Fellow Subsidiary

(iii) Key Management Personnel

Mr. Saahil Parikh

Whole time Director and CEO

Mr. Nilesh Jain

Whole time Director

Ms. Dipti Shah

Independent Director

Mr. R K P Verma

Independent Director

Mr. Prashant Godha

Additional Director

Mr. Vishal Jain

Additional Director

(All Figures are Rupees in Lacs unless otherwise stated)

(iv) Entities in which promoters have significant influence

Ipca Laboratories Ltd.
Unichem Laboratories Ltd

(v) Other Related Parties

Relative of Key Management Personnel
Mr. Umesh Parikh

B) Details of related party transaction are given in statement 1 Attached to the financial statement.

37. Contingent liabilities and Commitments

A) Contingent Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Guarantees given by the bank on behalf of the Group to Government Authorities and Others	63.10	63.10
Other moneys for which the Group is contingently liable for tax and other matters not accepted by the Group	286.05	242.36
Demand raised by MPCB disputed by the Group	121.64	121.64
Total	<u>470.79</u>	<u>427.10</u>

B) Commitments

Particulars	As at March 31, 2026	As at March 31, 2025
(a) Estimated amount of contracts remaining to be executed on capital account.(Net of Capital Advances) - Tangible Assets	-	28.70
(b) Outstanding Letter of Credit	501.51	206.40
	<u>501.51</u>	<u>235.10</u>

38. Disclosure of Interest in Other entities as per Ind AS 112

Consolidated financial statements comprises the financial statements of Makers Laboratories Limited and its subsidiary Resonance Specialties Limited.

The following table summarises the information relating to the subsidiary that has NCI. The amounts disclosed for each subsidiary are before intra-group eliminations.

Particulars	As at March 31, 2026	As at March 31, 2025
Non-current assets	2,555.14	2,333.99
Current assets	6,691.59	5,221.04
Non-current liabilities	296.97	380.25
Current liabilities	1,625.99	772.61
Net assets	7,323.77	6,402.17
Net assets attributable to NCI	4,955.23	4,468.60
Revenue	9,188.93	7,878.69
Profit for the year	1,039.58	656.62
Profit/(Loss) allocated to NCI	550.95	341.68
Other comprehensive income	(2.54)	(4.05)
OCI allocated to NCI	(1.38)	(2.21)

(All Figures are Rupees in Lacs unless otherwise stated)

Cash flow from operating activities	1,731.72	(252.25)
Cash flow from investing activities	(1,489.65)	355.99
Cash flow from financing activities	(246.59)	(120.13)
Net increase/ (decrease) in cash and cash equivalents	(4.52)	(16.39)

Note: All the figures have been taken from Standalone Financial Statements of the component.

39. Financial Instruments

The carrying value and fair value of financial instruments by categories is as follows:

<u>Particulars</u>	<u>Carrying Value</u>		<u>Fair Value</u>	
	<u>31-03-2026</u>	<u>31-03-2025</u>	<u>31-03-2026</u>	<u>31-03-2025</u>
Financial assets				
Amortised Cost				
Loans	-	0.17	-	0.17
Others	193.00	224.79	193.00	224.79
Trade receivables	1,986.35	2,762.99	1,986.35	2,762.99
Cash and cash equivalents	62.83	64.59	62.83	64.59
FVTPL				
Mutual Fund	1,157.40	-	1,157.40	-
FVTOCI				
Equity Instruments	15.37	14.42	15.37	14.42
Total Financial Assets	<u>3,414.95</u>	<u>3,066.96</u>	<u>3,414.95</u>	<u>3,066.96</u>
Financial liabilities				
Amortised Cost				
Borrowings	476.29	338.49	476.29	338.49
Trade payables	1,967.46	1,169.86	1,967.46	1,169.86
Others	566.35	433.70	566.35	433.70
Lease Liability	135.82	167.72	135.82	167.72
Total Financial Liabilities	<u>3,145.92</u>	<u>2,109.77</u>	<u>3,145.92</u>	<u>2,109.77</u>

The management assessed that fair value of cash and short-term deposits, trade receivables, trade payables, cash credit and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

40. Fair Value Hierarchy

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

(All Figures are Rupees in Lacs unless otherwise stated)

<u>Particulars</u>	<u>Date of Valuation</u>	<u>Quoted prices in active markets (Level 1)</u>	<u>Significant observable inputs (Level 2)</u>	<u>Significant unobservable inputs (Level 3)</u>	<u>Total</u>
Financial assets measured at fair value through P&L					
Kotak Liquid Fund	31-03-2026	816.32	-	-	816.32
Axis Liquid Fund - Reg Growth	31-03-2026	341.08	-	-	-
		1,157.40	-	-	816.32
Financial assets measured at fair value through OCI					
Listed Equity Investments	31-03-2026	15.37	-	-	15.37
		15.37	-	-	15.37
Financial assets measured at fair value through P&L					
Kotak Liquid Fund	31-03-2025	-	-	-	-
		-	-	-	-
Financial assets measured at fair value through OCI					
Listed Equity Investments	31-03-2025	14.42	-	-	14.42
		14.42	-	-	14.42

All the assets and liabilities carried at amortized cost and are equal to its fair value.

41. Financial Risk Factors

The Group's business activities are exposed to a variety of financial risks: Market/Business risk, credit risk, Exchange risk, etc. The Group's focus is to foresee the unpredictability of financial and business risks and seek to minimize potential adverse effects of these risks on its business and financial performance.

(i) Business/Market Risk

The primary business/market risk to the Group is the price risk on account of the drug pricing regime in the country. The Indian generic formulations market is currently in the growth phase. It is expected that use of generic formulations will gradually increase in India. However, cut throat competition, quality issues of generics manufactured in the country and non existence of organised generic formulations distribution and retailing system are a cause of concern and is hampering the growth of generic formulations market.

(ii) Credit Risk

The Group has exposure to credit risks associated with sales to various Customers. To mitigate these credit risks arising out of this, the Group on a regular basis evaluates the credit risk associated with a customer. Customer where no credit insurance is available, the Group monitors such risk by continuously monitoring its exposure to such customer. Based on the historical data, the Group has made adequate provisions for expected loss because of credit risk, which is neither significant nor material.

(iii) Foreign currency risk

The Group has a system of regularly monitoring its currency wise exposures. The significant part of Company's receivables and payables are in US Dollars which operates as a natural hedge against each other. The Company has a policy not to borrow in a currency where it has no business exposure. The company is in the process of starting currency hedging to safeguard currency exchange losses.

(All Figures are Rupees in Lacs unless otherwise stated)

(iv) The unhedged foreign currency exposure is as follows:

Particulars	Currency	As at March 31, 2026		As at March 31, 2025	
		Amount in Foreign Currency	Amount	Amount in Foreign Currency	Amount
i. Unhedged foreign exchange liability					
Trade and Other Payables	USD	-	-	-	-
Advances Received		-	-	-	-
i. Unhedged Receivables in foreign currency					
Trade and Other Receivables	USD	5.37	509.04	8.34	712.95
	EURO	-	-	0.41	37.29

Note: The above disclosure is after considering natural hedge between receivables and payables

Sensitivity Analysis

The following tables demonstrate the sensitivity to a reasonably possible change in USD and GBP exchange rates, with all other variables held constant. 5% is the sensitivity rate which represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items that are not hedged by derivative instruments and adjusts their translation at the year end for a 5% change in foreign currency rates. The sensitivity analysis includes foreign vendors. A positive number below indicates increase in profit or equity where the INR strengthens by 5% against the relevant currency. For a 5% weakening of the INR against the relevant currency, there would be a comparable impact on the profit.

Currency	% Change in Currency	Effect on Profit	
		As at March 31, 2026	As at March 31, 2025
USD	+5%	25.45	35.65
	-5%	(25.45)	(35.65)
EURO	+5%	-	1.86
	-5%	-	(1.86)

(v) Interest risk

The Company has domestic borrowings mainly in the nature of bank overdraft facilities. The domestic interest risk is exposed to the changes in the RBI bank rate. The Company manages this risk by managing its working capital effectively.

42. Capital Management

For the purpose of the Group's capital management, capital includes paid-up equity share capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Group's capital management is to maximise the shareholders' value.

The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Group may adjust its dividend payment ratio to shareholders, return capital to shareholders or issue fresh shares. The Group monitors capital using a gearing ratio, which is net debt divided by its total capital. The Group includes within its net debt the cash credit facilities, trade, lease and other payables less cash and cash equivalents.

(All Figures are Rupees in Lacs unless otherwise stated)

<u>Particulars</u>	<u>31/03/2026</u>	<u>31/03/2025</u>
Borrowings	476.29	338.49
Current Maturity	-	-
Less: Cash and Cash Equivalents	(19.68)	(24.29)
Net debt	456.61	314.20
Total Equity Capital and net debt	7,292.41	7,050.59
Gearing Ratio	0.06	0.04

No changes were made in the objectives, policies or processes for managing the capital during the year ended March 31, 2026 and March 31, 2025.

43. Disclosure as per Schedule III of Companies Act, 2013

<u>Particulars</u>	<u>Apr-Mar 26</u>			
	<u>Parent</u>	<u>Subsidiary</u>	<u>NCI</u>	<u>Total</u>
Net Assets , i.e. Total Assets minus Total Liabilities				
Amount	3,199.00	4,093.41	4,955.23	12,247.64
As % of consolidated Net assets	26.12	33.42	40.46	100.00
Share in Profit or (loss)				
Amount	(224.48)	459.61	550.950	786.08
As % of consolidated Profit or (Loss)	(28.56)	58.47	70.09	100.00
Share in Other Comprehensive Income				
Amount	7.85	(1.16)	(1.38)	5.31
As % of consolidated OCI Profit or (Loss)	147.83	(21.85)	(25.99)	100.00
Share in Total Comprehensive Income				
Amount	(216.63)	458.45	549.57	791.39
As % of consolidated Total OCI Profit or (Loss)	(27.37)	57.93	69.44	100.00

<u>Particulars</u>	<u>Apr-Mar 25</u>			
	<u>Parent</u>	<u>Subsidiary</u>	<u>NCI</u>	<u>Total</u>
Net Assets , i.e. Total Assets minus Total Liabilities				
Amount	3,361.79	3,688.80	4,468.60	11,519.19
As % of consolidated Net assets	29.18	32.02	38.79	100.00
Share in Profit or (loss)				
Amount	462.71	286.36	341.680	1,090.75
As % of consolidated Profit or (Loss)	42.42	26.25	31.33	100.00
Share in Other Comprehensive Income				
Amount	(1.29)	(1.84)	(2.21)	(5.34)
As % of consolidated OCI Profit or (Loss)	24.16	34.46	41.39	100.00
Share in Total Comprehensive Income				
Amount	461.42	284.52	339.47	1,085.41
As % of consolidated Total OCI Profit or (Loss)	42.51	26.21	31.28	100.00

(All Figures are Rupees in Lacs unless otherwise stated)

44. Audit Trail**In Case of Holding Company**

The Ministry of Corporate Affairs (MCA) by the Companies (Accounts) Amendment Rules 2021 and vide notification dated 24 March, 2021 has issued the "Companies (Audit and Auditors) Amendment Rules, 2021" has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

As required under above rules, the company uses in-house developed software for its financial accounting and MIS which works along with Database – Oracle as accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all transactions recorded and the audit trail feature has not been tampered with. Further, audit trail feature is enabled for direct changes on on November 24, 2024, to data when using certain access rights by the development team. However, due to system constraints, the audit trail for direct database changes done by the Database administrator is retained only for a period of three days and therefore, audit trail for the direct access changes is available only for said period.

Further, As regards the preservation of the audit trail as per the statutory requirements, at application level the same are retained for the period the edit log was enabled. In case of audit trail for direct database changes the audit trail prior to November 24, 2024 is not available since the direct database logs were enabled only from November 24, 2024 and due to system constrain the same are not retained for more than 3 days and thus to that extent the log retention are not retained by the Company.

45. Relationship with Struck off Companies

The information about transaction with struck off Companies (defined under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956) has been determined to the extent such parties have been identified on the basis of the information available with the Company and the same is relied upon by the auditors.

46. Figures for the previous year have been regrouped to conform to the requirements of Schedule III.

47. The balance sheet, statement of profit and loss, cash flow statement, statement of changes in equity, statement of material accounting policy information and the other explanatory notes forms an integral part of the financial statements of the Group for the period ended March 31,2026.

As per our report of even date attached**For N V C & Associates LLP**

Chartered Accountants

Firm Registration No. 106971W / W101085

Nuzhat Khan

Partner

M.No. 124960

Mumbai May 26, 2026

For and on behalf of the Board of Directors**Saahil Parikh**

(DIN 00400079)

Wholetime Director & CEO

Piyush Ajmera

ACS No : 58712

Company Secretary

Nilesh Jain

(DIN 05263110)

Wholetime Director

Sandeep Kadam

Chief Financial Officer

(All Figures are Rupees in Lacs unless otherwise stated)

Statement 1

Related Party Disclosure as required by Indian Accounting Standard – IND AS 24 “Related Party Transactions” of the Companies (Accounting Standards) Rule 2015.

Transactions with Related Parties

Description	Entities having control over the Company		Entities where Holding Company is having control Fellow Subsidiary		Key Management Personnel		Entities in which promoters have significant influence		Other Related Parties		Total	
	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25
Purchase of goods and services												
Ipca Laboratories Ltd	-	-	-	-	-	-	72.45	104.47	-	-	72.45	104.47
Unichem Laboratories Ltd	-	-	-	-	-	-	-	0.01	-	-	-	0.01
Kaygee Laboratories Pvt Ltd	-	-	1,678.10	1,729.83	-	-	-	-	-	-	1,678.10	1,729.83
TOTAL	-	-	1,678.10	1,729.83	-	-	72.45	104.48	-	-	1,750.55	1,834.31
Purchase of Assets												
Ipca Laboratories Ltd	-	-	-	-	-	-	7.12	0.27	-	-	7.12	0.27
TOTAL	-	-	-	-	-	-	7.12	0.27	-	-	7.12	0.27
Sales of goods and services												
Unichem Laboratories Ltd	-	-	-	-	-	-	-	4.15	-	-	-	4.15
Ipca Laboratories Ltd	-	-	-	-	-	-	1,699.54	1,140.25	-	-	1,699.54	1,140.25
TOTAL	-	-	-	-	-	-	1,699.54	1,144.40	-	-	1,699.54	1,144.40
Sale of Capital Assets												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	1,850.00	-	-	-	1,850.00
Unichem Laboratories Ltd	-	-	-	-	-	-	-	14.13	-	-	-	14.13
Kaygee Laboratories Pvt Ltd	-	-	57.14	-	-	-	-	-	-	-	57.14	-
TOTAL	-	-	57.14	-	-	-	-	1,864.13	-	-	57.14	1,864.13
Other expenses reimbursements												
Ipca Laboratories Ltd	-	-	-	-	-	-	0.03	6.91	-	-	0.03	6.91
TOTAL	-	-	-	-	-	-	0.03	6.91	-	-	0.03	6.91
Rent income Received												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	16.80	-	-	-	16.80
TOTAL	-	-	-	-	-	-	-	16.80	-	-	-	16.80
Rent paid												
Ipca Laboratories Ltd	-	-	-	-	-	-	6.00	3.33	-	-	6.00	3.33
TOTAL	-	-	-	-	-	-	6.00	3.33	-	-	6.00	3.33
Dividend Income :												
Ipca Laboratories Ltd	-	-	-	-	-	-	0.02	0.04	-	-	0.02	0.04
TOTAL	-	-	-	-	-	-	0.02	0.04	-	-	0.02	0.04
Dividend Paid :												
Kaygee Investments Pvt Ltd	10.12	-	-	-	-	-	-	-	-	-	10.12	-
TOTAL	10.12	-	-	-	-	-	-	-	-	-	10.12	-
Other expenses paid:												
Ipca Laboratories Ltd	-	-	-	-	-	-	40.01	29.02	-	-	40.01	29.02
TOTAL	-	-	-	-	-	-	40.01	29.02	-	-	40.01	29.02
Interest Received												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	0.17	-	-	-	0.17
Kaygee Laboratories Pvt Ltd	-	-	21.44	25.33	-	-	-	-	-	-	21.44	25.33
TOTAL	-	-	21.44	25.33	-	-	-	0.17	-	-	21.44	25.50

(All Figures are Rupees in Lacs unless otherwise stated)

Description	Entities having control over the Company		Entities where Holding Company is having control Fellow Subsidiary		Key Management Personnel		Entities in which promoters have significant influence		Other Related Parties		Total	
	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25	Mar' 26	Mar' 25
Advance received												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	150.00	-	-	-	150.00
TOTAL	-	-	-	-	-	-	-	150.00	-	-	-	150.00
ICD received												
Kaygee Investments Pvt Ltd	-	150.00							-	-	-	150.00
TOTAL	-	150.00	-	-	-	-	-	-	-	-	-	150.00
ICD paid												
Kaygee Investments Pvt Ltd	-	750.00	-		-	-	-	-	-	-	-	750.00
TOTAL	-	750.00	-	-	-	-	-	-	-	-	-	750.00
ICD interest paid												
Kaygee Investments Pvt Ltd	-	25.18	-		-	-	-	-	-	-	-	25.18
TOTAL	-	25.18	-	-	-	-	-	-	-	-	-	25.18
Remuneration to Directors												
Mr. Saahil Parikh	-	-	-	-	67.98	62.49	-	-	-	-	67.98	62.49
Mr. Nilesh Jain	-	-	-	-	38.50	35.37	-	-	-	-	38.50	35.37
TOTAL	-	-	-	-	106.48	97.86	-	-	-	-	106.48	97.86
Provident Fund												
Mr. Saahil Parikh	-	-	-	-	5.36	4.99	-	-	-	-	5.36	4.99
Mr. Nilesh Jain	-	-	-	-	3.25	3.03	-	-	-	-	3.25	3.03
TOTAL	-	-	-	-	8.61	8.02	-	-	-	-	8.61	8.02
Sitting Fees												
Mrs. Dipti Shah	-	-	-	-	1.65	1.65	-	-	-	-	1.65	1.65
Mr. R K P Verma	-	-	-	-	3.55	3.55	-	-	-	-	3.55	3.55
Mr. Prashant Godha	-	-	-	-	2.15	2.15	-	-	-	-	2.15	2.15
Mr. Nilesh Jain	-	-	-	-	1.20	1.20	-	-	-	-	1.20	1.20
Mr. Vishal Jain	-	-	-	-	2.05	2.05	-	-	-	-	2.05	2.05
TOTAL	-	-	-	-	10.60	10.60	-	-	-	-	10.60	10.60
Salaries Paid												
Mr. Umesh Parikh	-	-	-	-	-	-	-	-	23.61	23.88	23.61	23.88
TOTAL	-	-	-	-	-	-	-	-	23.61	23.88	23.61	23.88
Closing Balances of Related Parties												
Balance at year end												
Advances Against Supplies												
Kaygee Laboratories Pvt Ltd	-	-	275.40	82.71	-	-	-	-	-	-	275.40	82.71
TOTAL	-	-	275.40	82.71	-	-	-	-	-	-	275.40	82.71
Receivables												
Ipca Laboratories Ltd	-	-	-	-	-	-	-	8.34	-	-	-	8.34
TOTAL	-	-	-	-	-	-	-	8.34	-	-	-	8.34
Payables												
Ipca Laboratories Ltd	-	-	-	-	-	-	217.29	147.94	-	-	217.29	147.94
Unichem Laboratories Ltd	-	-	-	-	-	-	-	0.01	-	-	-	0.01
TOTAL	-	-	-	-	-	-	217.29	147.95	-	-	217.29	147.95

1 The above disclosure of Related Party Transaction is without considering the impacts of IND AS Adjustments and are based on the actual transaction values.

2 Managerial remuneration excludes provision for short term benefits as the incremental liability has been accounted by the Company as a whole

(All Figures are Rupees in Lacs unless otherwise stated)

Form AOC-I

(Pursuant to first proviso to section 129 (3) read with rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

Sr. No	Name of Subsidiary Company	Reporting Currency	Share Capital	Reserves & Surplus	Total Assets	Total Liabilities	Investments	Total Income/ Turnover	Profit/ (Loss) Before Taxation	Provision for Taxation	Profit After Taxation	Proposed Dividend (Re)	% of Shareholding
1	Resonance Specialties Ltd	INR	1,154.40	6,169.37	9,246.73	1,922.96	1,157.40	9,188.93	1,407.35	367.77	1,039.58	115.44	45.48%

- 1) Financials reporting period of all subsidiaries is 31st March.
- 2) The Company own 45.48% interest in above subsidiary.

For and on behalf of the Board of Directors

Saahil Parikh
(DIN 00400079)
Wholetime Director & CEO

Nilesh Jain
(DIN 05263110)
Wholetime Director

Piyush Ajmera
(ACS-58712)
Company Secretary

Sandeep Kadam
Chief Financial Officer

Mumbai
May 26, 2026



Makers Laboratories Limited

Registered Office:

54-D, Kandivli Industrial Estate,
Charkop, Kandivli (West),
Mumbai - 400 067.

CIN : L24230MH1984PLC033389

Ph : 022 - 2868 8544

Email : investors@makerslabs.com

Website : www.makerslabs.com